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Abstract 
Pantothenate kinase (PanK) enzymes catalyze the first reaction in the five step biosynthesis 
of the essential cofactor coenzyme A.   Enzymes representing each of the three identified 
PanK types have been studied and characterized and these PanK types exhibits a unique 
diversity between different organisms, therefore highlighting them as potential drug 
targets.  In this study the type III PanK of specifically pathogenic bacteria were characterized 
with the goal of developing type-specific inhibitors.  Several questions about the activity of 
the Mycobacterium tuberculosis enzyme was answered, which addresses the contradicting 
results achieved in related PanK studies performed to date.  Furthermore the first inhibitors, 
that are competitive to the pantothenate binding site, were designed, synthesized and 
tested against the Pseudomonas aeruginosa enzyme. This resulted in the discovery of the 
most potent inhibitors of the type III PanKs fto date. 
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Opsomming 
Pantoteensuurkinase-ensiem (PanK) kataliseer die eerste stap in die vyf stap biosintese van 
die lewens belangrike en essensiële kofaktor, koënsiem A (KoA).  Die meerderheid 
patogeniese bakterieë, waaronder die organisme wat tuberkulose veroorsaak, besit ‘n 
unieke vorm van die PanK-ensiem.  Gevolglik word hierdie ensieme as belangrike teikens vir 
die ontwikkeling van antibakteriële middels beskou. In hierdie studie is die aktiwiteit van die 
Mycobacterium tuberculosis ensiem gekarakteriseer wat verskeie teenstrydige bevindings 
oor hierdie ensiem beantwoord het.  Verder is nuwe inhibitore vir die Pseudomonas 
aeruginosa ensiem ontwerp, gesintetiseer en getoets.  Die beste inhibitore van hierdie tipe 
ensiem tot op hede is sodoende geïdentifiseer. 
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Chapter 1:  Overview of thesis 
 
Chapter 1:   
Overview of thesis 
1.1  Pantothenate kinase:  Remaining unanswered questions 
Pantothenate kinase (PanK) catalyses the first committed step in the biosynthesis of the 
universal and essential cofactor coenzyme A (CoA)1.  Specifically, PanK catalyzes the ATP-
dependent phosphorylation of pantothenic acid (Vitamin B5) to form 4’-phospho-
pantothenic acid as shown in Figure 1.1.   
 
Figure 1.1:  The ATP-dependent phosphorylation of pantothenic acid to form 4’-phosphopantothenic acid is 
catalyzed by the enzyme pantothenate kinase (PanK). 
Enzymes representing each of the three identified PanK types have been studied and 
characterized in several studies conducted since the cloning and production of the 
Escherichia coli enzyme in 1992.  However, significant gaps in our understanding of these 
kinases remain. This is especially true of type III PanKs, which were first characterized as 
recently as 2005, and represent an especially important target for antibacterial drug 
discovery. Summarized below are some of the most important questions regarding PanKs 
that still need to be addressed. 
 In 12% of the bacterial species with sequenced genomes, which are predicted to 
have pantothenate kinase activity – as in the case of Archaea – no PanK-encoding 
gene can be identified by homology.  This raises the question of whether significant 
variations of the three known types exist, or whether a fourth type remains to be 
discovered.2 
 The genomes of both Bacillus anthracis and Mycobacterium tuberculosis encodes for 
two PanK enzymes representing different types:  the former possesses Type II and III 
PanKs, while the latter has Type I and III enzymes.  However, in both cases one of 
these PanK types is reported to lack demonstrable pantothenate kinase activity.3,4   
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If this is really the case, why did both organisms retain these genes and why are the 
proteins still expressed? Is there a possibility that these enzymes have another 
function, or that they are only activated under certain conditions (and what would 
these conditions be)? 
 Type I and II PanKs are known for their substrate promiscuity,5 and a range of 
pantothenate analogs have been shown to act as substrates and/or inhibitors of 
these enzymes. However, little is known about compounds that could act as 
alternative substrates and inhibitors of type III PanK enzymes, and the question 
remains as to the type or class of analog that could play such a role in its case. 
 Type III PanKs have KM-values for ATP which fall in the range of 2-10 mM.
6  Although 
these values can be explained using the available structures, from a physiological 
perspective such high values makes much less sense.  What is the rationale for such 
low substrate specificity?  Is ATP really the co-substrate, or are there other 
phosphoryl donors that still need to be investigated?   
 The coaX homolog (the gene encoding for type III PanKs) from Bordella pertussis was 
first studied as an accessory protein in the regulation of pertussis toxin production 
by the BvgAS proteins.7  In many instances coaX homologs are still annotated as Baf 
(Bvg accessory factor) or as putative transcriptional regulators.  Are type III PanKs 
able to moonlight as both Baf proteins and PanKs, or was the activity observed in the 
B. pertussis study unique to the coaX-encoded protein from this organism? 
1.2  Aims of this study 
All the questions posed above cannot be answered in one study.  In the studies described in 
this thesis we mainly focused on the type III PanKs from pathogenic bacteria with the aim to 
find answers relating to inhibitor identification (chapter 3) and enzyme activity (chapter 4).  
However, we also attempted to purify and characterize the first example of a type IV PanK  
from Archaea (chapter 5), to address the question in regards to the supposed “missing” 
PanK in this domain of life.   
The outline of each chapter is given below. 
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1.2.1  Chapter 2 
The importance of CoA and PanKs are placed into perspective in the context of the global 
drug discovery programs for neglected diseases.  This is followed by a comprehensive 
outline of the PanKs in general, in which the PanK types are compared with each other and 
the gaps in knowledge are identified.   
1.2.2  Chapter 3 
This chapter describes the work done on the identification, synthesis and testing of 
potential inhibitors for the type III PanKs.  Our knowledge of the active site of Pseudomonas 
aeruginosa type III PanK was used to devise a strategy for the rational design of inhibitors.  
This is followed by a survey of the molecules that meet the specified criteria and discussions 
on the synthetic routes that were followed to create them. Finally the kinetic 
characterization of the molecules that showed potential as alternative substrate and/or 
inhibitors is provided.  
1.2.3  Chapter 4 
In published studies CoaX (hypothetical PanK-III) from M. tuberculosis is reported to be 
inactive.  Here we report the results of a comparative characterization of the putative 
PanK-III enzymes from Mycobacteria and several other pathogenic organisms, including the 
inactive B. anthracis BA2901 (hypothetical PanK-II), in an effort to explain the apparent 
contradictory results achieved in the PanK-related studies performed to date.   
1.2.4  Chapter 5 
In this chapter the work done towards the identification, heterologous expression, 
purification and kinetic characterization of the first type IV PanK from Archaea is described. 
1.2.5  Chapter 6 
In summary an overview is given of what is known of the type III PanKs at the conclusion of 
these studies.  Future work to address the remaining knowledge gaps is also identified and 
discussed. 
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Chapter 2:   
Introduction to CoA biosynthesis and PanKs 
2.1  Tuberculosis and the need for new antimicrobial agents 
Infectious diseases remain a leading cause of morbidity and mortality in third world and 
developing countries.  As part of the ongoing battle against these diseases the sixth goal of 
the United Nations’ Millennium Development Goals (MDGs) is to “Halt and begin to reverse 
the incidence of HIV/AIDS, malaria and other major diseases by 2015 (in comparison to 
1990)”.
1
  One of the “other major diseases” listed is tuberculosis (TB). 
The good news is that the worldwide number of TB incidences per capita is falling at an 
estimated 1% per year which satisfies both the MDGs and Stop TB Partnership goals for this 
disease.  However, with the world’s population growing at about 2% per year the total 
number of TB cases is still rising.  In 2010 there was an estimated 9.8 million new infections 
which is the largest number of new cases in any year to date.  This situation is aggravated by 
co-infection with the human immunodeficiency virus (HIV).  HIV is seen as the most 
powerful known risk factor for susceptibility to infection by Mycobaterium tuberculosis, the 
causative agent of TB, and the progression from latent infection to active disease.
2
 
According to the World Health Organization (WHO) HIV is also the main reason for failure to 
meet TB control targets with Sub-Saharan Africa bearing the brunt of the HIV-fuelled TB 
epidemic.
3
 In addition, years of misuse and abuse of known treatments, poor patient 
compliance and poor quality of available drugs led to the emergence of drug resistant 
pathogens.  
This increase of drug resistance strains highlights the need to find new classes of 
antimicrobials. The last drug with a new mechanism of action approved for TB was 
rifampicin, discovered in 1963.  Drug resistance to this compound and to other known TB 
treatments is already prevalent.  Multi-drug resistant TB (MDR-TB) is resistant to rifampicin 
and isoniazid and extensively-drug resistant TB (XDR-TB) to these treatments as well as to 
fluoroquinolone and the second-line anti-TB injectable drugs amikacin, kanamycin and 
capreomycin.
4
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M. tuberculosis is not the only example of a drug-resistant bacterium in which current 
treatment are rendered ineffective.  Other global examples include methicillin-resistant and 
multidrug-resistant Staphylococcus aureus, penicillin- and macrolide-resistant pneumococci, 
vancomycin-resistant enterococci and multidrug-resistant P. aeruginosa.  Resistance to 
chloroquine and other firstline antimalarial agents are also increasing in the Plasmodium 
spp.
5
 
The drug discovery program established in our group targets coenzyme A (CoA) biosynthesis 
in bacteria since CoA is an essential cofactor that has to be biosynthesized in the organism 
and is used in numerous metabolic processes.  The goal of this program is to use rational 
design to develop compounds that specifically target this pathway, and will therefore have a 
mechanism of action different to those of the known antibiotics already available.   
2.2  Coenzyme A – an essential cofactor 
CoA is a ubiquitous cofactor in all living organisms with an estimated 9% of the enzymes 
reported in the BRENDA database utilizing it in one way or another.
6
 The cofactor functions 
as an acyl group carrier and carbonyl-activating group for various processes in cells including 
Claisen condensations and amide-, ester- and thioester-forming reactions.  It is also involved 
in fatty acid biosynthesis and in the breakdown and in the biosynthesis of nonribosomally 
synthesized peptides and polyketides.
7
 
CoA is synthesized in five enzymatic steps from pantothenic acid (vitamin B5).  Bacteria, 
plants and fungi synthesizing pantothenic acid de novo, whereas animals and some 
microbes obtain the vitamin from their diets.
8
 The universal biosynthesis pathway of CoA is 
shown in Figure 2.1.   
Pantothenate kinase (PanK, CoaA) catalyses the first commited step of this pathway by 
phosphorylating pantothenic acid (2.2) to form 4’-phosphopantothenic acid (2.3).  The 
second step involves formation of 4’-phosphopantothenoylcysteine (2.4) from 2.3 and  
L-cysteine.  This reaction is catalyzed by phosphopantothenoylcysteine synthetase (PPCS, 
CoaB).  Decarboxylation of 2.4 by the flavoenzyme phosphopantothenoylcysteine decarbo-
xylase (PPCDC, CoaC) forms 4’-phosphopantetheine (2.4) as product.  Phosphopantetheine 
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adenylyltransferase (PPAT, CoaD) catalyzes the adenylation of 2.5 to 3’-dephospho-
Coenzyme A (2.6).  The final step is the phosphorylation of the 3’-hydroxyl of the ribose 
moiety of 2.6 to form CoA (2.1) as catalyzed by the enzyme dephospho-Coenzyme A kinase 
(DPCK, CoaE).
7
 
 
Figure 2.1:  The five-step biosynthesis of CoA (2.1) from pantothenic acid (2.2). 
 
Variations to this five-step pathway exist.  For example Bacteria, with the exception of the 
streptococci and enterococci, do not produce distinct PPCS and PPCDC enzymes.  Instead 
they contain a bifunctional CoaBC which catalyzes both steps.
6
 A similar scenario is seen in 
mammals, although here PPAT and DPCK are combined to form the bifunctional protein CoA 
syntethase.
8
 
2.3  CoA salvage pathway 
In Figure 2.2 an alternative method for the biosynthesis of CoA is shown.  The three-step 
CoA salvage pathway bypasses the PPCS and PPCDC enzymes by utilizing pantetheine (2.7) 
as substrate instead of pantothenic acid.  The viability of the pathway was recently 
confirmed when pantethine (the disulfide of pantetheine) was shown to rescue E. coli 
ΔcoaBC knockout mutants, while the addition of pantothenic acid, dephospho-CoA (2.6) and 
CoA (2.7) to the growth media failed to do so.  This also demonstrated that even though 2.6 
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and 2.7 are the penultimate and final products of the pathway respectively, their polarity 
would appear to prevent them from entering the cells.
9
 
Figure 2.2:  CoA salvage pathway converting pantetheine (2.7) to CoA (2.1). 
 
The CoA salvage pathway is possible due to the substrate promiscuity of PanK (specifically 
type I and II PanKs as will be discussed later) that allows pantetheine to be accepted as an 
alternative substrate.  Pantetheine (2.7) is phosphorylated to 4’-phosphopantetheine (2.5), 
which feeds into the normal CoA biosynthesis pathway.  The alternate activity has been 
characterized for E. coli PanK-I and the kinetic parameters are given in Table 2.1 in 
comparison to pantothenic acid.  These values translate into a specificity constant (kcat/KM) 
for pantetheine which is only about 6 times slower than that obtained for the natural 
substrate pantothenic acid.10,11 
Table 2.1:  Kinetic parameters for E. coli PanK-I with pantothenic acid and pantetheine. 
 
2.4  CoA metabolism as drug target  
The following three strategies have been identified to target CoA metabolism for drug 
development: 
 Uptake and/or biosynthesis of pantothenic acid, the precursor to CoA 
 CoA biosynthesis itself 
 The CoA utilization processes 
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2.4.1  Uptake and/or biosynthesis of pantothenic acid 
The first noticeable difference between CoA biosynthesis in pathogens and the human host 
is that the substrate, pantothenic acid, is biosynthesized de novo by the bacteria.  However, 
metabolic labeling experiments in E. coli
12
 and rat hearts13,14 have shown that the supply of 
pantothenic acid does not control the rate of CoA biosynthesis, but rather the utilization 
thereof.  Wild type E. coli produces 15 times more pantothenic acid than is required to 
maintain the intercellular CoA levels and the excess is excreted from the cells.12,15 A 
controlled study showed that this overproduction and excretion of pantothenic acid by the 
intestinal flora of ruminants is sufficient to sustain the animals without further supplemen-
tation.
16
  Furthermore, most organisms, regardless of their ability to synthesize pantothenic 
acid de novo, have various forms of transport systems that actively mediates the uptake of 
pantothenate.  Of these the E. coli pantothenate permease (PanF) is the best characterized.  
It consists of a unidirectional Na+-based symporter which is highly specific for pantothenate 
(Kt = 0.4 μM) and has a maximum velocity of 1.6 pmol/min per 10
8 cells.
17-20
 Pantetheine, 
the substrate of the CoA salvage pathway, is also transported into the cells although no 
pantetheine-specific transporter has been identified.
6
  Other transport systems  include the 
H+-coupled product of the FEN2 gene in Saccharomyces cerevisiae, the “new permeability 
pathways (NPP)” in Plasmodium falciparum-infected erythrocytes5 and Na+-dependent 
multivitamin transporters in higher organisms.
6
  Taking into account the relative abundance 
of pantothenic acid along with the excess in which it is produced and its facile transport, 
strategies that target the biosynthesis of this metabolite directly is unlikely to be successful 
in organisms such as E. coli and Plasmodium falciparum.  
In contrast pantothenic acid biosynthesis is essential for the growth in M. tuberculosis21  
and the pathogen displays pantothenate mediated virulence.22  In vaccine studies ΔpanCD 
knockout mutants were found to be auxotrophic for pantothenate with full virulence 
restored when the panCD wild type genes were reintegrated into the mutants.22  It was also 
observed that the ΔpanCD mutant bacteria can persist for over eight months in the severely 
compromised immune deficient (SCID) mouse model.22  Since no transport systems have 
been identified in M. tuberculosis to date, the pathogen may possess an alternative method 
of obtaining pantothenic acid;  albeit at levels barely sufficient for persistence. 
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2.4.2  CoA biosynthesis 
Two of the CoA biosynthetic enzymes are regulated by feedback inhibition – PanK and PPAT.  
The regulation of PanK will be discussed in detail later.  E. coli PPAT is allosterically regulated 
by feedback inhibition of CoA and to a lesser extent by acetyl-CoA.5,8  However, based on 
the high KM-value for phosphopantetheine and the mediocre Ki-value for CoA, this 
regulation is only physiologically relevant when the levels of CoA are high and 
phosphopantetheine low.
6
   In this study we focused on PanK as a drug target. 
2.4.3  CoA utilization processes 
CoA functions as the central acyl group carrier in central metabolism and constitutes the 
source of the 4’-phosphopantetheine moiety of the acyl carrier proteins (ACPs).23  ACPs are 
central to fatty acid biosynthesis, an essential process in bacteria.24 The 4’-phospho-
pantetheine moiety is transferred from CoA by phosphopantetheinyl transferase (PPTase) 
enzymes to apo-ACP to convert it to its holo- (active) form.  Thus modifications to the CoA 
molecule itself or decreases in the available CoA levels would affect the activation of the 
ACPs and subsequently affect all the ACP-dependent processes. 
Other enzymes dependent on CoA for the acyl moiety include HMG-CoA reductase, 3-
Hydroxyacyl-CoA dehydrogenase, 2-Enoyl-CoA reductase, Acyl-CoA oxidase, Acyl-CoA 
dehydrogenases, Benzoyl-CoA reductase, Stearoyl-CoA desaturase, 4-Chlorobenzoyl-CoA 
dehalogenase, Enoyl-CoA hydratase, 3-Hydroxybutyryl-CoA epimerase and Methylmalonyl-
CoA mutase.6 
2.5  Introduction to pantothenate kinases (PanK) 
PanK catalyses the phosphorylation of pantothenic acid (2.2) to 4’-phosphopantothenic acid 
(2.3) as shown in Figure 2.3.  
  
Figure 2.3:  Pantothenate kinase (PanK) reaction:  Phosphorylation of pantothenic acid (2.2) to 4’-phospho-
pantothenic acid (2.3) 
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PanK is the best studied enzyme of the CoA biosynthetic pathway.  The first prokaryotic 
PanK enzyme was produced and purified from E. coli as early as 1994.25  In 1999, when the 
first eukaryotic example was purified from Aspergillus nidulans,26 it was clear that the 
sequence of this enzyme had little similarity to the bacterial enzyme and that their primary 
structure and regulatory properties differed.  This led to the classification of subsequently 
identified PanKs as either prokaryotic or eukaryotic based on origin and similarity.  However, 
the phylogenetic split was shown not to be absolute when the enzyme from the Gram-
positive bacteria Staphylococcus aureus was found to be more closely related to the 
eukaryotic than the prokaryotic enzyme.27   
The existence of a third type of PanK was first proposed based on genome-wide analyses 
which revealed that bacteria, such as Helicobacter pylori and P. aeruginosa, possesses genes 
encoding homologs of the last four CoA biosynthetic enzymes, but had no PanK encoding 
genes.28,29  This was true both when the prokaryotic or eukaryotic PanKs were used as 
search terms.  A patent subsequently reported the discovery of a gene in the Gram-positive 
bacterium Bacillus subtilis which rescued a temperature-sensitive E. coli coaA mutant.  This 
gene was distinct from the predicted PanK-encoding coaA gene, and was subsequently 
named coaX.30  Furthermore, B. subtilis coaA deletion mutants remained viable, whereas 
double mutants in which both coaA and coaX were disrupted, failed to grow.  In conclusion 
this strongly suggested that the coaX gene product has PanK activity.  Homology searches of 
coaX indicated that most of the bacteria lacking PanKs indeed contain this homolog.  First 
examples of this third type of PanKs were cloned, purified and characterized from H. pylori 
and B. subtilis in 2005.31   
Today, PanKs are split into three distinct types based on sequence homology, enzyme 
structure, kinetic parameters and feedback inhibition.  For ease of distinction they are 
labeled as type I (PanK-I), type II (PanK-II) and type III (PanK-III).6  Moreover, type II PanKs –
mainly eukaryotic – frequently occurs as different isoforms in the same organism.  The term 
“PanK isoforms” implies that the same protein is expressed from different initiating exons 
(for example human PanK1α and PanK1β)20 or that the same enzyme is expressed in 
different tissues or is found in different cellular locations (for example human PanK2 and 
PanK3 respectively are restricted to the mitochondria and the cytosol).32 To distinguish PanK 
types and isoforms, the former use Roman numbers and the latter Latin numbers. 
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2.6  Distribution of the PanK types 
All three known PanK types are found in bacteria, whereas eukaryotes only produce type II 
PanKs. The PanK-IIs identified and characterized from eukaryotic sources include fungi 
(Aspergillus nidulans), plants (Arabidopsis thaliana and spinach), insects (Drosophila 
melanogaster) and mammals (human, mouse and rat).
6
  At the start of this study, no PanKs 
had been isolated or otherwise characterized from the archaea.   
The distribution of the PanK types in the ≈ 280 genome sequenced bacterial species is 
shown in in Figure 2.3.  It reveals that ≈ 80.5% species contain only a single PanK type, 
whereas ≈7.5% harbors more than one type.  A further ≈ 12% of species lack a recognizable 
PanK, though they are predicted to possess PanK activity.29 The considerable number of the 
latter bacterial species would appear to imply a greater variability in the sequences of the 
three established PanK types, or include the existence of a fourth PanK type. 
 
Figure 2.3:  The distribution of the PanK in the ≈ 280 Bacterial species with sequenced genomes. 
To survey the phylogenetic distribution of the PanK types in bacteria, the SEED genomic 
integration platform, with data from of than 400 complete or nearly complete sequenced 
bacterial genomes, was used.33,34  Table 2.2 contains a summary of the results of such a 
survey conducted in all 13 major bacterial groups.   
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  Table 2.2:  Phylogenetic distribution of the PanK types in 13 major bacterial groups. 
 
The results show that type III PanKs are found in the majority of the bacterial groups, and 
represent the only identified PanK in eight of the 13 groups.  Type I PanKs are found in five 
bacterial groups and type II PanKs in only one bacterial group.  To date, no PanK candidates 
have been identified in the Chlamydiae.  Certain species of the Actinobacteria and 
Firmicutes also harbors another type along with the type III PanK.  These species include the 
Mycobacterium spp. and Streptomyces spp. (Actinobacteria) which encodes both type I  
and III PanKs.  Most of the Bacilli (Firmicutes), such as B. subtilis,31 have combinations of 
type I and III PanKs, except B. anthracis,35 B. cereus and the Oceanobacillus spp which have 
type II and III PanKs. 
2.7  Comparison of PanK types 
In the following sections the PanK types are reviewed and compared to reflect current data.  
To provide a brief overview of the major similarities and differences between the types their 
main characteristics, as described by their primary structure sequences, tertiary structures, 
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cofactor requirements, kinetic parameters, regulation and ability to utilize the alternative 
substrates N-substituted pantothenamides, are summarized in Table 2.3.  Data obtained for 
the enzymes from E. coli
15
 (type I), P. aeruginosa36 (type III) and A nidulans26 (the 
prototypical type II PanK) are used as representative examples of the PanK types.  The 
atypical type II PanK from S. aureus27 is also included to highlight the differences.   
Table 2.3:  General comparison between the three known PanK types 
 
2.7.1  Gene sequence and expression 
Bacterial type I and II PanKs are both expressed by coaA gene.  The sequence homology 
between the genes of the types is however low.  Type III PanK is expressed by the coaX gene 
which bears no sequence homology to coaA.31 
The first coaA gene was identified from S. typhimurium,37 but most of what is known about 
coaA is based on the studies of the E. coli gene.25 One of the ways in which CoA production 
is regulated in E. coli is by the gene expression of coaA.8  The coaA promoter region has poor 
homology in comparison to consensus E. coli promoter sequences and at 0.565 the optimal 
codon usage frequency is low.25 This translates into a low abundance of PanK-I relative to 
that of other E. coli proteins.  However, this regulatory effect is secondary to the feedback 
inhibition of PanK by CoA.  Overproduction of PanK-I in E. coli (containing multiple copies of 
the coaA-gene) leads to a 76-fold increase in specific activity of the kinase, but only 
increases the steady-state concentration of CoA ≈ 2.7-fold.25 
Translation of E. coli coaA produces two isoforms of 36.4 kDa and 35.4 kDa respectively.  
The only known difference between these isoforms is that the smaller protein lacks the first 
eight N-terminal amino acids.25 The reason and the significance thereof remain unknown.7   
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Eukaryotic PanK-II enzymes are encoded by PANK-genes.  Some organisms have more than 
one PANK-gene encoding different PanK-II isoforms that exhibit tissue specific expression 
levels.  In some cases these isoforms can be functionally distinguished as demonstrated by 
the human genetic disorder known as pantothenate kinase-associated neurodegeneration 
(PKAN) which has been linked to mutations in PANK2.38-40 
Of the four known human isoforms, PanK1 is mostly expressed in the liver and kidneys and 
to a lesser extent in the heart and muscles.  PanK2 expression is limited to the mitochondria 
of most tissue, PanK3 to the liver and PanK4 to the heart and skeletal muscles.6  In some 
cases a single gene also gives rise to two isoforms being expressed, as in the case of PANK1 
in mice and humans.  In the latter case different initiating exons lead to two distinct 
catalytically active isoforms – PanK1α and PanK1β.20   
The coaX homolog from B. pertussis was the first to be studied, albeit as an accessory 
protein in pertussis toxin production via interaction with the two component transcriptional 
regulator BvgAS.  This protein was therefore named Bvg accessory protein (Baf).41,42  
Baf does not have significant sequence homology to any of the known bacterial 
transcriptional regulators but has 28% identity and 49% similarity to PanK-III of B. subtilis.43 
Most coaX homologs are still annotated as Bvg accessory factors or as putative 
transcriptional regulators. 
2.7.2  Gene essentiality 
Since CoA is an essential cofactor in all organisms which must be produced de novo from 
pantothenic acid, a logical conclusion is that some of the genes encoding the biosynthetic 
enzymes should be essential (or conditionally essential).6  In respect to the PanK-I encoding 
gene coaA, this has been shown to be the case in E. coli, M. tuberculosis44 and  
H. influenzae.45 These genes are listed in the database of essential genes  
(DEG; http://tubic.tju.edu.cn/deg/) which currently holds gene essentiality data for ten 
bacterial genomes and S. cerevisiae.6  
The PanK-III encoding coaX genes of B. anthracis46 and B. pertussis41 are also labeled as 
essential.  The apparent essentiality of the M. tuberculosis coaA and B. anthracis coaX genes 
are surprising since the genomes of both organisms encode two PanKs of different types.  
The essentiality data would thus only be valid if the other type present in these organisms 
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were not to function as a pantothenate kinase or if the functional pantothenate kinase 
encoded by coaX is only expressed under certain conditions, although this would be highly 
unexpected. 
2.7.3  Structure classification and active site geometry 
In general kinase enzymes are classified into families and fold groups based on structure, 
sequence and functional specificities.  This classification system consists of 25 families of 
homologous proteins of which 22 falls into one of the 10 defined fold groups.47,48   Type I 
PanKs belong to the Rossman fold group and form part of the P-loop kinase family.  Other 
kinases in this family are the nucleotide and nucleoside kinases.  Type II and III PanKs by 
contrast both belong to the ribonuclease H-like kinase group and are part of the acetate and 
sugar kinase/heat-shock protein 70/actin (ASKHA) superfamily.31   
E. coli PanK-I binds pantothenic acid at the end of a large surface groove that stretches from 
the nucleotide binding domain on the one side and continues across the surface of the 
enzyme.  ATP is bound in a groove formed by residues of the P-loop and connecting 
strands.49  M. tuberculosis PanK-I is highly similar to E. coli PanK-I.50  A few amino acid 
differences in the ATP binding domain allow the M. tuberculosis enzyme to accept both ATP 
and GTP as substrates as opposed to the E. coli enzyme that can only utilize ATP.51   
Although the type II and III PanKs have the same conserved folds and key catalytic residues, 
there are significant differences in their ATP and pantothenate binding sites. Type II PanKs 
bind pantothenate in an open pocket, while type III PanKs have a fully enclosed binding 
pocket.  On the other hand, ATP is tightly bound by PanK-II in a cavity that displays classical 
P-loop architecture combined with very specific interactions to the adenine moiety.36 
Analysis of T. maritima PanK-III bound to ATP indicates a low binding affinity for ATP.  The 
nucleotide is bound in a solvent exposed cleft between the enzyme domains with few 
specific interactions to both the adenine and ribose moieties.  This “loose” binding 
correlates with the high KM-values for ATP of PanK-III enzymes.
52  
2.7.4  Available crystal structures 
Several crystal structures of each PanK type are listed in the RCSB protein database  
(PDB: www.pdb.org).  These include crystal structures for the PanK-I enzymes from E. coli 
(PDB: 1SQ5, 1ESN, 1ESM)49,53 and M. tuberculosis (22 available structure).50,54,55  For the 
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type II PanKs crystal structures have been obtained for human PanK1α (PDB: 2I7N)32, human 
PanK3 (PDB: 2I7P)32 and S. aureus PanK-II (PDB: 2EWS).36  The PanK-IIIs with solved crystal 
structures include T. maritima PanK (PDB:  2GTD, 3BEX, 3BF1 and 3BF3),52,56 P. aeruginosa 
PanK (PDB:  2F9T and 2F9W)36 and B. anthracis PanK (PDB: 2H3G).35   
2.7.5  Cofactor requirements 
In common with most kinases, type I and II PanKs require Mg2+ for activation.  The activity of 
the first isolated PanK-IIIs from B. subtilis and H. pylori were tested in buffer containing both 
MgCl2 and KCl.
31  P. aeruginosa PanK-III was only slightly active when tested under these 
same conditions.  Further studies established that PanK-IIIs require a monovalent cation, i.e. 
K+, NH4
+ or Rb+, for activity and that P. aeruginosa PanK-III prefers NH4
+.  Although the 
activation by NH4
+ has no effect on the enzyme’s activity towards pantothenic acid, it affects 
both the KM and the kcat for ATP with an overall four- to five-fold increase in the specificity 
constant for this substrate.36 
2.7.6  Reaction mechanism   
a)  Chemical mechanism 
All PanKs are homodimers with each monomer containing a single nucleotide binding site.  
The pantothenate binding site of PanK-I is highly flexible such that the binding of each ligand 
causes a distinct conformational change in the protein.49 PanK-I follows an ordered 
sequential mechanism with ATP binding occurring first.7  ATP binding is highly cooperative 
and a Hill coefficient of 1.46 was determined for the E. coli enzyme.  Pantothenic acid 
binding, by contrast, is not cooperative.15  
The reaction mechanism for A. nidulans PanK-II was determined as an ordered bi-bi 
system.26 An ordered mechanism was also observed with human PanK3 with ATP binding 
occurring first.57 In contrast S. aureus PanK-II has two solvent-exposed openings to the 
active site and it is likely that ATP enters from one and pantothenic acid from the other 
direction.  This would result in nonsequential binding.36 
Little is known about the mechanism of the PanK-III enzymes except that sequential binding 
is expected with pantothenate binding before ATP. 40,51,54   
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b)  Kinetic mechanism 
E. coli PanK-I has been proposed to follow a concerted mechanism with a dissociative 
transition state, despite strong evidence for an associative mechanism.36,49 Crystal 
structures of PanK-ADP-pantothenic acid and PanK-AMP-PNP (AMP-PNP is a non-
hydrolysable ATP analog) complexes show that there are many positively charged residues 
(Lys101 and Arg243) as well as Mg+2 present in the active site.  These residues and ions 
support a kinetic mechanism with an associative transition state as the positive charges 
offset the multiple negative charges that develop during the reaction.  In addition Asp127 
interacts with the 1’-hydroxyl-group of pantothenic acid to increase its nucleophilicity which 
promotes an SN2-like attack on the γ-phosphate of ATP.
49 Another prediction method used 
to determine the mechanism type is to measure the distance between the entering atom 
and the phosphorus-group undergoing substitution before the reaction begins. For 
distances below 4.9 Å the mechanism is likely to be associative while distances below 4.9 Å 
indicate a dissociative mechanism.  These distances between the γ-phosphate in an AMP-
PNP complex and the 4’-hydroxyl oxygen of pantothenate was determined to be 4.5 Å in  
M. tuberculosis PanK-I and 4.1 Å in the E. coli PanK-I.55 These data thus also support an 
associative mechanism, although this conclusion would require further validation. 
The PanK-III phosphorylation reaction is predicted to proceed via a dissociative mechanism 
with an active site Asp residue acting as catalytic base.36,52,56  This hypothesis is based on the 
observation that in a PanK-AMP-PNP complex the metaphosphate leaving group is stabilized 
by electrostatic interactions between the γ-phosphate of ATP and the K+/NH4
+ and Mg2+ 
cations.  These interactions for the phosphoryl transfer part are perceived to be of higher 
importance In the P. aeruginosa PanK-III active site than substrate activation for nucleophilic 
SN2 attack and hence a dissociative mechanism was proposed.
49  
No information was found on the kinetic mechanism of the PanK-IIs. 
2.7.7  Kinetic parameters 
Broadly the largest difference in kinetic parameters between PanK types involves the  
KM-values for ATP.  For PanK-III enzymes it is in the mM range, usually 2-10 mM, with the 
lowest reported KM-value being 510 μM for B. anthracis PanK-III and the highest 9.59 mM 
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for the H. pylori enzyme.31,35,36,52,56  Type I and II PanKs typically have KM-values for ATP of 
100 – 200 μM, with the exception of S. aureus PanK-II with has a value of 34 μM.   
Table 2.4 summarizes the kinetic parameter for representative examples of the PanK types, 
including data from the enzymes from E. coli
15
 (type I), A nidulans26 (the prototypical type II 
PanK), S. aureus27 (the atypical type II PanK) and P. aeruginosa36 (type III).  The KM-values for 
pantothenate is below 100 μM for all the types and the turnover number or kcat is much 
smaller for type I PanKs than for other types. 
Table 2.4:  Comparison of the kinetic parameters from selective organisms for each PanK type. 
 
2.7.8  Regulation mechanism 
E. coli PanK-I is inhibited both in vivo and in vitro by CoA and its thioesters.15,58  Various 
kinetic and site-directed mutagenesis studies have shown that the feedback inhibition by 
CoA is competitive with respect to ATP (CoA binds in the ATP binding site) and 
uncompetitive towards pantothenic acid.  This is seen by the 24-fold increase in the 
apparent KM (KM
app) of ATP in the presence of as little as 100 μM CoA.45  Superimposition of 
the crystal structures of PanK-I in complex with either CoA or AMP-PNP shows that CoA and 
ATP bind in different orientations in the active site and that the adenine moieties are bound 
by different amino acid residues.  The one similarity is that both use Lys101 to neutralize the 
charge on their respective phosphoryl groups (pyrophosphate moiety of CoA and β- and γ-
phosphates of AMP-PNP).  The competition for the same binding site by the respective 
phophoryl groups of the different molecules explains the competitive inhibition.  The more 
potent inhibition exhibited by CoA relative to CoA thioesters is caused by a hydrophobic 
pocket of aromatic amino acids that binds the thiol group of CoA.  The size of the pocket 
disfavors the bulkier thioester groups leading to poor binding of acetyl-CoA and hence to 
weaker feedback inhibition.53 This explains why the inhibition by acetyl-CoA is only about 
20% of that of the nonesterfied CoA.45 
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Mammalian PanK-IIs are regulated by CoA and its thioesters and plant PanK-IIs by malonyl-
CoA.  In general, acetyl-CoA is a more potent inhibitor of the eukaryotic enzymes40 and CoA 
inhibition in mammals is noncompetitive towards pantothenic acid.15 A. nidulans PanK-II is 
selectively and potently inhibited by acetyl-CoA and the inhibition is competitive with 
respect to ATP.26  The stronger inhibition by acetyl-CoA is attributed to hydrogen bond 
formation between the thioester carbonyl oxygen and the main chain amide of Val.  This 
bond stabilization is not possible with the shorter pantetheine chain of CoA.  The acetyl-CoA 
binding pocket is also partially exposed to solvent which provides space for the binding of 
molecules with longer acyl chains.32  
By contrast, S. aureus PanK-II is refractory to feedback inhibition by CoA and its thioesters.59 
The structural basis for this lack of feedback inhibition was identified by comparing the S. 
aureus enzyme to the human PanK3 structure and is attributed to mutations of two residues 
in the putative acetyl-CoA binding pocket.  An Ala to Tyr mutation appears to sterically 
prevent the binding of an allosteric inhibitor, while exchange of Trp to Arg disrupts the 
hydrophobic thiol (CoA) or the acetyl group (thioester) binding pocket.32   
A possible explanation for this lack of feedback inhibition is that S. aureus lacks glutathione 
which other bacteria use to maintain redox balance for subsequent protection from 
oxidative stress.  Instead this pathogen relies on a CoA / CoA disulfide reductase system and 
the lack of feedback inhibition allows for the accumulation of millimolar levels of CoA for 
this purpose.   
PanK-III is not feedback inhibited by CoA or acetyl-CoA.31 The pantothenate binding pocket 
is enclosed on both ends which prevents the enzyme from accepting and binding the 
pantetheine moiety of CoA.36,52 
2.7.9  Alternative substrates 
a)  N-substituted pantothenamides 
The substrate specificity of E. coli PanK-I and S. aureus PanK-II has been well studied due to 
their use in biocatalysis.60 Both enzymes are further known for their substrate 
promiscuity.61,62  E. coli PanK-I accepts N-substituted pantothenamides as substrates with 
significant differences in its catalytic efficiency of natural substrate compared to the 
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analogs.6  The S. aureus enzyme has low kcat values for N-substituted pantothenamides and 
low KM-values.  The resulting specificity constants are only slightly lower than that for 
pantothenic acid.  Additionally, S. aureus PanK-II phosphorylates a wider range of 
pantothenate analogs, such as the pantothenate thioesters, which E. coli PanK-I does not 
accept as substrates.63 
N-substituted pantothenamides are not alternative substrates of type III enzymes.31 The 
enclosed pantothenate binding pocket prevents both feedback inhibition and binding of the 
extended hydrophobic alkyl chains of the pantothenamide substrate analogs.36,52  The 
narrow specificity of this enzyme has been highlighted by the fact that pantethine (the 
disulfide of pantetheine and substrate of the CoA salvage pathway) rescues E. coli ΔcoaBC 
knockout mutants, but not the same P. aeruginosa mutants.9  Treponema pallidum PanK-III 
is similarly unable to phosphorylate pantetheine.6 
b)  Phosphoryl donors 
Phosphoryl donors other than ATP are of potential interest due to the high ATP KM-values 
for type III enzymes.  As shown in Table 2.4, both type I and II PanKs have low KM-values for 
ATP, clearly establishing this nucleotide as the main co-substrate.  Some promiscuity has 
been noted for M. tuberculosis PanK-I.  Its catalytic efficiency using either ATP or GTP is 
similar to that of E. coli using ATP, while GTP is clearly disfavored by E. coli PanK-I.51   
A. nidulans PanK-II prefers ATP, with GTP resulting in a drop of 30% in catalysis, whereas CTP 
and TTP reduce catalytic efficiency even further.26 
This scenario is a little more complicated for the PanK-IIIs.  The enzymes from B. anthracis 
and P. aeruginosa utilize a wide range of NTPs, some resulting in greater catalytic efficiency 
than ATP.36,64  H. pylori utilizes CTP and GTP, but less efficiently than ATP and B. subtilis 
cannot utilize CTP, GTP or UTP.31   The H. pylori and B. subtilis enzymes are unable to use 
PEP, acetyl- and carbamoyl-phosphate, phosphoserine and phosphothreonine as phosphoryl 
donors,31 whereas P. aeruginosa PanK-III cannot utilize PEP, acetylphosphate, 
pyrophoshates, tripolyphosphates and polyphosphates (not defined).36 
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2.8  Drug development strategies utilizing PanKs 
PanK is believed to catalyze the rate limiting step in CoA biosynthesis in most organisms, 
although pathway modeling studies still need to confirm this.  Plasmodium falciparum 
constitutes an exception as 4’-phosphopantothenic acid is known to accumulate in its cells.5  
PanKs may be useful for drug development programs either by exploiting PanK as a gate-
keeper to CoA biosynthesis and inhibiting down-stream enzymes and applications, or by 
targeting the enzyme itself. 
2.8.1  PanK as gatekeeper 
The promiscuity of type I and II PanKs may potentially be exploited to phosphorylate small 
molecule analogs of pantothenic acid that inhibit the down-stream enzymes in CoA biosyn-
thesis or be converted to CoA antimetabolites.61,65  N-pentylpantothenamide is an example 
of such an analog.  It inhibits E. coli cell growth with a MIC of ≈ 2 μM.  Initially the inhibition 
was ascribed to inhibition of PanK, but it was later shown to be due to the biosynthetic 
conversion of N-pentylpantothenamide to the corresponding CoA analog, ethyldethia-CoA, 
which acts as an antimetabolite of CoA in normal cell metabolism.60,61 
More recent examples are the Michael acceptor-containing CoA analogs synthesized by van 
der Westhuyzen et al.66 shown in Figure 2.4.  The CoA antimetabolites, obtained by the 
conversion of the corresponding pantothenamides by the CoA biosynthetic enzymes, inhibit 
the CoA disulfide reductase enzyme of S. aureus requires to maintain the intracellular redox 
balance in this organism by converting CoA disulfide to CoA. The best Ki-value measured in 
this study was for the phenyl sulfone analog (R = SO2Ph) which has a Ki ≈ 40 nM.  This is 50-
fold smaller than the KM-value of the substrate, CoA disulfide, of ≈ 2.0 μM. 
 
Figure 2.4:  Michael acceptor pantothenamides transformed by the CoA biosynthetic enzymes to CoA analogs. 
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2.8.2  PanK as target 
Although some PanK specific inhibitors have been identified, many molecules designed as 
inhibitors for the PanKs prove to be substrates that inhibit down-stream enzymes (for 
example the N-substituted pantothenamides and pantothenol).67 An example of type 
specific inhibition is PanK-I from M. tuberculosis.  This enzyme is essential for growth of the 
pathogen in vitro,6 and has been targeted in extensive inhibitor discovery programs by both 
AstraZeneca and Novartis.  Though several inhibitors of PanK-I were identified, none 
inhibited cell growth.69 M. tuberculosis harbors two PanKs.  The finding from the inhibition 
studies may suggest that the putative PanK-III (CoaX) functionally replaces PanK-I despite 
PanK-III being reported as inactive.44 Were this true, the success of any drug discovery 
program would depend on the parallel inhibition of PanK-III.  There is no record of substrate 
promiscuity for PanK-IIIs and no pantothenamides function as substrates or inhibitors there-
of.  The challenge thus remains to identify molecules that would inhibit PanK-III activity. 
2.9  Known PanK-III inhibitors 
To date the only known inhibitors for PanK-IIIs are nucleoside triphoshate mimetics of 
ATP.64  In a recent study a library of compounds replacing the triphosphate sidechain of ATP 
by uncharged, methylene-triazole linked monosaccharide groups was created and screened 
using the PanK-III from B. anthracis.  The removal of the phosphates disrupts the Mg2+ che-
lating ability of the nucleoside which in turn prevents binding to the enzyme.  B. anthracis, 
the causative agent of anthrax, encodes both type II and III enzymes. PanK-III is the essential 
and active pantothenate kinase35,46 while BA2901 (the putative PanK-II) was shown to be 
inactive in all in vitro studies using pantothenic acid as substrate.  BA2901 also failed to 
rescue E. coli coaA(Ts) strain DV70 (transcription of the coaA gene in this strain is deacti-
vated at 42C) under conditions where an S. aureus construct, containing a functional PanK-
II, restored growth.35  Since the PanK-III seems to be the only functional pantothenate 
kinase, it is an essential target in this category A biodefense organism. 
Most compounds in the library screen discussed above had very little effect on the enzyme, 
an exception being the mimetic shown in Figure 2.5.  This compound competes with ATP 
binding in vitro with a Ki = 164 μM.  This represents a three-fold decrease of the B. anthracis 
PanK-III KM-value for ATP of 510 μM.   
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Figure 2.5:  ATP and the nucleoside mimetic which gave the best inhibition in a screen for competitive 
inhibitors of B. anthracis PanK-III. 
Although this study yielded good results, the reported Ki-value is still too high to be of 
pharmaceutical interest.  Also no in vivo work was reported to demonstrate any inhibition of 
cell growth.   
Another problem is that PanK-IIIs bind ATP very weakly in an open cavity with no 
interactions between the enzyme and the adenosine moiety.  Since the question has been 
raised as to whether ATP is really the co-substrate of these enzymes31,36 an ATP mimetic 
may not be the best lead to develop further.   
In this study pantothenic acid analogs are evaluated and tested as a starting point in the 
development of potential competitive inhibitors for the PanK-IIIs. 
2.10  Survey of pantothenic acid analogs 
Pantothenic acid (D-3-(2,4-dihydroxy-3,3-dimethylbutyramido)propionic acid) (1.2), the 
natural substrate of PanK, can be divided into 2 moieties based on the biosynthesis thereof 
in bacteria (shown in Figure 2.6).  It is the condensation product of pantoic acid (pantoyl 
moiety) and β-alanine (β-alanine moiety).  Synthetically it is created in much the same way 
with a melting reaction of β-alanine with D-(-)-pantolactone (α-hydroxy-β,β-dimethyl-γ-
butyrolactone) instead of pantoic acid.70 
 
Figure 2.6:  The moieties of pantothenic acid (2.2) 
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The structure determination of pantothenic acid in the 194071 was followed by a surge of 
activity to synthesize pantothenic acid analogs in an effort to produce molecules with similar 
biological activity as the original vitamin.72  These compounds were mainly tested in growth 
assays on yeast and the Lactobacillus spp., although their effects on Streptococcus 
haemolyticus and strains of Corynebacterium diptheriaeare were also investigated.5  Some 
of the analogs, such as hydroxypantothenic acid and pantothenol, were reported to 
promote growth. Many lacked activity but there were a few, like pantoyltaurine5,73 that 
antagonize the growth-promoting activity of pantothenic acid.  In general the most 
successful inhibitors were those in which the pantoyl moiety has remained unmodified.  
Examples of these compounds include pantoyltaurine, pantoyltauramide74,75 and α-methyl 
pantothenic acid.76  
Recent studies indicate that pantothenol inhibit growth in P. falciparum suggesting 
competitive inhibition of PanK as the reason.77,78  This theory was disproved when both  
M. tuberculosis and E. coli PanK-Is were shown to accept this compound as substrate and 
phosphorylated it to 4’-phosphopantothenol.  The phosphorylated product however, 
competitively inhibits the utilization of 4’-phosphopantothenate by CoaBC effectively 
blocking further CoA biosynthesis.67 
Most molecules obtained by modifying the pantoyl moiety in earlier studies were either 
inactive or slightly stimulatory when tested on organisms requiring vitamin B5 for growth.
79 
These compounds include, but are not limited to, hydroxyl pantothenic acid,80 2’-
aminopantothenic acid,81,82 4’-deoxypantothenic acid and 4’-deoxy-pantoyltaurine.79   Slight 
inhibitory activity was observed for  2’-deoxypantothenic acid,79 but this was reversed by 
the addition of pantothenic acid.5,72,74,75  The only pantoyl-modified analog that was an 
effective antagonist of pantothenic acid was ω-methyl-pantothenic acid.5,83  This compound 
was able to inhibit the growth of the lactic acid bacteria and to protect mice from 
Streptococcus infections when administered orally.84  Other ω-methylpantothenic acid 
analogs were synthesized following the success of the original compound and although they 
all inhibit lactic acid bacteria, none were consistently more active than the parent 
compound.85  We are not aware of any studies in which any of these compounds was tested 
on the pathogenic bacteria relevant to our study, i.e. B. anthracis, H. pylori, M. tuberculosis  
and P. aeruginosa. 
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To determine which of these compounds could be the most suitable for our analysis, we 
first studied the active site geometry of the P. aeruginosa PanK-III enzyme.   
2.11  PanK-III active site 
The crystal structure for P. aeruginosa PanK-III (Pa PanK-III) was solved in 2006 and is shown 
in Figure 2.7.36  Pantothenic acid binds to a fully enclosed binding pocket with numerous 
amino acid residues participating in binding and stabilizing the vitamin. 40,54   
 
Figure 2.7:  The crystal structure of P. aeruginosa PanK-III enzyme (PDB: 2F9W).
86
  Top:  Representation of 
pantothenic acid bound to the active site showing the interactions between the substrate and the active site 
amino acids.  Bottom: Surface representation of the enzyme binding pantothenic acid (stick representation) 
with a solvent exposed opening to the side of the active site.   
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The tight binding pocket explains the inability of the PanK-IIIs to accept longer 
pantothenamides as alternative substrates.  The pantothenic acid binding pocket is 
furthermore situated above the ATP-binding cleft and is only accessible by passing through 
the ATP binding site.  This tight conformation makes it difficult to identify molecules that 
can access and bind to the pantothenic acid binding pocket.   
In binding to PanK-II, the carboxyl group of the β-alanine moiety specifically interacts with 
Tyr92, Arg102, Thr180 and the backbone nitrogen of Gly99 to form H-bonds.   Asp101 acts 
as a catalytic base and forms side chain hydrogen bonds to the 2’- and 4’-hydroxyl groups of 
the pantoyl moiety,52 while His156 stabilizes the 4’-hydroxyl group via a water molecule.  
Further stabilization is obtained by van der Waals interactions between the 3’-geminal 
dimethyl groups with the side chains of Val55, Ile143 and Ile160.   These interactions are 
shown in Figure 2.7 (top). 
The crystal structure of Pa PanK-III was obtained with pantothenic acid bound in the active 
site (PDB: 2F9W).86  As can be seen from the enzyme structure (Figure 2.7, bottom), there is 
a small opening to the side of the active site which exposes the –CH2-groups of pantothenic 
acid (stick representation) to solvent.  The conformation of the bound substrate also 
appears to force the flanking amine- and carboxyl groups into a “cis” conformation.   
2.12  Conclusion 
PanKs have been the focus of many inhibitor studies by pharmaceutical companies including 
AstraZeneca and Novartis.69  Lead compounds have been identified that can inhibit type I 
and II enzymes.  These compounds are however not effective on the type III enzymes.  The 
only known inhibitors of the PanK-IIIs are ATP mimetics which has limited efficiency.  The 
question thus remains as to the type or class of analog that could inhibit PanK-IIIs.  A closer 
look at the active site of the P. aeruginosa PanK-III enzyme showed that there is a slight 
opening to the side of the active site which exposes the methylene-groups of pantothenic 
acid.  It might therefore be possilbe that this opening could provide sufficient leeway to 
design type specific inhibitors for this PanK type. 
  
Stellenbosch University  http://scholar.sun.ac.za
 28 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
2.13  References 
1. United Nations (UN), The millennium mevelopment goals report, L. Jensen, Editor. 
2010, United Nations Department of Economic and Social Affairs. p. 75. 
2. Dye, C. and Williams B.G., The population dynamics and control of tuberculosis. 
Science, 2010. 328 (5980): p. 856-61. 
3. World Health Organisation (WHO), TB/HIV facts 2011. 
4. Koul, A., Arnoult E., Lounis N., Guillemont J. and Andries K., The challenge of new 
drug discovery for Tuberculosis. Nature, 2011. 469 (7331): p. 483-90. 
5. Spry, C., Kirk K. and Saliba K.J., Coenzyme A biosynthesis: an antimicrobial drug 
target. FEMS Microbiology Reviews, 2008. 32 (1): p. 56-106. 
6. Strauss, E., Coenzyme A biosynthesis and enzymology, in Comprehensive Natural 
Products II, M. Lew and L. Hung-Wen, Editors. 2010, Elsevier: Oxford. p. 351-410. 
7. Begley, T.P., Kinsland C. and Strauss E., The biosynthesis of coenzyme A in bacteria. 
Vitamins and Hormones (New York), 2001. 61: p. 157-71. 
8. Leonardi, R., Zhang Y.-M., Rock C.O. and Jackowski S., Coenzyme A: Back in action. 
Progress in Lipid Research, 2005. 44 (2-3): p. 125-53. 
9. Balibar, C.J., Hollis-Symynkywicz M.F. and Tao J., Pantethine rescues 
phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine 
decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa.  
J. Bacteriol., 2011: p. JB.00334-11. 
10. Meier, J.L., Mercer A.C., Rivera H. and Burkart M.D., Synthesis and evaluation of 
bioorthogonal pantetheine analogues for in vivo Ppotein modification. Journal of the 
American Chemical Society, 2006. 128 (37): p. 12174-84. 
11. Worthington, A.S. and Burkart M.D., One-pot chemo-enzymatic synthesis of 
reporter-modified proteins. Organic & Biomolecular Chemistry, 2006. 4 (1): p. 44-46. 
12. Jackowski, S. and Rock C.O., Regulation of coenzyme A biosynthesis. Journal of 
Bacteriology, 1981. 148 (3): p. 926-32. 
13. Robishaw, J.D., Berkich D. and Neely J.R., Rate-limiting step and control of coenzyme 
A synthesis in cardiac muscle. Journal of Biological Chemistry, 1982. 257 (18):  
p. 10967-72. 
Stellenbosch University  http://scholar.sun.ac.za
 29 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
14. Robishaw, J.D. and Neely J.R., Pantothenate kinase and control of CoA synthesis in 
heart. American Journal of Physiology, 1984. 246 (4, Pt. 2): p. H532-H41. 
15. Song, W.-J. and Jackowski S., Kinetics and regulation of pantothenate kinase from 
Escherichia coli. Journal of Biological Chemistry, 1994. 269 (43): p. 27051-8. 
16. Finlayson, H.J. and Seeley R.C., The synthesis and absorption of pantothenic acid in 
the gastrointestinal tract of the adult sheep. Journal of the Science of Food and 
Agriculture, 1983. 34 (5): p. 427-32. 
17. Nakamura, H. and Tamura Z., Pantothenate uptake in Escherichia coli K12. Journal of 
Nutritional Science and Vitaminology, 1973. 19 (5): p. 389-400. 
18. Vallari, D.S. and Rock C.O., Pantothenate transport in Escherichia coli. Journal of 
Bacteriology, 1985. 162 (3): p. 1156-61. 
19. Jackowski, S. and Alix J.H., Cloning, sequence, and expression of the pantothenate 
permease (panF) gene of Escherichia coli. Journal of Bacteriology, 1990. 172 (7):  
p. 3842-8. 
20. Rock, C.O., Karim M.A., Zhang Y.-M. and Jackowski S., The murine pantothenate 
kinase (PANK1) gene encodes two differentially regulated pantothenate kinase 
isozymes. Gene, 2002. 291 (1-2): p. 35-43. 
21. Zheng, R. and Blanchard J.S., Steady-State and pre-steady-state kinetic analysis of 
Mycobacterium tuberculosis pantothenate synthetase†. Biochemistry, 2001. 40 (43): 
p. 12904-12. 
22. Sambandamurthy, V.K., Wang X., Chen B., Russell R.G., Derrick S., Collins F.M., 
Morris S.L. and Jacobs W.R., A pantothenate auxotroph of Mycobacterium 
tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med, 
2002. 8 (10): p. 1171-74. 
23. Mercer, A.C. and Burkart M.D., The ubiquitous carrier protein-a window to 
metabolite biosynthesis. Natural Product Reports, 2007. 24 (4): p. 750-73. 
24. Lambalot, R.H. and Walsh C.T., Cloning, overproduction, and characterization of the 
Escherichia coli Holo-acyl carrier protein synthase. Journal of Biological Chemistry, 
1995. 270 (42): p. 24658-61. 
25. Song, W.J. and Jackowski S., Cloning, sequencing, and expression of the 
pantothenate kinase (coaA) gene of Escherichia coli. Journal of Bacteriology, 1992. 
174 (20): p. 6411-17. 
Stellenbosch University  http://scholar.sun.ac.za
 30 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
26. Calder, R.B., Williams R.S.B., Ramaswamy G., Rock C.O., Campbell E., Unkles S.E., 
Kinghorn J.R. and Jackowski S., Cloning and characterization of a eukaryotic 
pantothenate kinase gene (panK) from Aspergillus nidulans. Journal of Biological 
Chemistry, 1999. 274 (4): p. 2014-20. 
27. Choudhry, A.E., Mandichak T.L., Broskey J.P., Egolf R.W., Kinsland C., Begley T.P., 
Seefeld M.A., Ku T.W., Brown J.R., Zalacain M. and Ratnam K., Inhibitors of 
pantothenate kinase: Novel antibiotics for staphylococcal infections. Antimicrobial 
Agents and Chemotherapy, 2003. 47 (6): p. 2051-55. 
28. Gerdes, S.Y., Scholle M.D., D'Souza M., Bernal A., Baev M.V., Farrell M., Kurnasov 
O.V., Daugherty M.D., Mseeh F., Polanuyer B.M., Campbell J.W., Anantha S., Shatalin 
K.Y., Chowdhury S.A.K., Fonstein M.Y. and Osterman A.L., From genetic footprinting 
to antimicrobial drug targets: examples in cofactor biosynthetic pathways. Journal of 
Bacteriology, 2002. 184 (16): p. 4555-72. 
29. Osterman, A. and Overbeek R., Missing genes in metabolic pathways: a comparative 
genomics approach. Current Opinion in Chemical Biology, 2003. 7 (2): p. 238-51. 
30. Yocum, R.R. and Patterson T.A., Microorganisms and assays for the identification of 
antibiotics acting on the pantothenate kinase encoded by the coaX gene. 2002, 
(Omnigene Bioproducts, Inc., USA). Application: WO. p. 128 pp. 
31. Brand, L.A. and Strauss E., Characterization of a new pantothenate kinase isoform 
from Helicobacter pylori. Journal of Biological Chemistry, 2005. 280 (21): p. 20185-
88. 
32. Hong, B.S., Senisterra G., Rabeh W.M., Vedadi M., Leonardi R., Zhang Y.-M., Rock 
C.O., Jackowski S. and Park H.-W., Crystal structures of human pantothenate kinases: 
insights into allosteric regulation and mutations linked to a neurodegeneration 
disorder. Journal of Biological Chemistry, 2007. 282 (38):  
p. 27984-93. 
33. Ye, Y., Osterman A., Overbeek R. and Godzik A., Automatic detection of 
subsystem/pathway variants in genome analysis. Bioinformatics, 2005. 21 Suppl 1:  
p. i478-i86. 
34. Overbeek, R., Begley T., Butler R.M., Choudhuri J.V., Chuang H.Y., Cohoon M., de 
Crecy-Lagard V., Diaz N., Disz T., Edwards R., Fonstein M., Frank E.D., Gerdes S., Glass 
E.M., Goesmann A., Hanson A., Iwata-Reuyl D., Jensen R., Jamshidi N., Krause L., 
Stellenbosch University  http://scholar.sun.ac.za
 31 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
Kubal M., Larsen N., Linke B., McHardy A.C., Meyer F., Neuweger H., Olsen G., Olson 
R., Osterman A., Portnoy V., Pusch G.D., Rodionov D.A., Ruckert C., Steiner J., 
Stevens R., Thiele I., Vassieva O., Ye Y., Zagnitko O. and Vonstein V., The subsystems 
approach to genome annotation and its use in the project to annotate 1000 
genomes. Nucleic Acids Research, 2005. 33 (17): p. 5691-702. 
35. Nicely, N.I., Parsonage D., Paige C., Newton G.L., Fahey R.C., Leonardi R., Jackowski 
S., Mallett T.C. and Claiborne A., Structure of the type III pantothenate kinase from 
Bacillus anthracis at 2.0 Å. Resolution: implications for coenzyme A-dependent redox 
biology. Biochemistry, 2007. 46 (11): p. 3234-45. 
36. Hong, B.S., Yun M.K., Zhang Y.-M., Chohnan S., Rock C.O., White S.W., Jackowski S., 
Park H.-W. and Leonardi R., Prokaryotic type II and type III pantothenate kinases:  
the same monomer fold creates dimers with distinct catalytic properties. Structure, 
2006. 14 (8): p. 1251-61. 
37. Dunn, S.D. and Snell E.E., Isolation of temperature-sensitive pantothenate kinase 
mutants of Salmonella typhimurium and mapping of the coaA gene. Journal of 
Bacteriology, 1979. 140 (3): p. 805-8. 
38. Zhou, B., Westaway H.K., Levinson B., Johnson M.A., Gitschier J. and Hayflick S.J., A 
novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz 
syndrome. Nature Genetics, 2001. 28 (4): p. 345-49. 
39. Wu, Z., Li C., Lv S. and Zhou B., Pantothenate Kinase-Associated Neurodegeneration: 
insights from a Drosophila model. Human Molecular Genetics, 2009. 
40. Zhang, Y.-M., Rock C.O. and Jackowski S., Biochemical properties of human 
pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-
associated neurodegeneration. Journal of Biological Chemistry, 2006. 281 (1): p. 107-
14. 
41. Wood, G.E. and Friedman R.L., The Bvg accessory factor (Baf) enhances pertussis 
toxin expression in Escherichia coli and is essential for Bordetella pertussis viability. 
FEMS Microbiology Letters, 2000. 193 (1): p. 25-30. 
42. DeShazer, D., Wood G.E. and Friedman R.L., Identification of a Bordetella pertussis 
regulatory factor required for transcription of the pertussis toxin operon in 
Escherichia coli. Journal of Bacteriology, 1995. 177 (13): p. 3801-7. 
Stellenbosch University  http://scholar.sun.ac.za
 32 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
43. Brand, L.A., Comparative characterisation and mutational analysis of type III 
pantothenate kinases, M.Sc thesis (Biochemistry). 2006, Stellenbosch university:  
p. 121. 
44. Awasthy, D., Ambady A., Bhat J., Sheikh G., Ravishankar S., Subbulakshmi V., 
Mukherjee K., Sambandamurthy V. and Sharma U., Essentiality and functional 
analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis. 
Microbiology, 2010. 156:  p. 2691-701. 
45. Vallari, D.S., Jackowski S. and Rock C.O., Regulation of pantothenate kinase by 
coenzyme A and its thioesters. Journal of Biological Chemistry, 1987. 262 (6):  
p. 2468-71. 
46. Paige, C., Reid S.D., Hanna P.C. and Claiborne A., The type III pantothenate kinase 
encoded by coaX is essential for growth of Bacillus anthracis. J. Bacteriol., 2008. 190 
(18):  p. 6271-75. 
47. Cheek, S., Zhang H. and Grishin N.V., Sequence and structure classification of 
kKinases. Journal of Molecular Biology, 2002. 320 (4):  p. 855-81. 
48. Cheek, S., Ginalski K., Zhang H. and Grishin N.V., A comprehensive update of the 
sequence and structure classification of kinases. BMC Structural Biology, 2005. 5:  
p. No pp given. 
49. Ivey, R.A., Zhang Y.-M., Virga K.G., Hevener K., Lee R.E., Rock C.O., Jackowski S. and 
Park H.-W., The structure of the pantothenate kinase-ADP-pantothenate ternary 
complex reveals the relationship between the binding sites for substrate, allosteric 
regulator, and antimetabolites. Journal of Biological Chemistry, 2004. 279 (34):  
p. 35622-29. 
50. Das, S., Kumar P., Bhor V., Surolia A. and Vijayan M., Invariance and variability in 
bacterial PanK:  a study based on the crystal structure of Mycobacterium tuberculosis 
PanK. Acta Crystallographica, Section D: Biological Crystallography, 2006. D62 (6):  
p. 628-38. 
51. Chetnani, B., Kumar P., Surolia A. and Vijayan M., M. tuberculosis pantothenate 
kinase:  dual substrate specificity and unusual changes in ligand locations. Journal of 
Molecular Biology, 2010. 400 (2): p. 171-85. 
Stellenbosch University  http://scholar.sun.ac.za
 33 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
52. Yang, K., Strauss E., Huerta C. and Zhang H., Structural basis for substrate binding 
and the catalytic mechanism of type III pantothenate kinase. Biochemistry, 2008. 47 
(5): p. 1369-80. 
53. Yun, M., Park C.-G., Kim J.-Y., Rock C.O., Jackowski S. and Park H.-W., Structural basis 
for the feedback regulation of Escherichia coli pantothenate kinase by coenzyme A. 
Journal of Biological Chemistry, 2000. 275 (36): p. 28093-99. 
54. Das, S., Kumar P., Bhor V., Surolia A. and Vijayan M., Expression, purification, 
crystallization and preliminary X-ray crystallographic analysis of pantothenate kinase 
from Mycobacterium tuberculosis. Acta Crystallographica Section F, 2005. 61 (1):  
p. 65-67. 
55. Chetnani, B., Das S., Kumar P., Surolia A. and Vijayan M., Mycobacterium tuberculosis 
pantothenate kinase: possible changes in location of ligands during enzyme action. 
Acta Crystallographica Section D, 2009. 65 (4):  p. 312-25. 
56. Yang, K., Eyobo Y., Brand L.A., Martynowski D., Tomchick D., Strauss E. and Zhang H., 
Crystal structure of a type III pantothenate kinase: insight into the mechanism of an 
essential coenzyme A biosynthetic enzyme universally distributed in bacteria. Journal 
of Bacteriology, 2006. 188 (15):  p. 5532-40. 
57. Leonardi, R., Zhang Y.-M., Yun M.-K., Zhou R., Zeng F.-Y., Lin W., Cui J., Chen T., Rock 
C.O., White S.W. and Jackowski S., Modulation of pantothenate kinase 3 activity by 
small molecules that interact with the substrate/allosteric regulatory domain. 
Chemistry & biology, 2010. 17 (8): p. 892-902. 
58. Rock, C.O., Park H.-W. and Jackowski S., Role of feedback regulation of pantothenate 
kinase (CoaA) in control of coenzyme A levels in Escherichia coli. Journal of 
Bacteriology, 2003. 185 (11): p. 3410-15. 
59. Leonardi, R., Chohnan S., Zhang Y.-M., Virga K.G., Lee R.E., Rock C.O. and Jackowski 
S., A pantothenate kinase from Staphylococcus aureus refractory to feedback 
regulation by coenzyme A. Journal of Biological Chemistry, 2005. 280 (5): p. 3314-22. 
60. Strauss, E., de Villiers M. and Rootman I., Biocatalytic production of coenzyme A 
analogues. ChemCatChem, 2010. 2 (8): p. 929-37. 
61. Strauss, E. and Begley T.P., The antibiotic activity of N-pentylpantothenamide results 
from its conversion to ethyldethia-coenzyme A, a coenzyme A antimetabolite. 
Journal of Biological Chemistry, 2002. 277 (50): p. 48205-09. 
Stellenbosch University  http://scholar.sun.ac.za
 34 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
62. Virga, K.G., Zhang Y.-M., Leonardi R., Ivey R.A., Hevener K., Park H.-W., Jackowski S., 
Rock C.O. and Lee R.E., Structure-activity relationships and enzyme inhibition of 
pantothenamide-type pantothenate kinase inhibitors. Bioorganic & Medicinal 
Chemistry, 2006. 14 (4):  p. 1007-20. 
63. van Wyk, M. and Strauss E., One-pot preparation of coenzyme A analogues via an 
improved chemo-enzymatic synthesis of pre-CoA thioester synthons. Chemical 
Communications, 2007(4):  p. 398-400. 
64. Rowan, A.S., Nicely N.I., Cochrane N., Wlassoff W.A., Claiborne A. and Hamilton C.J., 
Nucleoside triphosphate mimicry: a sugar triazolyl nucleoside as an ATP-competitive 
inhibitor of B. anthracis pantothenate kinase. Organic & Biomolecular Chemistry, 
2009. 7 (19):  p. 4029-36. 
65. van Wyk, M. and Strauss E., Development of a method for the parallel synthesis and 
purification of N-substituted pantothenamides, known inhibitors of coenzyme A bio-
synthesis and utilization. Organic & Biomolecular Chemistry, 2008. 6 (23): p. 4348-55. 
66. van der Westhuyzen, R. and Strauss E., Michael acceptor-containing coenzyme A 
analogues as inhibitors of the atypical coenzyme A disulfide reductase from 
Staphylococcus aureus. J. Am. Chem. Soc., 2010. 132:  p. 12853-55. 
67. Kumar, P., Chhibber M. and Surolia A., How pantothenol intervenes in coenzyme-A 
biosynthesis of Mycobacterium tuberculosis. Biochemical and Biophysical Research 
Communications, 2007. 361 (4): p. 903-09. 
68. Sassetti, C.M., Boyd D.H. and Rubin E.J., Genes required for mycobacterial growth 
defined by high density mutagenesis. Molecular Microbiology, 2003. 48 (1): p. 77-84. 
69. Keller, T.H. Lead Finding For TB Pantothenate Kinase: Lessons Learned. in ICS-UNIDO 
workshop: “Advanced Design and Development of potential Drugs against 
Tuberculosis. 2009. 
70. Shimizu, S., Vitamins and related compounds:  Microbial production, in 
Biotechnology Set. 2008, Wiley-VCH Verlag GmbH. p. 318-40. 
71. Williams, R.J., Weinstock H.H., Jr., Rohrmann E., Truesdail J.H., Mitchell H.K. and 
Meyer C.E., Pantothenic acid. III. Analysis and determination of constituent groups. 
Journal of the American Chemical Society, 1939. 61: p. 454-7. 
72. Barnett, J.W. and Robinson F.A., Analogues of pantothenic acid: Attempted 
preparation of growth promoters. Biochem. J., 1942. 36 (3-4): p. 357-0. 
Stellenbosch University  http://scholar.sun.ac.za
 35 
 
Chapter 2:  Introduction to CoA biosynthesis and PanKs 
 
73. Snell, E.E., Growth inhibition by N-(α,γ-dihydroxy-β,β-dimethylbutyryl)taurine and its 
reversal by pantothenic acid. Journal of Biological Chemistry, 1941. 141: p. 121-8. 
74. Barnett, J.W. and Robinson F.A., Analogues of pantothenic acid: Preparation of 
growth inhibitors. Biochem. J., 1942. 36 (3-4): p. 364-0. 
75. McIlwain, H., Bacterial inhibition by metabolite analogues: Analogues of pantothenic 
acid. Biochem. J., 1942. 36 (5-6): p. 417-0. 
76. Pollack, M.A., Growth effects of α-methyl homologs of pantothenic acid and  
β-alanine. Journal of the American Chemical Society, 1943. 65 (7): p. 1335-39. 
77. Spry, C., Chai C.L.L., Kirk K. and Saliba K.J., A class of pantothenic acid analogs inhibits 
Plasmodium falciparum pantothenate kinase and represses the proliferation of 
malaria parasites Antimicrobial Agents and Chemotherapy, 2005. 49 (11): p. 4649-57. 
78. Saliba, K.J., Ferru I. and Kirk K., Provitamin B5 (Pantothenol) inhibits growth of the 
intraerythrocytic malaria parasite. Antimicrob. Agents Chemother., 2005. 49 (2):  
p. 632-37. 
79. Cheldelin, V.H. and Schink C.A., Pantothenic acid studies. I. Growth effect of pantoic 
acid analogs. J. Am. Chem. Soc., 1947. 69: p. 2625-8. 
80. Mitchell, H.K., Snell E.E. and Williams R.J., Pantothenic acid. IX. The biological activity 
of hydroxypantothenic acid. Journal of the American Chemical Society, 1940. 62:  
p. 1791-2. 
81. Lipton, S.H. and Strong F.M., Synthesis of compounds related to pantothenic acid. 
Journal of the American Chemical Society, 1949. 71 (7): p. 2364-67. 
82. Holly, F.W., Barnes R.A., Koniuszy F.R. and Folkers K., An amino analog of 
pantothenic acid. Journal of the American Chemical Society, 1948. 70 (9): p. 3088-90. 
83. Drell, W. and Dunn M.S., Growth inhibition of lactic acid bacteria by N-(α,γ-
dihydroxy-β,β-dimethylvaleryl)-β-alanine and its reversal by pantothenic acid. 
Journal of the American Chemical Society, 1946. 68 (9): p. 1868-68. 
84. Drell, W. and Dunn M.S., Inhibition of lactic acid bacteria by analogs of pantothenic 
acid 1. Journal of the American Chemical Society, 1948. 70 (6): p. 2057-63. 
85. Drell, W. and Dunn M.S., Inhibition of lactic acid bacteria by ω-substituted analogs of 
pantothenic acid. J. Am. Chem. Soc., 1954. 76: p. 2804-8. 
86. Image from the RCSB protein database (PDB) (www.pdb.org);  PDB ID 2F9W.  Last 
accessed:  1 September 2011 
Stellenbosch University  http://scholar.sun.ac.za
  36 
 
Chapter 3: Synthesis and characterization of PanK-III 
inhibitors 
 
Chapter 3:   
Synthesis and characterization of PanK-III inhibitors  
3.1  Introduction 
PanK-III enzymes are widely distributed in Bacteria (see section 2.6) and are surprisingly 
common in bacterial pathogens, such as M. tuberculosis, B. anthracis, the category A 
biodefense organism Fransicella tularensis and Neissera meningitis.  This fact, and because 
Type III PanKs are distinct from human PanK-IIs, make these enzymes excellent targets for 
drug development.  However, to date the only known inhibitors for PanK-IIIs are ATP 
mimetics that were found to be mediocre competitive inhibitors of the B. anthracis enzyme 
(see section 2.9).1  In this part of the study our goal was to identify and develop pantothenic 
acid analogs as inhibitors of the PanK-III enzyme from P. aeruginosa. 
3.2  Strategy 
The crystal structure of P. aeruginosa PanK-III (Pa PanK-III) shows that pantothenic acid 
binds to a fully enclosed binding pocket and that numerous charged amino acid residues are 
involved in the binding and stabilization of the vitamin (section 2.11).2,3  The active site 
pocket further has a small opening to the surrounding solvent which could potentially be 
exploited for the rational design of inhibitors that would occupy this opening.  For this study 
pantothenic acid analogs were designed, synthesized and tested as alternate substrates 
and/or inhibitors of Pa PanK-III to probe the most important binding interactions in its active 
site. Our goal was to interrogate these interactions in a manner that would allow the 
individual contributions of three distinct factors to be evaluated.  These were:  
 Factors influenced by steric considerations 
 Factors influenced by electrostatic interactions 
 Factors affecting catalysis 
 
3.2.1  Probing factors influenced by steric considerations 
Due to their enclosed pantothenate binding pockets, PanK-IIIs enzymes do not accept N-
substituted pantothenamides as substrates. However, little is known about their ability to 
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accept and phosphorylate other pantothenic acid analogs.  We were specifically interested 
in exploring the tolerance of the PanK-III active site for modifications that would increase 
the steric bulk of the β-alanine moiety of the pantothenic acid backbone, and to determine 
whether the opening on the side of the active site would accommodate such modifications. 
3.2.2  Probing factors influenced by electrostatic interactions 
The strong electrostatic interactions between the active site residues and the carboxyl 
group of the bound pantothenic acid constitute a unique feature of PanK-IIIs in comparison 
to other PanK types (refer to section 2.11).  The addition or removal of electronegative 
substituents close to the carboxyl group could change the nature of these electrostatic 
interactions to such a degree as to increase affinity of substrate binding to the enzyme, or to 
destabilize the substrate-enzyme complex. 
3.2.3  Probing factors involved in catalysis 
A major drawback of using pantothenic acid analogs as inhibitors is that they can potentially 
also act as substrates of the PanK-III enzymes.  In such a case they would be phosphorylated 
and effectively be removed as potential occupants of the active site.  However, this problem 
can be overcome by preventing the phosphorylation of the 4’-hydroxyl group of pantothenic 
acid.  This can be achieved by the derivatizing, reducing or substituting the 4’-hydroxyl 
group, or by introducing groups around the 4’-carbon that sterically hinder phosphate-group 
transfer.  Alternatively, the active site residues involved in catalysis could potentially be 
restricted through novel interactions with the inhibitor. 
3.4  Pantothenic acid analogs used in this study 
The molecules shown in Figure 3.1 are proposed as suitable pantothenate analogs to 
individually probe the three factors discussed above.  To probe the influence of steric effects 
the methyl derivatives 3.1 – 3.3 were synthesized, while α-pantothenic acid (3.4) and homo-
pantothenic acid (3.5) were available in our laboratory.4  Commercially available panto-
thenol (3.6) and pantoyltaurine (3.7) were used to evaluate the electrostatic interactions 
between the substrate and enzyme, while the fluorinated methyl derivative (3.8) was 
synthesized to simultaneously test the effect of increased steric bulk and improved 
electrostatic interactions.  To study the factors involved in catalysis, three molecules with 
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modifications in or close to the 4’-hydroxyl group were identified as analogs that could block 
or otherwise prevent catalysis – 4’-methoxypantothenic acid (3.9), ω-methylpantothenic 
acid (3.10) and 4’-deoxypantothenic acid (3.11).  Molecules 3.9 and 3.11 were successfully 
synthesized, while the synthesis of 3.10 was abandoned due to various difficulties 
experienced (discussed in detail in section 3.5.2b). 
 
 
Figure 3.1:  The molecules tested as alternative substrates and potential inhibitors of P. aeruginosa PanK-III. 
 
3.5  Results 
3.5.1  Synthesis of pantothenate analogs modified in the β-alanine moiety 
All four molecules containing modifications in the β-alanine moiety were synthesized 
according to the general procedure shown in Scheme 3.1. 
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Scheme 3.1:  General synthetic scheme for the preparation of methylated derivatives of pantothenic acid. 
 
a)  (R,S)-β-methylpantothenic acid (3.1) 
In 2006 Meier et al. synthesized pantetheine analogs from D-pantolactone and various 
amines.5  We based our first synthetic attempt of 3.1 on this procedure, in which a mixture 
of 3.0 eq. of pantolactone, 3.0 eq. NEt3 and 1.0 eq. of amine was refluxed in methanol for  
7 h.  Although coupling was obtained, we experienced several problems with the 
purification of the product.  An alternative method, which previously was used in our 
laboratory to synthesize homo- and α-pantothenic acid,4 was therefore employed instead.  
Deprotonated 3-aminobutyric acid (1.1 eq.) was mixed with 1.0 eq. of pantolactone and 
melted together at 130°C under inert conditions overnight.  This procedure allowed for the 
successful isolation of the desired product after removal of unreacted amine by cation 
exchange chromatography and unreacted pantolactone by flash chromatography. The final 
product was obtained in 31% yield. 
b)  (R,S)-α-methylpantothenic acid (3.2) 
Pollack published a synthetic procedure for the preparation of 3.2 in 1943.6  In the original 
synthesis, the deprotonated 3-aminoisobutyric acid was refluxed with pantolactone in a 
solvent mixture of 2:1 isopropanol: ethanol. This solvent mixture was used due to the low 
solubility of the compounds in organic solvents.  After refluxing for 3 h, the mixture was 
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filtered hot to remove the undissolved starting materials, after which the product was 
crystalized from an isopropanol/petroleum ether mixture. Pollack reported that the 
resulting α-methylpantothenate sodium salt was extremely difficult to handle and analyze 
due to its hygroscopic nature, but that, based on elemental analysis, they believed they 
essentially had the correct compound.  In contrast we were able to prepare α-
methylpantothenic acid using the same procedure as described for β-methylpantothenic 
acid above, except that pantolactone was used in 1.1 eq. excess.  In our hands α-
methylpantothenic acid did not give any of the handling problems reported by Pollack and 
was obtained in 40% yield.   
c)  α,α-dimethylpantothenic acid (3.3) 
This compound was synthesized in 28% yield from pantolactone and 3-amino-2,2-dimethyl-
propanoic acid using the same melting reaction and column purifications as described for  
β-methylpantothenic acid above.   
d)  (R,S)-β-trifluoromethylpantothenic acid (3.8)  
β-trifluoromethylpantothenic acid was synthesized from pantolactone and (R,S)-3-amino-
4,4,4-trifluorobutyric acid using the same procedure as described above. The product was 
obtained in a very low yield (≈ 6.5%) presumably due to the lower nucleophilicity of the 
amine caused by the electron-withdrawing nature of the adjacent -CF3 group.  
 
3.5.2  Synthesis of pantothenate analogs modified in the pantoyl moiety 
Different strategies were used to synthesize each of the molecules containing modifications 
in the pantoyl moiety.  The synthesis of each molecule is discussed separately in the 
following sections. 
a)  4’-methoxypantothenic acid (3.9) 
The synthesis of 3.9 was undertaken as shown in Scheme 3.2. Pantothenic acid (2.2) was 
protected as the benzyl ester by the reaction of calcium pantothenate with benzylbromide 
according to an established procedure7 to give 3.12 and was obtained in 57% yield. 
The first attempts at the synthesis of 3.13 was based on a Haworth type methylation using 
dimethyl sulfate (Me2SO4) and a strong base to deprotonate the 4’-hydroxyl group.  
Stellenbosch University  http://scholar.sun.ac.za
  41 
 
Chapter 3: Synthesis and characterization of PanK-III 
inhibitors 
 
Unfortunately the bases that were used in these attempts (NaH and NaOH) caused 
decomposition of 3.12 (based on TLC analysis).  However, deprotonation with anhydrous 
K2CO3 and methyl iodide (MeI) as methylation agent resulted in the desired product 3.13.  
Deprotection was done according to a standard published procedure using Pd (black) in 
4.4% formic acid/methanol.8 The product 3.9 was subsequently purified by flash 
chromatography and obtained in a final overall yield of 15%.  To determine whether the 
correct hydroxyl group had been methylated, 1H NMR and COSY analyses were performed.  
Both spectra are shown in Figure 3.2 together with the peak assignments. 
 
Scheme 3.2:  Synthesis of 4’-methoxypantothenic acid (3.9).   
 
The three protons of the –OCH3 group (labeled nr. 2 in the figure) are represented by the 
peaks found at 3.34 ppm, while the two protons of the 4’–CH2-O- (nr. 3) are represented by 
a doublet of doublets at 3.29 ppm.  In the proton spectrum, one of the peaks of this doublet 
of doublet overlaps with the –OCH3 singlet.  In the COSY spectrum it is clear that these peaks 
do not only overlap, but that they also couple with each other (shown in the block in the 
figure), indicating that the methyl group was introduced on the 4’-OH. On the other hand, 
the proton on the 2’-carbon (nr. 5) is shifted further downfield to 3.96 ppm. The COSY 
spectrum shows no interactions between this proton and any other proton, confirming that 
the 2’-hydroxyl group had not been methylated. 
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Figure 3.2:  
1
H NMR and COSY spectra of 4’-methoxypantothenic acid 
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b)  ω-methylpantothenic acid (3.10) 
ω-Methylpantothenic acid (3.10) was the most promising inhibitory lead from the 1940s 
studies, in which the effects of pantothenic acid analogs on the lactic acid bacteria had been 
investigated.  The chemical synthesis of this analog was first published in 1946.9  In Scheme 
3.3 a retrosynthetic analysis of the molecule is given.  Three disconnections are possible in 
the pantoyl moiety, each of which leads to a different synthetic route:  between 1’- and 2’-
carbons (the original synthetic route), 2’- and 3’-carbons (aldol route) and the 3’- and 4’-
carbons (multi-component reaction (MCR) route). 
 
 
Scheme 3.3:  Retrosynthetic analysis of ω-methylpantothenic acid (3.10) suggesting possible routes for its 
synthesis.  
  
Originally, ω-methylpantothenic acid was synthesized by the condensation of β-alanine and 
α-hydroxy-β,β-dimethyl-γ-valerolactone.  The lactone was obtained from hydrolysis of the 
cyanohydrin synthesized from α,α-dimethyl-β-hydroxybutyraldehyde and CN-.9,10  Due to the 
use of CN- and the extensive extraction and purifications steps of the original procedure, 
other protocols were investigated to identify a simpler and safer synthetic route. 
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Based on the other disconnects two additional synthetic strategies were proposed.  The first 
strategy relies on an aldol condensation. A synthetic procedure, based on the methods of 
Evans et al.11 and Alam et al.12, was devised in which methylbutane acts as donor by 
trapping its enol as the TMS ether.  The glyoxalamide acts as acceptor to form the new C–C 
bond between the 2’- and 3’-carbons of the pantoyl moiety.   
The second strategy was based on a study by Pellissier et al. 13 and involves the formation of 
two new C–C bonds.  The bond between the 3’- and 4’-carbons is formed first by an aldol 
condensation between acetaldehyde as acceptor and methylpropanal as donor, while the 
bond between the 1’- and 2’-carbons is formed by nucleophilic attack of an isocyanide on 
the aldehyde product that results from this aldol reaction.   The overall reaction is a multi-
component reaction (MCR) that bears similarity to the Passerini and Ugi reactions. 
Strategy 1:  Aldol 
A synthetic procedure based on the aldol condensation is given in Scheme 3.4.   
Scheme 3.4:  Proposed synthesis of 3.10 based on an aldol condensation (Strategy 1). 
The acrylamide 3.16 was prepared by reaction of 3.14 in its free amine form (prepared by 
extraction from the commercially available β-alanine benzyl ester tosylate salt) with 
acryloylchloride (3.15) according to the procedure of Cho et al.14 with N,N-diisopropyl-
ethylamine (iPr2NEt) as base.  The product 3.16 was obtained in 57% yield.   
There are two possible methodologies to oxidatively cleave 3.16 to form 3.17.  The first 
method, the Lemieux-Johnson oxidation, is a two-step reaction in which the double bond is 
first dihydroxylated with OsO4 before cleavage of the vicinal diol with NaIO4.
15,16  
Alternatively, ozonolysis followed by reductive cleavage can be used, although a drawback 
of this procedure is that the resulting peroxide intermediates can cause further unwanted 
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oxidations.17  Many reducing agents have been identified and are used for the reductive 
cleavage reaction; these include acetic anhydride/NEt3,
18 Me2S,
19 Zn/CH3COOH
20, P(OMe)3,
21 
Pt/H2, BH3 and LiAlH4.
17  We chose to focus our efforts on employing this procedure, 
because of the toxicity of OsO4 in the first method, and difficulty in obtaining the reagent.   
A recent study by Schiaffo et al. used ozonolysis to oxidatively cleave a variety of alkenes at 
0°C (in comparison to the normal −80°C) in a 5% H2O/acetone solvent system.
17 The 
attractiveness of this method lies in milder reaction conditions and a reducing agent not 
being required.  We oxidatively cleaved 3.16 using this method with Sudan red III (solvent 
red 23) as indicator.22  Based on TLC analysis, all the starting reagent in the reaction was 
consumed, which was confirmed by the disappearance of the alkene peaks in 1H NMR 
analysis.  Unfortunately, product formation could not be conclusively confirmed because the 
aldehyde peak of the observed product did not yield the expected integration values 
relative to the other proton peaks.  MS analysis of the product was also inconclusive.   
In the procedure of Evans et al. a glyoxylate ester and TMS enol ether is coupled using 
Sc(OTf)2 as catalyst under extreme dry and inert conditions (in a glove box) at −78°C.
11  In 
the Alam et al. protocol Mukaiyama couplings are executed with the same type of reactants 
by stirring the compounds together in sodium phosphate buffer, pH 7.0, at room 
temperature in the dark for 24 h.12  For the coupling of 3.17 to 3.18 the latter method was 
used with the minor adjustment of dissolving 3.17 in acetonitrile as it is insoluble in H2O.  
Unfortunately the coupling reaction was unsuccessful.  This could be due to bad quality 
starting material as the formation of 3.17 could not be conclusively confirmed with either  
1H NMR and MS.  Alternatively the procedure of Alam et al. could also be ineffective for this 
specific reaction and a better result might have been obtained with the Sc(OTf)2 catalyst.  
Due to the problems experienced this procedure was abandoned. 
Strategy 2:  MCR 
Strategy 2 is based on a multi-component reaction (MCR) that makes use of an isocyanide as 
one of the reactants.  Isocyanides (isonitriles, carbylamines) are organic molecules in which 
bonding occurs through reaction with the N- instead of the C-atom (in comparison to 
cyanide CN-, where carbon exclusively acts as the nucleophile).23 Isocyanides are known for 
their applications in the Passerini and Ugi MCRs, shown schematically in Scheme 3.5.   
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Scheme 3.5:  Generalized scheme of the Passerini and the Ugi reactions 
The Passerini reaction is a three component reaction utilizing an oxo-compound, an 
isocyanide and a nucleophile and the four component Ugi reaction requires a Schiff base/ 
enamine, a nucleophile and an isocyanide.  Of the two, the Ugi reaction is more versatile in 
terms of the library sizes that can be assembled and in the range of scaffolds that can be 
used.  The reaction of Strategy 2 is a three component MCR, but unlike the Ugi and Passerini 
reactions only C–C bonds are formed.  The proposed mechanism is shown in Scheme 3.6. 
 
Scheme 3.6:  Proposed mechanism of the MCR 
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The synthetic route to 3.10 based on this MCR strategy is given in Scheme 3.7.  Isocyanide 
3.21 was synthesized from 3.14 according to a modified procedure of Elders et al.24   
β-Alanine benzyl ester (3.14) was formylated by addition of acetic formic anhydride in a 
single portion, followed by stirring at 70°C for 2 h.  For purification Elders et al. only 
removed the volatiles in vacuo, but in our hands we were not satisfied that the CH3COOH 
produced as side product was completely removed.  An aqueous work-up step was 
therefore introduced in which the reaction mixture was dissolved in DCM and the organic 
layer subsequently washed with saturated NaHCO3 and H2O before the DCM was removed 
in vacuo to obtain the product.  The changes in the purification procedure were sufficient to 
remove the CH3COOH and increased the recovery of pure 3.21 from 18.9% to 63.9% (in 
comparison to purification with flash chromatography). 
 
 
Scheme 3.7:  Proposed synthesis of 3.10 based on an MCR (Strategy 2). The dehydration of 3.20 to 3.21 was 
done by the slow addition of the dehydration agent, POCl3, to the solution at -78°C. The reactions stirred for an 
additional 3 h at 0°C.  During this time the color changed from yellow to dark brown. 
 
The procedure of Pellissier et al. was used as a starting point in the synthesis of 3.24.13  In 
their method, the reaction was performed at −60°C for 3h under inert conditions with a 
reagent ratio of 1.0 eq. acetal: 1.1 eq. TMS enol ether: 1.2 eq. isocyanide.  The catalyst, 
TiCl4, was diluted to 1.0 M using dry DCM and was added last to the reaction mixture via a 
dropping funnel.  All our attempts to reproduce this MCR, including several variations of this 
original procedure, are summarized in Table 3.1.  
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Table 3:1:  Summary of the variations made to the MCR. 
 
 
Entry 1 reflects the literature procedure, except that the amount of catalyst was increased.  
In Entries 2 to 4 the ratio of reactants was changed to render the isocyanide the limiting 
reagent; the same addition order was used as before.  These changes were made mainly 
due to difficulties in the preparation of the isocyanide.  In Entry 3, the temperature at which 
the reaction occurred was lowered further to −78°C from −60°C.  The work-up was changed 
for Entry 4 by replacing diethyl ether with DCM.  However, none of these modifications led 
to the formation of the desired product. 
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Based on the proposed mechanism shown in Scheme 3.5 the catalyst is required early in the 
mechanism, while the isocyanide is only involved later.  In Variation 2 the sequence of 
addition was therefore changed - TiCl4 was first added to a mixture of the acetal and TMS 
enol ether before addition of the isocyanide.  The second change we made was to replace 
the acetal with benzaldehyde, since aldehydes are more reactive than acetals and 
benzyaldehyde is easier to detect by TLC, which makes the reaction easier to follow.  
Unfortunately again none of these reactions (Entries 5-7 in Table 3.1) were successful, even 
with increased reaction times and elevated temperatures.  
The last variation attempted is shown in Entry 8.  This reaction was done with a 
commercially available isocyanide.  Several other changes were made to the procedure 
which included increasing the temperature at which the additions were made to 0°C, 
increasing the reaction temperature to 25°C, shortening the reaction time to 2 h and adding 
the catalyst in undiluted form.  A product that was formed under these conditions was 
isolated, but 1H NMR analysis showed that the benzaldehyde coupled directly to the 
isocyanide without involvement of the TMS enol ether.  Due to these continued failures to 
prepare ω-methylpantothenic acid 3.10, its synthesis was abandoned.  
 
c)  4’-deoxypantothenic acid (3.11): 
Our finding that an aldehyde couples directly to the isocyanide (result of Entry 8, Table 3.1 
above) proved advantageous in our attempts at the synthesis of 4’-deoxypantothenic acid 
(3.11).  A proposed synthesis that makes use of this reaction is shown in Scheme 3.8. 
 
Scheme 3.8:  Synthesis of 4’-dehydroxypantothenic acid (3.11).  
 
Isocyanide 3.21 was coupled to pivaldehyde (3.26) according to the adapted methodology 
summarized in Variation 3 in Table 3.1.  The catalyst was added neat to a solution of 3.21 
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and 3.26 in DCM at 0°C, after which the reaction was stirred at 25°C for 2 h.  The work-up 
was performed with DCM as organic solvent.  A 17% overall yield was obtained for the 
benzyl protected product 3.27 (based on the formylation of 3.14 as the first step).   
4’-Deoxypantothenic acid (3.11) was formed in 16% overall yield after deprotection with Pd 
(black) in 4.4% formic acid/methanol.8   
The drawback of the methodology is that a racemic mixture was obtained due to lack of 
steric control on the formation of the new chiral center.  PanK enzymes require the 2’-OH 
group of its substrates to be in the R-configuration, and the consequence of a racemic 
mixture is only one of the enantiomers would be an alternative substrate/inhibitor.  In 
general steric control on the formation of new stereocenters in MCRs are challenging25 and 
only two options have been identified for stereoselective synthesis under certain conditions 
– the use of chiral starting compounds23 and the use of chiral Lewis acid catalysts.26  Since 
the starting materials for our MCR are achiral, the use of a chiral catalyst is the only viable 
option.  Based on the activity results obtained for this compound with Pa PanK-III (discussed 
in next section), the asymmetric synthesis was not investigated further.   
3.5.3 Activity screening of pantothenate analogs as substrates/inhibitors 
All the pantothenate analogs (Figure 3.1) were first screened to determine whether they are 
substrates or inhibitors (or both) of Pa PanK-III.  For activity determination a coupled 
enzymatic assay was used which links the formation of ADP to the consumption of NADH.27 
This assay is extensively used to characterize PanK activity and coupling enzymes were 
added in excess as to not be rate-limiting.  To test whether the compounds were substrates, 
reaction mixtures containing 500 μM of a particular analog were assayed by monitoring the 
decrease in absorbance of NADH followed at 340 nm.  The absorbance profiles were 
compared to that of a blank (in which substrate was replaced with water) and a positive 
control (in which pantothenic acid was added as substrate). In cases where the absorbance 
profile showed a noticeable decrease in absorbance at 340 nm over time, the compound 
was considered to act as an alternate substrate and its activity was characterized further.  
To determine if the analogs function as inhibitors of the normal PanK-catalyzed reaction, 
reaction mixtures containing equal amounts of pantothenic acid and a particular analog 
were assayed.  Any reaction mixture which showed reduced activity compared to a positive 
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control reaction (containing only pantothenic acid), was deemed to contain a compound 
that acted as an inhibitor that could be characterized further.  The results of this initial 
screen are given in Table 3.2.   
Table 3.2:  Results from initial screen for substrates and inhibitors 
 
The results show that the substrate specificity of PanK-III is even more stringent than 
originally anticipated, since only one analog, β-methylpantothenic acid, acted as an 
alternate substrate. Moreover, only three analogs were found to act as inhibitors:  α- and β-
methylpantothenic acid, and β-trifluoromethylpantothenic acid.  
3.5.4  Characterization of alternate substrate 
The kinetic characterization of β-methylpantothenic acid was done using the same assay as 
described above in the presence of a final concentration of 5.0 mM ATP.  The initial rates 
were measured and plotted against the concentrations of the respective substrates used 
(Figure 3.3).  The kinetic parameters were obtained by fitting the data to the Michaelis-
Menten equation (1) and are given in Table 3.3 along with previously reported values for 
pantothenic acid for comparison purposes.3 
  
        
       
                                        
Stellenbosch University  http://scholar.sun.ac.za
  52 
 
Chapter 3: Synthesis and characterization of PanK-III 
inhibitors 
 
 
Figure 3.3: The steady state kinetics of P. aeruginosa PanK-III with pantothenic acid (•) and β-methylpanto-
thenic acid (Δ) as substrates.  Each point represents the average of three readings and the bars the standard 
error.  Solid lines represent the best-fit of the data to the Michaelis-Menten equation.  
 
Table 3.3:  Kinetic parameters of the PanK-III substrates. 
 
3.5.5  Inhibitor characterization 
For the inhibitor characterization, the initial rates were measured over a range of 
pantothenic acid concentrations in the presence of increasing concentrations of inhibitor.  
The initial rates were measured and plotted against the concentrations of the substrates 
used and fitted to the Michaelis-Menten equation to obtain the apparent KM-values (KM
app).  
This data was subsequently used to determine the type of inhibition and the respective  
Ki-values. 
Both α-methylpantothenic acid 3.2 and β-trifluoromethylpantothenic acid 3.8 were found to 
act as competitive inhibitors based on the observed increase in the KM
app-values with 
increasing inhibitor concentration (Figure 3.4A and B).  Moreover, a plot of KM
app against 
inhibitor concentration clearly gave straight lines in both cases, indicating a directly 
proportional relationship between KM
app and KM/Ki as expected for competitive inhibitors. 
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The kinetic parameters, Vmax, KM and Ki, for these two inhibitors were therefore determined 
by non-linear regression analysis by fitting the data to the equation describing single 
substrate/single inhibitor competitive inhibition (Equation 2).   
  
       
          
   
  
  
                              
However, the Michaelis-Menten fits suggest that β-methylpantothenic acid 3.1 shows 
classical uncompetitive behavior as shown in Figure 3.4C.  The apparent Vmax decreases as 
the concentration of inhibitor increases, while the KM
app values stay nearly constant.  For 
uncompetitive inhibition a plot of 1/Vmax against the inhibitor concentration should result in 
a straight line.  For β-methylpantothenic acid  only the lowest three inhibitor concentrations 
appear to follow this trend (a linear regression fit through these points and the control 
without inhibitor yields a R2 = 0.999).  In contrast, a plot of KM
app-values against the inhibitor 
concentrations gives a straight line for the inhibitor concentrations higher than  
150 μM (R2 = 0.985), suggesting that competitive inhibition predominates at higher inhibitor 
concentrations.  The inhibition modality of β-methylpantothenic acid therefore seems to be 
dependent on inhibitor concentration, and may in fact be influenced by this analog’s dual 
ability to act as both substrate and inhibitor. 
The kinetic parameters for β-methylpantothenic acid were determined by fitting the high 
inhibitor concentrations data to equation 2 (to obtain the parameters for competitive 
inhibition) while low concentrations data were fitted to the equation describing single 
substrate/single inhibitor uncompetitive inhibition (Equation 3).   
  
    
   
   
  
 
  
   
 
                                        
Legend for Figure 3.4 (next page): 
Characterization of the inhibition of Pa PanK-III by various pantothenic acid analogs.   
Panel A:  Inhibitor:  α-methylpantothenic acid, Panel B:  Inhibitor:  β-trifluoromethylpantothenic acid, Panel C:  
Inhibitor:  β-methylpantothenic acid. 
Left:  Michaelis-Menten fits to the plots of initial rates over a range of pantothenic acid concentrations in the 
presence of increasing concentrations of inhibitor.  Each point represents the average of three readings and 
the bars the standard error.   
Right (top three graphs):  Plots of the KM
app
-values vs. inhibitor concentration for competitive inhibition. Right 
(bottom graph): Plot of 1/Vmax vs. inhibitor concentration for uncompetitive inhibition  
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Figure 3.4:  Characterization of the inhibition of Pa PanK-III by various pantothenic acid analogs.  Legend 
supplied on previous page. 
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The kinetic parameters obtained in this manner for all the analogs are summarized in  
Table 3.4.  Interestingly the Ki-values obtained for β-methylpantothenic acid for the high 
inhibitor concentrations was lower than the inhibitor concentrations where competitive 
inhibition was observed.  Although this effect is not clearly understood at present, it might 
largely be due to the analog’s dual ability to act as substrate and inhibitor. 
Table 3.4:  Summary of inhibition data 
 
3.6  Discussion 
3.6.1  Synthesis of pantothenate analogs modified in the β-alanine moiety 
The synthesis of the compounds containing modified β-alanine moieties was done by the 
nucleophilic ring-opening of pantolactone by the relevant amines.  These reactions were 
initially performed according to the method of Meier et al.5 in which a three-fold excess of 
pantolactone relative to amine was used. However, we found that since both the desired 
analogs and pantolactone were water-soluble, organic extraction could not successfully be 
used for removal of the unreacted starting material.  In addition, the removal of excess NEt3 
by cation exchange chromatography resulted in some of the product reverting back to 
pantolactone due to acid-catalyzed lactonization.  In contrast, the melting reaction that was 
used instead made use of only two starting materials – pantolactone and the amine – in 
equal amounts.  This greatly simplified the purification of the products, successfully 
achieved using flash chromatography on silica gel as final purification step. 
However, a drawback of these melting reactions were that the overall yields were found to 
be low, ranging between 6.5% for β-trifluoromethylpantothenic acid to 40% for  
α-methylpanthothenic acid.  Attempts to increase yields by increasing the amount of 
pantolactone from 1.0 to 1.1 eq. only gave a slightly increased yield in the case of α-methyl-
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panthothenic acid.  For α,α-dimethylpantothenic acid the low yield may be due to the steric 
bulk of the geminal dimethyl-groups on the amine which interferes with the nucleophilic 
ring-opening reaction. Similarly, the highly electronegative F-substituents would decrease 
the nucleophilicity of the amine group of 3-amino-4,4,4-trifluorobutyric acid, which in turn 
would hinder the formation of the amide bond in the case of β-trifluoromethylpantothenic 
acid.  This analog also proved to be especially difficult to purify due to problems with 
removal of the solvents, and required repeated dissolution and lyophilization cycles to be 
isolated.  We postulate that the electronegative F’s form strong interactions with the 
solvents molecules (methanol and ethylacetate) which made them difficult to evaporate.   
None of these syntheses were optimized further beyond these initial synthesis attempts as 
sufficient amounts of pure products were obtained to undertake the in vitro activity screens. 
3.6.2  Synthesis of pantothenate analogs modified in the pantoyl moiety 
For the modification of the 4’-OH of pantothenate we exploited the fact that the primary 
hydroxyl group is more reactive than the secondary 2’-OH.  This difference in reactivity is 
further influenced by the steric hindrance of the latter by adjacent geminal dimethyl-groups.  
Selective methylation of the 4’-OH could therefore be performed as confirmed by COSY 
NMR analysis.  However, benzyl pantothenate (3.12) proved to be less stable than 
anticipated and the molecule was found to decompose with the addition of bases such as 
NaH and NaOH, but the synthesis was successful when anhydrous carbonate was used as 
base instead.   
The synthesis of ω-methylpantothenic acid proved more difficult.  The first reported 
synthesis of this analog used CN- and required extensive extraction and purification steps.  
In an attempt to design a safer and less complicated procedure, aldol condensations and 
multi-component reactions (MCRs) were investigated to introduce the key carbon-carbon 
bonds.  Unfortunately, the aldol condensation failed to give products regardless of the 
strategy used, mainly due to the failure of the aldehyde acceptors to react with the TMS 
enol ether donors, which were both commercially obtained and synthesized before use.  
Currently it remains unclear why these reactions failed, as examples of similar reactions are 
well documented.  In the case of the MCR reaction, the isocyanide was found to couple 
directly to the aldehyde without any participation of the TMS enol ether.  Although this 
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finding made it impossible to prepare ω-methylpantothenic acid according to this route, the 
reaction was subsequently exploited in the successful synthesis of for 4’-deoxypantothenic 
acid (3.11). 
3.6.3  In vitro assays 
P. aeruginosa PanK-III was used in all the in vitro activity studies as a crystal structure is 
available (PDB:  2F9T and 2F9W) and its kinetic parameters are the most representative of 
this type of PanK.  For B. anthracis PanK-III by contrast a crystal structure is also available, 
but it exhibits an uncommonly “low” KM-value for ATP. 
Pa PanK-III showed a surprisingly high selectivity for its substrate.  Of the 11 pantothenate 
analogs tested, only β-methylpantothenic acid 3.1 was characterized as an alternative 
substrate for the enzyme.  The kinetic characterization was done with a coupled enzymatic 
assay that links the amount of ADP produced to the consumption of NADH.27  A good 
correlation was obtained for the parameters determined using this assay and published 
kinetic parameters determined by radioactive assay with D-[1-14C] pantothenic acid.3  The 
kinetic parameters indicate that β-methylpantothenic acid had a KM-value of only about 
three times higher than pantothenic acid, but its specificity constant was ≈ 25 times lower 
(1.32 s-1.mM-1 compared to the 32.3 s-1.mM-1 of pantothenic acid).  The differences in both 
parameters suggest that the introduced methyl group not only influences the binding of the 
analog, but also the enzyme’s ability to phosphorylate its 4’-OH. 
Only three compounds were identified as PanK-III inhibitors:  α-methylpantothenic acid 3.2, 
β-methylpantothenic acid 3.1 and β-trifluoromethylpantothenic acid 3.8.  Surprisingly, none 
of the analogs with modified pantoyl moieties – including 4’-deoxypantothenic acid, in 
which the only modification is the exchange of an OH-group for a hydrogen – was observed 
to be inhibitors.  This suggests that active site interactions with the 4’-OH group of the 
substrate is not only important for catalysis, but also for binding.   
There are three types of inhibition - competitive, uncompetitive and noncompetitive.  In 
competitive inhibition the inhibitor competes with the natural substrate (S) for binding to 
the free enzyme (E).  Uncompetitive inhibitors bind to the substrate bound enzyme (ES) 
binary complex and not to the free enzyme (E), while noncompetitive inhibitors bind both 
the free enzyme (E) and the ES binary complex.29 The results show that  
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α-methylpantothenic acid and β-trifluoromethylpantothenic acid both function as 
competitive inhibitors, while β-methylpantothenic acid shows a mixed behavior, acting as 
uncompetitive inhibitor at low inhibitor concentrations, but as a competitive inhibitor at 
high concentrations. 
Inhibitor analysis showed that α-methylpantothenic acid and β-trifluoromethylpantothenic 
acid have very similar Ki-values, in the range of 80-90 μM.  Importantly, when the methyl 
group of β-methylpantothenic acid was substituted for CF3, the observed Ki-value decreased 
by three-fold.  This strongly suggests that the electronegative nature of the F’s increases the 
potency of the inhibitor, and that that factors that influence electrostatic interactions 
therefore have greater potential for inhibitor development than those that depend on steric 
effect.  Based on this result, it would be interesting to determine whether this same 
lowering in Ki would be observed if α-trifluoromethylpantothenic acid was tested as 
inhibitor.  Since the measured Ki-value for α-methylpantothenic acid is already below  
≈ 100 μM, a further reduction could lower the Ki-value to ≈ 30 μM, which would be an 
important step closer to PanK-III inhibitors with Ki-values in the nM range. 
3.7  Conclusion 
In this part of the study several pantothenic acid analogs were tested as PanK-III inhibitors. 
Although the Ki-values obtained for the active inhibitors are all in the μM range, these 
values are an important improvement on the inhibition characteristics of the best hit 
obtained from the study of ATP mimetics as PanK-III inhibitors.1  It is important to note, 
however, that in this study all compounds were tested as mixtures of the stereoisomers (in 
regards to the stereochemistry of the introduced methyl groups).  It may therefore be 
possible that of the two stereoisomers tested in each case (the 2’-OH of all three active 
inhibitors had the required R-configuration), only one acts as an inhibitor.   The true Ki-
values may therefore be half or less of those reported in this study, assuming that the 
stereoisomers were present in equal amounts (this assumption was not confirmed with 
polarimetry).  With this said, only two compounds have Ki-values low enough to justify 
resolution of the stereoisomers and testing of this proposal, namely α-methylpantothenic 
acid 3.2 and β-rifluoromethylpantothenic acid 3.8. Such resolution studies will be attempted 
in future work. 
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Other future work will also include redesigning the synthesis of ω-methylpantothenic acid 
and, based on the initial success of the fluorinated analog 3.8, the synthesis of other 
selected fluorinated compounds. 
3.8  Experimental 
3.8.1  Synthesis 
a)  (R,S) -β-methyl-pantothenic acid (3.1) 
(R,S) -3-aminobutyric acid (222.7 mg, 2.16 mmol) was dissolved in 4.0 M NaOH (540 μl, 2.16 
mmol) and lyophilized.  Pantolactone (246.6 mg, 1.89 mmol) was added to the flask and 
stirred at 130°C overnight under inert atmosphere.  The resulting black, sticky substance 
was dissolved in water and purified by ion exchange chromatography with weakly acidic 
Amberlite IRC-86 resin (≈ 1.0 g). The eluent was lyophilized and purified with flash 
chromatography (silica, 5:1:1:1 ethylacetate: methanol: acetonitrile: H2O).  Rf = 0.38;  
Product: Yellow oil, very hygroscopic;  Yield: 128.2 mg, 0.67 mmol, 31%;  1H NMR (300 MHz, 
D2O, 25°C):  δ = 0.88 (d, J = 1.8 Hz, 3H, -CH3) 0.91 (d, J = 3.18 Hz, 3H, -CH3) 1.21 (dd, J = 6.75 
Hz, J = 2.27 Hz, 3H, -CH3) 2.58 (m, J = 2.02 Hz, 2H, -CH2) 3.37 (dd, J = 36.5 Hz, J = 11.2 Hz, 2H,  
-CH2-O) 3.95 (d, J = 5.02 Hz, 1H, -CH-O) 4.29 ppm (m, J = 6.45 Hz, 1H, -CH-N);  
13C NMR (300 
MHz, D2O, 25°C):  δ = 14.93, 19.76, 21.12, 39.22, 40.24, 42.22, 42.26, 69.08, 76.48, 77.60 
ppm; MS–ESI: m/z [M+1]+ calculated for C10H20NO5: 234.13, found: 234.24;  [M-1]
- 
calculated for C10H18NO5:  232.12;  found:  232.09 
b)  (R,S) -α-methyl-pantothenic acid (3.2) 
(R,S)-3-amino-isobutyric acid (47.9 mg, 0.465 mmol) was dissolved in 1.3 M NaOH (357 μl, 
0.465 mmol) and lyophilized.  Pantolactone (80.2 mg, 0.616 mmol) was added to the flask 
and stirred at 130°C overnight under inert atmosphere.  The resulting black, sticky substance 
was dissolved in water and purified by ion exchange chromatography with weakly acidic 
Amberlite IRC-86 resin (≈ 1.0 g).  The eluent was lyophilized and purified with flash 
chromatography (silica, 5:1:1:1 ethylacetate: methanol: acetonitrile: H2O). Rf = 0.38; 
Product: Pinkish yellow oil;  Yield:  23.8 mg, 0.186 mmol, 40%;  1H NMR (400 MHz, D2O, 
25°C):  δ = 0.90 (s, 3H, -CH3) 0.93 (s, 3H, -CH3) 1.17 (d, J = 7.12 Hz, 3H, -CH3) 2.74 (q, J = 7.21 
Hz, 1H, -CH-) 3.38 (m,  J = 7.88 Hz, 2H, - CH2) 3.39 (dd, J = 48.2 Hz, J = 11.5 Hz, 2H, -CH2-N) 
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3.99 ppm (d, J = 2.37 Hz, 1H, - CH-O); 13C NMR (400 MHz, D2O, 25°C):  δ = 14.93, 19.77, 
21.12, 39.22, 40.24, 40.28, 42.22, 42.26, 69.08, 76.48 ppm;  MS–ESI: m/z [M+1]+ calculated 
for C10H20NO5:  234.13, found:  234.14;  [M-1]
- calculated for C10H18NO5:  232.12;  found:  
232.09  
c)  α,α-dimethyl-pantothenic acid (3.3) 
3-amino- 2,2-dimetyl propanoic acid hydrochloric salt (75.1 mg, 0.49 mmol) was dissolved in 
2 eq. 1.0 M NaOH (978 μl, 0.98 mmol) and lyophilized.  Pantolactone (57.9 mg, 0.45 mmol) 
was added to the flask and stirred at 130°C overnight under inert atmosphere.  The resulting 
black, sticky substance was dissolved in water and purified by ion exchange chromatography 
with weakly acidic Amberlite IRC-86 resin (≈ 1.0 g). The eluent was lyophilized and purified 
with flash chromatography (silica, 5:1:1:1 ethylacetate: methanol: acetonitrile: H2O).  
Product: white powder;  Rf = 0.33;  Yield:  33.7 mg, 0.137 mmol, 28%;  
1H NMR (400 MHz, 
D2O, 25°C):  δ = 0.91 (s, 3H, -CH3) 0.94 (s, 3H, -CH3) 1.21 (s, 6H, 2 × -CH3) 3.39 (dd, J = 47.52 
Hz, J = 11.9 7Hz, 2H, -CH2-) 3.41 (s, 2H, - CH2) 4.03 ppm (s, 1H, -CH-O);  
13C NMR (400 MHz, 
D2O, 25°C):  δ = 19.80, 21.09, 23.16, 23.20, 39.22, 43.67, 47.29, 69.05, 76.47, 175.72 ppm; 
MS–ESI: m/z [M+1]+ calculated for C11H21NO5: 248.15, found: 248; [M-1]
- calculated for 
C11H19NO5:  246.13;  found:  246  
d)  (R,S) - β-trifluoromethyl pantothenic acid (3.8) 
(R,S) -3-amino-4,4,4-trifluorobutyric acid (54.2 mg, 0.35 mmol) was dissolved in 1.3 M NaOH 
(265 μl, 0.35 mmol) and lyophilized.  Pantolactone (64.1 mg, 0.49 mmol) was added to the 
flask and stirred at 130°C overnight under inert atmosphere.  The resulting residue was 
dissolved in water and purified by ion exchange chromatography with weakly acidic 
Amberlite IRC-86 resin (≈ 1.0 g).  The eluent was lyophilized and purified with flash 
chromatography (silica, 5:1:1:1 ethylacetate: methanol: acetonitrile: H2O).  Rf = 0.38 
Product:  yellow oil.  Yield:  6.5 mg, 0.023 mmol, 6.5%;  1H NMR (400 MHz, D2O, 25°C):  
δ = 0.90 (d, J = 2.95 Hz, 3H, -CH3) 0.94 (d, J = 3.37 Hz, 3H, -CH3) 2.74 (dm, J = 80.37 Hz, 2H,  
-CH2) 3.38 (qd, J = 43.53 Hz, J = 11.01 Hz, J = 2.27 Hz, 2H, - CH2) 4.06 (d, J = 9.29 Hz, 1H,  
-CH-O) 5.02 ppm (broad s, 1H, - CH-CF3);  
19F NMR (400 MHz, D2O, 25°C): δ = -75.00 ppm (d,  
J = 7.62 Hz, 3F); m/z [M+1]+ calculated for C10H17F3NO5: 288.10, found: 288; [M-1]
- 
calculated for C10H15F3NO5:  286.09, found:  286  
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e)  Pantothenate benzyl ester (3.12) 
Benzyl bromide (500 μl, 4.02 mmol) was added to calcium pantothenate (1.00 g, 4,26 mmol) 
dissolved in 15 ml dry DMF and heated at 70°C overnight.  DMF was removed in vacuo, 
ethylacetate (100 ml) added to the residue and the organic layer washed with aq NaCl  
(3 × 20 ml) before drying over Na2SO4.  After the solvent was removed in vacuo, 3.12 was 
purified with flash chromatography (silica gel; ethylacetate:hexane, gradient from 2:1 to 
4:1). The product was confirmed by 1H NMR and MS.  Product: yellow oil; Rf = 0.23;   
Yield:  704.2 mg, 2.27 mmol, 56.6%. 
f)  4’-methoxy pantothenate benzyl ester (3.13) 
To 3.12 (100 mg, 0.32 mmol) dissolved in 1.6 M dry DMF (final concentration = 0.2 M) was 
added 0.55 eq. K2CO3 (24.5 mg, 0.18 mmol) and 1.1 eq. MeI (53 μl, 0.35 mmol) and heated 
at 70°C overnight.  DMF was removed in vacuo, ethylacetate (25 ml) added, the organic 
layer washed with H2O (3 ×5.0 ml) and dried over Na2SO4.  After the solvent was removed 
the product was purified with flash chromatography (silica gel; ethylacetate:hexane, 3:1). 
Product:  yellow oil; Rf = 0.45; Yield:39 mg, 0.12 mmol, 38%;  
1H NMR (400 MHz, CDCl3, 
25°C):  δ = 0.90 (s, 3H, -CH3) 0.96 (d, J = 3.21 Hz, 6H, 2 × -CH3) 2.59 (t, J = 6.32 Hz, 2H, -CH2) 
3.19 (dd, J = 38.22 Hz,J = 8.94 Hz, 2H, -CH2) 3.33(3, 3H, - CH3) 3.54 (m, 2H, -CH2-N) 3.94 (d, 
J = 3.79 Hz, 1H, -CH-O) 4.21 (d, J = 4.36 Hz, 2H, unknown) 5.13, (s, 2H, -CH2) 7.13 (broad s, 
1H, -NH) 7.35 ppm (m, 5H, benzyl ring);  13C NMR (400 MHz, CDCl3, 25°C):  δ = 20.59, 22.09, 
34.53, 34.75, 38.57, 59.57, 66.82, 78.79, 82.66, 128.56, 128.64, 128.89, 172.33, 172.40 ppm; 
Methylation was also confirmed by COSY (400 MHz, CDCl3, 25°C);  m/z [M+1]
+ calculated for 
C17H26NO5: 324.18;  found: 324.5 
g)  4’-methoxy pantothenic acid (3.9) 
Compound 3.13 (34 mg, 0.11 mmol) was dissolved in 4.4% formic acid/methanol (2.0 ml) 
and stirred at room temperature.  Pd (black) (20 mg) was added and the reaction and stirred 
until all starting material was consumed (based on TLC analysis, 3:1 ethylacetate: hexane,  
Rf = 0.54).  The Pd (black) was removed by filtration through a cotton wool plug and washed 
with methanol (10 ml).  The solvent was removed in vacuo, the residue dissolved in 1.0 M 
HCl (10 ml) and heated to reflux for 24 h.  The reaction mixture was cooled to room 
temperature and lyophilized and purified with flash chromatography (silica, 5:1:1:1 
ethylacetate: methanol: acetonitrile acetonitrile: H2O).  Rf = 0.40;  Product:  yellow oil;  Yield: 
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11.68 mg, 0.05 mmol, 45% yield for step, 15% overall yield;  1H NMR (300 MHz, D2O, 25°C):  
δ = 0.93 (s, 3H,-CH3) 0.95 (s, 3H, -CH3), 2.61 (t, J = 6.53 Hz, 2H, -CH2) 3.29 (dd, J = 26.99 Hz,  
J = 9.69 Hz, 2H,-CH2-O) 3.34 (s, 3H, -O-CH3) 3.49 (td, J = 6.39 Hz, J = 2.09 Hz, 2H, -CH2-N) 3.96 
ppm (s, 1H,O-CH-N);  13C NMR (300 MHz, D2O, 25°C):  δ = 20.57, 21.50, 34.34, 35.44, 38.76, 
59.34, 76.41, 79.70, 175.50, 176.97 ppm;  Methylation was confirmed by COSY (300 MHz, 
D2O, 25 °C);  m/z [M+1]
+ calculated for C10H20NO5:  234.14, found:  234;  [M-1]
- calculated for 
C10H18NO5:  232.12,  found: 232  
h)  β-alanine benzyl ester  hydrochloric salt (3.14) 
To β-alanine (4.15 g, 47 mmol) was added benzyl alcohol (25 ml) and TMS-Cl (10 ml).  After 
stirring at 100°C for 3 h the mixture was poured in diethyl ether (500 ml) and left at 4.0°C 
overnight.  The resulting white crystals were filtered, washed with cold diethyl ether and 
oven dried.  The product was confirmed by 1H NMR and MS.  Yield:  8.95 g (2:1 mixture of 
3.14 and β-alanine). 
i)  N-acryloyl β-alanine benzyl ester (3.16) 
To 3.14 (366 mg, 2.04 mmol) dissolved in DCM (10 ml) was added iPr2NEt (365 μl,  
2.13 mmol) and acryloylchloride (3.15) (182 μl, 2.24 mmol).  After stirring at 0°C for 4  the 
reaction was quenched by the addition of 1.0 M HCl (5.0 ml).  The organic layer was washed 
with saturated NaHCO3 (2 × 5.0 ml) and the solvent removed in vacuo.   The product was 
purified with flash chromatography (silica, 3:1 ethylacetate:hexane); Rf = 0.47;  Product: light 
yellow oil; Yield: 273 mg, 1.17 mmol, 57.4%;  1H NMR (400 MHz, CDCl3, 25°C):  δ = 2.62 (t, J = 
5.81 Hz, 2H,-CH2) 3.60 (q, J = 6.12, 2H, -CH2) 5.14 (s, 2H, -CH2) 5.62 (d, J = 10.03 Hz, 1H, =CH2) 
6.00 (dd, J = 16.97 Hz, J = 10.18 Hz, 1H, =CH-) 6.15 (broad s, 1H, -NH) 6.23 (d, J=18.42 Hz 1H, 
=CH2), 7.35 ppm (m, 5H, benzyl ring);  
13C NMR (400 MHz, CDCl3, 25°C): δ = 33.96, 35.08, 
66.46, 126.31, 128.13, 128.31, 128.57, 130.85, 165.90, 172.16 ppm 
j)  Oxidative cleavage product 3.17 
N-acryloyl β-alanine benzyl ester (3.16) (137 mg, 0.59 mmol) was dissolved in 7.5 ml 5.0% 
H2O/acetone and Sudan Red III added until the mixture was slightly pink.  The flask was 
cooled to 0°C and O3 bubbled through until the solution turned colorless.  The reaction was 
purged by bubbling O2 through the solution for 1 min after which H2O was added (25 ml), 
the aqueous layer extracted with DCM (2 × 25 ml) and dried over Na2SO4.  Based on NMR 
Stellenbosch University  http://scholar.sun.ac.za
  63 
 
Chapter 3: Synthesis and characterization of PanK-III 
inhibitors 
 
analysis ≈ 20% of 3.16 was converted to the desired product 3.17.  Yield: not calculated;  
1H NMR (400 MHz, CDCl3, 25°C) only given as indication since characterization results are 
dubious:  δ = 2.64 (m, 2H, -CH2) 3.56 (m, 2H, -CH2) 5.14 (s, 2H, -CH2) 7.35 (m, 5H, benzyl ring) 
9.27 ppm (s, theoretically 1H, H-CO);   MS:  analysis unsuccessful.  
k)  TMS silyl enol (3.18) 
To 3-methyl-2-butanone (500 μL, 4.67 mmol) dissolved in DMF (12.5 ml) was added NEt3 
(2.2 ml, 15.77 mmol) and TMS-Cl (1.2 ml, 9.46 mmol).  The reaction was stirred at 130°C 
overnight; hexane (50 ml) added and the organic layer washed with saturated NaHCO3  
(3 × 2 5 ml) and brine (1 × 25 ml).  After drying overnight on anhydrous K2CO3, the solvent 
was removed in vacuo to give 3.18 as a dark brown oil. The product was confirmed by 1H 
NMR; Yield:  87 mg, 0.3 mmol, 1.3%. 
l)  ω-methyl pantothenic acid precursor 3.19 
To 3.17 (119 mg, 0.51 mmol) was dissolved in acetonitrile (500 μl) and added to 3.18  
(87 mg, 0.3 mmol) in sodium phosphate buffer, pH 7.0 (2.5 ml, 25 mM).  The reaction was 
stirred at room temperature for 36 h in the dark, the aqueous layer extracted with 
ethylacetate (5 × 5 ml) and purified with flash chromatography (silica, 3:1 ethylacetate: 
hexane).  The isolated products were not the desired product. 
m)  N-formyl β-alanine benzyl ester (3.20) 
β-alanine benzyl ester tosylate salt (1.0 g, 2.8 mmol) was dissolved in H2O and NaHCO3.  
NaOH was added until the pH ≈ 10.5 and 3.14 extracted from the aqueous solution with 
DCM (4  × 25 ml).  The solvent was removed in vacuo with a recovery efficiency of 75%.  To 
the colorless oil (437 mg, 2.44 mmol) was added acetic formic anhydride which was 
prepared by stirring acetic anhydride (2.5 ml) with formic acid (1.1 ml) for 2.5 h at 55°C.  The 
reaction was stirred at 70°C for a further 2 h, the volatiles removed in vacuo and redissolved 
in DCM (25 ml).  The organic layer was washed consecutively with saturated NaHCO3 (2 × 25 
ml) and H2O (2 × 25 ml) before removing the solvent in vacuo to give 3.20.  Product:  yellow 
oil, Yield: 323 mg, 1.56 mmol, 63.9% (calculated from after the recovery step).  Rf = 0.36 (3:1 
ethylacetate: hexane).  The product was confirmed by 1H NMR and MS.  
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n)  N-isocyanide β-alanine benzyl ester (3.21) 
To a solution of 3.20 (323 mg, 1.56 mmol) was added NEt3 (1.7 ml) in dry THF (6 ml) at -78°C 
under inert atmosphere.  POCl3 (300 μl) in dry THF (6 ml) was added slowly while stirring 
continuously.  After the addition was completed the reaction was stirred for an additional  
3 h at 0°C.  Over this period the color changed from yellow to dark orange to brown.  The 
reaction was quenched by the addition of cold H2O (50 ml) and the aqueous layer extracted 
with dietyl ether (3 × 30 ml).  The combined organic layers were washed with H2O (3 × 30 
ml), dried over MgSO4 and the solvent removed in vacuo.  Product:  black, foul smelling oil.  
The product was used as is without further purification. The product was confirmed by 1H 
NMR and MS.  Yield:  ≈ 289.1 mg, ≈ 1.5 mmol, ≈ 97%. 
o)  4’-deoxy pantothenic acid benzyl ester (3.27) 
A solution of 3.22 (≈ 289.1 mg, ≈ 1.5 mmol) in dry DCM (10 ml) was cooled to 0°C under 
inert conditions.  To the solution neat TiCl4 was added and the reaction mixed thoroughly 
before addition of pivaldehyde (3.26) (200 μl, 1.84 mmol).  The reaction was warmed to  
25°C and stirred for a further 2 h before it was quenched by pouring into saturated K2CO3 
(50 ml).  The mixture was filtered through celite and the aqueous layer extracted with DCM 
(3 × 30 ml).  The combined organic layers were washed with H2O (3 × 30 ml), dried on 
MgSO4 and the solvent removed in vacuo before purification with flash chromatography 
(silica, 1:1 ethylacetate: hexane). Rf = 0.25, Product: very light yellow, almost colorless oil;   
Yield:  123 mg, 0.42 mmol, 17%;  1H NMR (400 MHz, CDCl3, 25°C):  δ = 0.94 (s, 9H, 3 × -CH3) 
2.59 (t, J = 6.12 Hz, 2H, -CH2) 3.54 (q, J = 12.93 Hz, J = 6.67 Hz, 2H, -CH2) 3.64 (d, J = 5.04 Hz, 
1H, -O-CH) 5.13 (s, 2H, CH2) 6.68 (broad s, 1H, -NH)  7.34 ppm (m, 5H, benzyl group);  
m/z [M+1]+ calculated for C16H24NO4:  294.17, found:  294.2; [M-1]
- calculated for C16H22NO4: 
292.15;  found:  292.2 
p)  4’-deoxy pantothenic acid (3.11) 
To 3.27 (m = 123 mg, 0.42 mol) in 20 ml 4.4% formic acid/methanol was added 200 mg Pd 
(black) and the reaction stirred overnight at room temperature.  The Pd (black) was 
removed by filtration through a cotton wool plug and washed with methanol (3 ×1 0 ml).  
The solvent was removed in vacuo, the residue dissolved in 5.0 M HCl (20 ml) and refluxed 
for 24 h. The reaction mixture was cooled to room temperature and lyophilized.  The 
resulting yellow oil was dissolved in a minimal amount of water and separated from the 
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insoluble residue.  NMR confirmed that the water fraction, which contained the majority of 
the mass, was the desired product.  Product:  dark yellow oil.  Yield:  116 mg, 0.40 mmol, 
95%  for step, 16%  overall.  1H NMR (400 MHz, D2O, 25°C):  δ = 0.94 (s, 9H, 3×-CH3) 2.61 (t,  
J = 6.14 Hz, 2H, -CH2) 3.48 (q, J = 12.09 Hz, J = 6.67 Hz, 2H, -CH2) 3.76 ppm (s, 1H, -O-CH);  
13C NMR (400 MHz, D2O, 25°C): δ = 25.90, 34.20, 34.65, 35.3, 79.88, 175.86, 176.74 ppm; 
m/z [M+1]+ calculated for C9H18NO4: 204.12, found: 204.1; [M-1]
- calculated for C9H16NO4: 
202.11;  found: 202.1 
3.8.2  Activity determination 
All reactions were performed in triplicate at 25°C in 96-well plates and the decrease of 
NADH measured with the Thermo Varioskan™ spectrophotometer at 340 nm over a period 
of 5 min.  Each 300 μl contained 100 mM HEPES, pH 7.5, 1.0 mM MgCl2, 60 mM  NH4Cl2,  
2.0 mM PEP, 0.5 mM NADH, 5.0 mM ATP, 2.75 U lactate dehydrogenase (LDH), 2.0 U 
pyruvate kinase (PK) and enzyme.  The reactions were initiated with the addition of 500 μM 
substrate.  To test whether a compound was an inhibitor, 500 μM pantothenic acid was 
added to each reaction. 
3.8.3  Kinetic characterization 
The assays were done as above.  For the characterization as substrates, a range of increasing 
substrate concentrations was used. In the inhibitor studies a range of pantothenic acid 
concentrations were tested in the presence of a set concentration of inhibitor.  All graphs 
were plotted and kinetic parameters determined using the SigmaPlot vs. 11 statistical 
package.   
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Chapter 4:   
M. tuberculosis CoaX 
4.1  Introduction   
The genome of M. tuberculosis (Mtb) encodes both PanK-I and PanK-III enzymes.  The PanK-I 
(the coaA gene product) was identified as essential for growth in vitro,1 and has  been 
targeted in extensive inhibitor discovery programs by AstraZeneca and Novartis.  On the 
other hand, its PanK-III (the coaX gene product) was reported to be inactive based on 
various genetic complementation and in vitro activity studies.  In fact, it has been suggested 
that this enzyme may have a different native activity altogether.2 While these findings are in 
agreement with the apparent essentiality of the PanK-I enzyme in Mtb, they do not help to 
explain why Mtb maintains an apparently inactive second PanK, while other organisms such 
as Bacillus subtilis  (also has type I and III PanKs) both enzymes are active.   
In this part of the study the evidence for and against Mtb CoaX – the organism’s putative 
PanK-III enzyme – as a functional pantothenate kinase were examined.  We also examined 
the methodologies used to study this enzyme as well as the reported problems related to 
working with Mtb CoaX – all relevant in explaining the contradictory results achieved to 
date.  Based on these analyses, new experiments were executed to provide additional 
insight into the apparent inactivity of this enzyme.  Finally, this chapter concludes with the 
results of an investigation into another organism that has an inactive second PanK homolog: 
B. anthracis and its putative type II PanK.3  Taken together, these studies suggest that we do 
not have a complete understanding of the catalytic diversity of PanK enzymes as yet, and 
that the apparent redundancy of multiple PanK enzymes may have a functional role in 
certain cases.     
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4.2  Evidence supporting Mtb CoaX having PanK activity 
4.2.1  PanK-I inhibitors do not translate into cell growth inhibitors 
In a study by Novartis several promising leads were identified as in vitro inhibitors for of 
Mtb’s PanK-I, but none of these compounds translated into cell growth inhibitors that 
showed MIC < 20 μM.4  A range of hypotheses were presented to explain this finding, 
including the potential inability of the inhibitors to cross the cell membranes, their rapid 
elimination by efflux pumps, compound insolubility and target insensitivity.  However, none 
of these provided a conclusive answer.  Another alternative explanation for the lack of cell 
growth inhibition by PanK-I inhibitors is that Mtb’s putative PanK-III might functionally 
replace PanK-I under conditions where the latter enzyme is inhibited, or not present.   
PanK-III enzymes are structurally distinct from PanK-I enzymes (see section 2.7.3) and would 
therefore not be affected by PanK-I inhibitors.  They would thus remain functional in 
conditions where the type I PanK is inhibited.  
4.2.2  CoaX shows sequence and structural similarity with other PanK-IIIs 
To evaluate whether mycobacterial CoaX proteins have all the structural elements and 
conserved catalytic residues present in other PanK-III enzymes, we performed a multiple 
sequence alignment of the Mtb and Mycobacterium smegmatis (Ms) CoaX proteins with 
known and characterized PanK-IIIs (Figure 4.1).   
The mycobacterial proteins show high sequence similarity to the other PanK-IIIs of which 
crystal structures have been determined.  They are predicted to contain all equivalent 
secondary structure elements of these enzymes which include the relevant motifs that are 
conserved among members of the ASKHA superfamily.5-7  They further contain all the motifs 
unique to PanK-IIIs, all three highly conserved Asp residues necessary for catalysis as well as 
all the residues involved in ATP and pantothenic acid binding.8-10  
The six identifiable PanK-III motifs (three belonging to all ASKHA superfamily members, as 
well as the three motifs that are specific to PanK-IIIs) are underlined in Figure 4.1. The 
conserved sequences of these motifs are given in Table 4.1.  The secondary structure 
elements are indicated at the top of the alignment with arrows representing β-strands and 
cylinders representing α-helices.   
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Figure 4.1:  Multiple sequence alignment of selected PanK-III sequences including those with available 3D 
structures and the putative Mtb and Ms proteins.  Secondary structure elements are indicated at the top with 
arrows representing β-strands and cylinders representing α-helices.  The conserved motifs within the ASKHA 
superfamily (PHOSPHATE 1, PHOSPHATE 2 and ADENOSINE) and those specific for PanK-III (“pan motif”, “pan 
cap” and INTERFACE) are underlined.  Residues that interact with bound substrates are shaded in blue, and 
indicated on top of the secondary structure cartoon (using TmPanK-III numbering).  The generally conserved 
hydrophobic or neutral amino acid residues are shaded in yellow, while conserved small residues (G, P, S, A, T) 
are shaded in gray.  The alignment was done according to the methodology outlined by Yang et al.
8 
Ba – Bacillus anthracis;  Bs - Bacillus subtilis;  Hp – Helicobacter pylori;  Pa – Pseudomonas aeruginosa;  Tm – 
Thermotoga maritima;   Mt – Mycobacterium tuberculosis;  Ms – Mycobacterium smegmatis. 
Table 4.1:  The characteristic motifs of the ASKHA superfamily and PanK-IIIs with their conserved residues.  No 
information on the conserved residue pattern was found for the “pan cap” motif. 
 
Legend:  one letter code = type of amino acid (hydrophobic, polar etc.); letters in brackets = specific amino 
acids that can by encoded by the one letter code.   h = hydrophobic (VLIFWY), f = partly hydrophobic (VLIFWYM 
CGATKHR), t = tiny (GSAT), s = small (GSATNDVCP), p = tiny and polar (GSATNDQEKHR), x = any amino acid 
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The three characteristic motifs of the ASKHA superfamily are PHOSPHATE 1, PHOSPHATE 2 
and the ADENOSINE motif.  These three motifs are involved in recognition and binding of 
ATP, as well as in the coordination of a divalent metal ion (such as Mg2+) for 
phosphotransferase activity.  These motifs also contain two of the three highly conserved 
Asp residues.  Mutagenesis studies have shown that a conserved mutation of any of these 
Asp residues to either Asn or Glu reduces activity to less than 6%, suggesting a critical role 
for these residues in catalysis.  Asp6 (using TmPanK-III numbering as indicated at the top of 
Figure 4.1) is found in the PHOSPHATE 1 motif and coordinates the Mg2+ which interacts 
with the β- and γ-phosphates of ATP.  The second residue, Asp125, forms part of the 
PHOSPHATE 2 motif and coordinates Mg2+/K+ /NH4
+ through an H2O molecule.
9-12 
The three motifs specific to the PanK-IIIs are the “Pan motif”,12 “Pan cap”8,9 and 
INTERFACE.12  The “Pan motif” incorporates the third important Asp residue which is located 
in close proximity to the phosphoryl acceptor group.  Asp105 has been proposed that act as 
a catalytic base since it forms side chain hydrogen bonds with the 2’- and 4’-hydroxyl groups 
of pantothenic acid.12 The other highly conserved residues in the pantothenic acid binding 
pocket include Asn9, Arg106, Ile145, Leu163 and Thr179.9  Ile145 is found in the INTERFACE 
motif and forms a Van der Waals interaction with the bound pantothenic acid.  The two 
conserved small glycine residues in INTERFACE, Gly142 and Gly143, create space for the 
substrate in the active site.  Lastly, the conserved Pro147 and Gly148 plays a role in the 
protein dimerization.12 
Based on this analysis, and the fact that it apparently has all the conserved residues and 
binding motifs required for PanK activity, Mtb CoaX should function as a pantothenate 
kinase. 
4.2.3 Mtb’s coaX gene is expressed in actively growing Mtb 
One of the theories for the lack of activity of the CoaX was that the coaX-gene is not 
expressed.  However, when the gene expression was analyzed by RT-PCR in actively growing 
M. tuberculosis bacteria, the results indicated that both the coaA- and coaX-genes are 
transcribed,2 indicating that this gene was expressed in mycobacteria.    
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4.3  Evidence against Mtb CoaX having PanK activity 
4.3.1  Mycobacterial coaX genes are not essential 
In a 2003 study Sassetti et al. set out to identify the genes required for optimal growth of 
Mycobacteria,1  which included Mtb strain H37Rv, M. bovis and the closely related vaccine 
strain M. bovis BCG Pasteur.  The study was done using transposon site hybridization 
(TraSH), in which a gene was labeled as essential for optimal growth only if it had an 
insertion: genomic probe ratio of less than 0.2 and if the results could be reproduced in both 
Mtb and M. bovis.  Mutants were only considered to be reproducibly attenuated after the 
libraries were analyzed twice, and if the average of the resulting ratios were significantly 
different from 1.0 with P < 0.05 (determined by student t-test).  In this study the gene 
encoding for PanK-I (coaA, Rv1092c) was identified as essential for optimal growth, while 
the gene encoding the putative PanK-III (coaX, Rv3600c) was not.  This result has since been 
confirmed with directed gene knockout and genetic silencing experiments.2  
4.3.2  Mtb coaX does not functionally complement coaA mutations 
In vivo functional complementation is often used to demonstrate that a protein has a 
particular enzyme activity.  In the case of PanK activity, this complementation is usually 
done using E. coli strains that have a temperature sensitive mutation in their PanK-I-
encoding coaA genes (such as DV62).  At temperatures of 42°C and higher the PanK-I 
enzyme encoded by the mutant coaA gene of these strains is deactivated and subsequently 
the bacteria do not grow at this temperature.  However, normal growth occurs at 30°C 
which allows for a positive control test to be performed at this temperature.13   
In a study by AstraZeneca scientists, Awasthy et al. tested the ability of Mtb coaA and Mtb 
coaX to rescue E. coli DV62 grown at elevated temperatures.2  Cells transformed with 
plasmids containing either the coaA- or coaX-genes were plated on rich solid media (LB 
agar) and incubated at 30°C (positive controls) or 42°C (experiments) for 24 h.  At 30°C, the 
cultures transformed with either the coaA- or coaX-containing plasmids grew as expected, 
but at 42°C those complemented with coaX failed to rescue the growth of the E. coli DV62 
cells.   To ascertain if this result was not merely due to a lack of expression the CoaX protein, 
or to its expression in an insoluble (and therefore inactive form), a Western blot analysis 
was performed using anti-CoaX antibodies.  Analysis of the cytosolic fractions of the cell 
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lysate indicated that sufficient amounts of the protein were expressed and lack of 
expression could therefore not explain the negative complementation result. 
4.3.3  Mtb CoaX does not show PanK activity in vitro 
In the same study by Awasthy et al.2 the Mtb CoaX protein was purified and assayed for in 
vitro PanK activity using the PK/LDH-dependent coupled enzymatic assay14 described in  
Chapter 3 (section 3.5.4). This test also indicated that Mtb CoaX does not have PanK activity. 
4.4 Reevaluating the evidence:  Results from our studies 
4.4.1  Reevaluation of the functional complementation studies 
To determine whether the negative functional complementation results of the reported 
studies could be dependent on the conditions under which the tests were conducted, we 
prepared constructs of coaX genes from several organisms. We repeated the functional 
complementation experiments with pBAD-DEST49 constructs in the E. coli DV64 mutant 
strain on solid rich medium.  Among these were the coaXs from H. pylori and B. subtilis, as 
the PanK-IIIs encoded by these genes have confirmed PanK activity5 and have been used in 
functional complementation studies before on both solid and in liquid media.15 The 
constructs were prepared using Gateway™ pBAD-DEST49 as acceptor vector, because this 
plasmid places the gene in question under control of a tightly-controlled arabinose-inducible 
araBAD (PBAD) promoter.  This is in contrast to the T7 promoters of the expression plasmids, 
pDEST and pET, which allow a degree of leaky expression.  In addition, the tight regulation of 
PBAD by araC is useful for the expression of potential toxic or essential enzymes.
16   
We subsequently repeated the functional complementation experiments using the E. coli 
DV64 mutant strain and the PanK-I-encoding E. coli coaA as positive control.  The results of 
this experiment, which was also conducted on solid LB agar medium, are shown in  
Figure 4.2.   
Both the positive control and the cultures containing the plasmid with the B. subtilis coaX 
gene grew as expected, while the constructs containing the Mtb and H. pylori coaX genes 
failed to grow.  This result was in agreement with previous reports of the Mtb studies, but is 
contradictory to the fact that the activity of H. pylori PanK-III (encoded by its coaX gene) has 
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been confirmed in several in vitro assays.  This finding shows that complementation studies 
performed on solid LB agar medium may not necessarily give accurate results.   
 
Figure 4.2: Functional complementation studies done on solid LB media.  The relevant genes were cloned into 
the complementation vector, pBAD-DEST52 and transformed into E. coli DV62.  At 30°C all cultures grew as 
expected, but at 42 °C only B. subtilis coaX and the positive control (E. coli coaA) rescued the mutant strain.   
 
In previous studies conducted in our laboratory we achieved more reliable results in 
functional complementation studies when these were conducted using a liquid minimal 
medium (2% E-salts, 0.2% glycerol, with relevant supplements for growth, induction and 
selection) instead of solid media. We therefore repeated the experiment under these 
conditions by inoculating the media with starter cultures of the E. coli DV64 strains 
containing the relevant constructs.  Cell growth was subsequently followed for 30 h by 
monitoring the increase in optical density (OD600) at 600 nm. All experiments were done in 
triplicate. The absorbance plots obtained from one of the repeats of this experiment are 
shown in Figure 4.3.   
The results show that under these conditions, Mtb coaX rescued the E. coli DV64 strain in 
one out of every three repeats of the experiment.  H. pylori coaX again failed to 
complement in all experiments, and this was observed even with increased incubation 
times.  B. subtilis coaX did provide functional rescue, but at a slower rate than would 
normally be expected for an enzyme with confirmed pantothenate kinase activity.5  
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Figure 4.3:  Functional complementation studies done in liquid minimal media clearly shows complementation 
of the temperature sensitive E. coli DV62 strain by Mtb coaX. However, constructs with genes encoding 
proteins with known PanK activity either failed to complement (H. pylori) or did so at a slower rate than 
expected (B. subtilis).  Each point represents the average of three readings. 
4.4.2  Constructing expression vectors containing Mycobacterial coaX genes 
Based on the ambiguous results obtained in the cell growth studies, we set out to determine 
the in vitro activity of the coaX gene product.   We decided to include the homologous coaX-
gene from M. smegmatis (Ms CoaX) in this study, since the proteins obtained from this 
organism are highly similar to their Mtb homologs, but are often easier to handle and purify. 
The first attempt to amplify the coaX gene from genomic DNA failed for both homologs.  We 
postulated that the reason for this might be due to secondary effects caused by the fact that 
the mycobacterial genomes are known to be unusually rich in GC nucleotides.17  This 
problem was subsequently solved either by extension of the primers at the 3’ side, or by the 
addition of DMSO to the amplification mixture to disrupt the formation of secondary 
structures.18    
Mtb coaX was cloned into pET28a(+) and pPROEX using the NdeI and XhoI restriction sites.  
Both pET28a(+) and pPROEX plasmids are used for the heterologous expression of proteins 
as N-terminal His6-tag fusions, but they differ in the cleavage sites between the tag and 
target protein.  Novagen’s pET28a(+) contains a thrombin cleavage site, while Invitrogen’s 
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pPROEX has a TEV-cleavage site.  It has been postulated that the differences in residues that 
surround the His6-tag may affect the strength of the interactions between the tag and the 
imidazole (a structural analog of histidine) used during the immobilized metal affinity 
chromatography (IMAC) purification of the target protein. 
Furthermore, the heterologous expression of Mtb proteins in E. coli is known to be 
problematic, often giving low expression levels or leading to the expression of insoluble 
protein in inclusion bodies.  Such difficulties in protein synthesis and folding may be due to 
the differences in codon usage between the organisms.19  Eleven scarce codons, i.e. codons 
that are not generally used by E. coli for expression of its native proteins,20  were identified 
in the Mtb coaX-gene:  7 × CGG (Arg), 3 × GGA (Gly) and 1 × CCA (Pro).  This gives a ≈ 4% 
scarce codon incorporation.  To circumvent this as a possible cause of poor soluble 
expression, an optimized version of the coaX-gene (i.e. a version in which the scarce codons 
were replaced with codons more regularly used by E. coli) was synthesized by GenScript USA 
INC and cloned into pET20b(+) for expression of the CoaX protein with a C-terminal His6-tag 
fusion. 
The amplified Ms coaX was only cloned into pET28a(+) with NdeI and NotI restriction 
enzymes.  NotI was used instead of XhoI since the gene has an internal XhoI site.   
4.4.3  Expression and purification of the recombinant CoaX proteins 
a)  Mtb CoaX 
The native Mtb coaX gene contained in the pET28a(+) and pPROEX plasmids was expressed 
with an N-terminal His6-tag by induction with 1.0 mM isopropyl-β-D-thiogalactoside (IPTG) 
at 37°C overnight.  The resulting proteins were subsequently purified by IMAC using Ni2+ as 
the bound metal ion.  The success of expression and purification was evaluated by SDS PAGE 
analysis of the proteins obtained during various stages of the process (Figure 4.4).  This 
shows that both plasmid constructs are expressed and that the resulting protein could be 
successfully purified using IMAC. 
The optimized gene cloned into a pET20b(+) construct was similarly expressed (albeit with a 
C-terminal instead of an N-terminal His6-tag) following the same procedures as described 
above.  However, there were no noticeable differences in the amount or the purity of the 
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protein obtained in this case compared to the protein expressed from the genes that were 
not codon optimized (results not shown). 
 
Figure 4.4:  Expression and purification of Mtb CoaX from pET28a(+) and pPROEX.  The amount of pure protein 
shown in the lane marked “Protein” is normalized and is not an indication of the amount expressed or purified. 
M = PageRuler marker (Fermentas), CE = crude extract, FT = flow through (proteins that are not retained by  
IMAC, Wash = non-specifically bound proteins, Protein = Mtb CoaX. 
The proteins from all three expression constructs were found to be unstable and 
precipitated during buffer exchange by gel filtration using desalting columns.  This suggested 
that the CoaX protein was highly sensitive to buffer conditions or to possible contaminants 
present on the desalting columns.  Since the use of new desalting columns did not solve the 
problem, we concentrated our investigation on the use of various purification conditions to 
stabilize the protein and prevent precipitation.  The first set of experiments focused on 
optimizing the IMAC purification and subsequent gel filtration by evaluating various the 
buffer systems. The conditions tested are summarized in Table 4.2. 
Three different buffers are normally used for the purification of His6-tagged proteins by 
IMAC:  binding buffer, which is used for cell lysis and to load the sample onto the column; 
elution buffer, which is used to elute the protein from the column and which therefore 
contains high concentrations of imidazole, and gel filtration buffer, which is used to 
exchange the purified protein to buffers containing no imidazole and lower concentrations 
of salts.  We evaluated several different systems that make up these three buffers to 
determine whether it influenced protein stability. The Tris-buffer system (entry 1) is a 
standard system for protein purification.  Alternatively, a phosphate-based system with a 
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lower pH is often used if the target protein is not stable in Tris-buffer.  If problems with 
stability persist, the last system (entry 3), in which 10% glycerol is added to the binding and 
elution buffers to further stabilize the target protein, is used.  The concentration of 
imidazole can also be decreased, since the removal of tightly-bound imidazole during gel 
filtration could be an important cause of the protein precipitation.  Unfortunately, none of 
these systems improved protein stability, and coaX was found to precipitate in all cases 
upon buffer exchange by gel filtration.  
Table 4.2:  Different buffer systems used for IMAC purification of Mtb CoaX. 
 
As an alternative to the buffer exchange by gel filtration, dialysis experiments were 
performed in which the concentration of NaCl and imidazole was gradually decreased.   
Regardless of the buffering system used, buffer exchange was only successful if the 
concentration of NaCl and imidazole were not reduced below 250 μM respectively.   
b)  Ms CoaX 
Ms CoaX was expressed at 20°C overnight after inducing with 1.0 mM IPTG. It was purified 
using phosphate-based buffers (refer to entry 2 in Table 4.1), but the same precipitation 
issues were experienced.  The enzyme-containing fractions were therefore not desalted or 
dialyzed.  
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4.4.4  In vitro activity of Mtb and Ms CoaX proteins 
To determine whether CoaX proteins display pantothenate kinase activity, the coupled 
enzymatic assay described in Chapter 3 (section 3.5.4), was used.27  The protein fractions 
were tested in the salt- and imidazole-containing buffers used for protein purification. 
Initial activity determinations failed to show any PanK activity for the Mtb CoaX containing 
fractions. The Ms CoaX homolog by contrast did prove active.  This protein was therefore 
characterized further using the described coupled enzymatic assay.2  The initial rates were 
determined and plotted against the substrate concentration (Figure 4.5).  The kinetic 
parameters were obtained by fitting the data to the Michaelis-Menten equation (1). 
  
        
      
                                        
The kinetic parameters obtained in this manner are summarized in the table given in  
Figure 4.5 (right).  The parameters for P. aeruginosa PanK-III with pantothenic acid is also 
shown for comparison.  
 
Figure 4.5:  Left:  Steady state kinetics of M. smegmatis CoaX with pantothenic acid. Each point represents the 
average of three readings, while the error bars denote the standard deviation.  Solid lines represent the best-
fit of the data to the Michaelis-Menten equation.  
Right: Table summarizing the kinetic parameters for M. smegmatis CoaX and P. aeruginosa PanK-III. 
4.4.5  Alternate Phosphoryl donors 
One of the main characteristics of PanK-III enzymes is their unusually high KM-values for ATP, 
which seems to indicate that this is not the main phophoryl donor of these enzymes.  To test 
whether this might be the reason for the apparent inactivity of Mtb CoaX, i.e. that it 
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requires a different activated phosphate for activity, UTP, CTP, GTP and PEP (at a final 
concentration of 1.5 mM) were tested as alternative phosphoryl donors for the 
phosphorylation of pantothenate using the PanK-IIIs from B. subtilis, H. pylori 5 and Mtb 
(L.A. Brand, unpublished data).  The reaction mixture with PEP was analyzed by a two 
enzyme coupled assay, while the rest of the reaction mixtures were analyzed by ESI-MS for 
the presence of 4’-phosphopantothenate.  The results were compared with mixtures 
containing ATP as well as to control reactions with E. coli PanK-I.  Only CTP and GTP could 
substitute for ATP in the case of H. pylori PanK-III, albeit to a lesser extent.  None of the 
other potential phosphoryl donor was active in the reactions catalyzed by B. subtilis PanK-III 
and Mtb CoaX.   
4.4.6  Modeling 
The multiple sequence alignment shown in Figure 4.1 indicated that the Mtb and Ms CoaXs 
bear high sequence similarity to known PanK-III enzymes, and contained the conserved 
motifs and residues required for activity.  However, closer examination shows that the 
mycobacterial protein sequences diverges from the normal PHOSPHATE 1 and ADENOSINE 
binding motifs as shown in Figure 4.6.   
 
Figure 4.6:  PHOSPHATE 1 and ADENOSINE motifs showing the Gly to Arg and Gly to His mutations in the 
mycobacterial CoaX proteins. 
In PHOSPHATE 1 the highly conserved signature residue, Gly8, is replaced by Asp, while the 
Gly229 in the ADENOSINE motif is replaced by His.  To evaluate the effect of these 
substitutions on the protein structure, we modeled the Mtb enzyme based on the structure 
of T. maritima PanK-III (TmPanK-III) with pantothenic acid and ADP bound.  A comparison of 
the Mtb CoaX model and the TmPanK-III structure clearly shows that in the case of the Mtb 
protein the substitutions give rise to an additional negative charge involving the His and Arg 
residues.  These negative charges lead to H-bonding which closes the ATP binding site. 
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To disrupt the H-bonds, mutagenesis studies were subsequently performed to create Mtb 
CoaX H229G in which the His at position 229 was mutationally replaced by Gly to resemble 
the CoaX from non-mycobacterial proteins.  The effective removal of one of the charged 
residues should prevent H-bond formation and allow ATP to enter into the active site.  
However, this was found not to be the case, as this protein still failed to show activity.  Due 
to the instability of the protein, circular dichroism (CD) studies could not be performed to 
verify that the folding of the protein was not compromised by the mutational change. 
 
Figure 4.7:  Comparison of the structures of TmPanK-III and a model of the Mtb enzyme illustrating the 
consequence of the mutation of the conserved Gly residues to Arg and His respectively. 
Panel A:  The structure of TmPanK-III bound to pantothenic acid and ADP.  A1, Structure showing the solvent 
accessible surface of the protein. The red ribbon represents the helix and adjacent loop of the “Pan cap” from 
the adjacent monomer. A2, Ribbon structure showing the binding of pantothenic acid and ADP in the active 
site. For clarity the helix loop of the “Pan cap” was omitted. 
Panel B: The modeled structure of Mtb CoaX based on that of TmPanK-III. B1, Structure showing the solvent 
accessible surface of the protein (the "Pan cap" was omitted for clarity). The salt bridge that forms between 
the His and Arg residues clearly prevents ADP from binding in the same way it does in the TmPanK-III structure. 
B2, Ribbon structure of the model highlighting the H-bonding that is formed and its clash with the phosphate 
groups of ADP. 
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4.4.7  B. anthracis BA2901 
The only other bacterial PanK reported inactive to date is the hypothetical PanK-II from  
B. anthracis (BaPanK-II).12  The protein, BA2901, was unable to rescue an E. coli DV70 
temperature deactivated coaA mutant at 42°C and no in vitro activity was observed with 
pantothenic acid as substrate.  Since PanK-IIs are normally known to have the ability to 
phosphorylate alternative substrates (section 2.7.9), we wanted to test the enzyme with 
another known PanK substrate before also dismissing its potential as a pantothenate kinase.  
Pantetheine (the substrate of the CoA salvage pathway) was therefore tested as an 
alternative substrate, and Ba PanK-II was found to be active with this substrate. 
BA2901 was assayed using the PK/LDH-dependent coupled enzymatic assay14 described in 
Chapter 3 (section 3.5.4).  The initial rates were determined at various substrate 
concentrations and plotted against the concentrations of the substrate used (Figure 4.8).  
The plots were fitted with the equation for substrate inhibition 2 (graph on right).   
  
    
   
  
   
 
   
  
  
                               
 
Figure 4.8:  The steady state kinetics of B. anthracis BA2901 with pantetheine. Each point represents the 
average of three readings and the bars the standard error. Left:  Solid line represents the best-fit of the data to 
the Michaelis-Menten equation.  Right:  Solid line represents the best-fit of the data to the Substrate inhibition 
equation. 
The kinetic parameters obtained are summarized in the table in Figure 4.8 (right).  For 
comparison the parameters for E. coli PanK-II with pantetheine are provided. The enzyme 
was found to be subject to substrate inhibition at high concentrations, as demonstrated by 
the activity profile.   
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4.7  Discussion 
4.7.1  Functional complementation 
The design of functional complementation studies needs to be done with care as the results 
can otherwise be ambiguous and misleading. This is highlighted by the contradictory results 
shown in Figure 4.2 and 4.3 where, the construct containing H. pylori coaX failed to rescue 
the temperature sensitive E. coli mutants on both solid and liquid media.  The pantothenate 
kinase activity of H. pylori PanK-III has been confirmed in vitro and one could therefore 
expect a construct containing its coaX gene to rescue the E. coli mutant strain.  Moreover, 
the complementation studies with the B. subtilis coaX construct worked much better on 
solid than in liquid media, although in the latter growth occurred at a slower rate than with 
the cultures containing the constructs for the positive control (Ec coaA) and Mtb coaX.   
Our studies reveal that, contrary to the result of Awasthy et al. in 2010, Mtb coaX does 
complement the E. coli DV64 strain in liquid media. However, this result was not 
reproducible, and showed positive complementation on average only in one of every three 
repeats of the experiment.  The reason for this is currently unknown. 
4.7.2  Purification, gel filtration and dialysis 
Mtb CoaX enzymes were successfully expressed from three different constructs and purified 
by immobilized metal affinity chromatography (IMAC) with Ni2+.  However, the resulting 
proteins were all unstable and precipitated during buffer exchange by gel filtration or 
dialysis.  The three constructs were used to investigate the link between gel filtration 
induced degradation and tight binding of the imidazole to the 6xhistidine-tag.  While it has 
been suggested that the amino acid residues surrounding the 6xhistidine-tags may influence 
the strength of the interactions with imidazole, and that this may subsequently destabilize 
the enzyme when the imidazole is removed during gel filtration, we found no noticeable 
difference in stability of proteins expressed from either the pET28 or pPROEX constructs.  
Buffer exchange procedures by dialysis were more successful than those by gel filtration, 
although the NaCl and imidazole concentrations could only be reduced to half the initial 
values.  No further stabilization was observed by changing either the buffer (Tris-HCl, 
phosphate, MES and HEPES), or by varying the pH of the buffers over a range of 6.5 to 8.5. 
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4.7.3  Determination of in vitro enzymatic activity  
All Mtb CoaX enzyme variants produced as part of this analysis proved inactive in vitro, 
regardless of the buffer used for purification and gel filtration/dialysis as well as the 
phosphoryl donors tested.  In contrast the M. smegmatis CoaX homolog was indeed 
observed to be active.  Compared to P. aeruginosa PanK-III, the activity levels of Ms CoaX 
were low as exemplified by a ≈ 15 fold lower specificity constant than that of Pa PanK-III.  
Interestingly this is largely due to a lower binding affinity:  the KM for pantothenic acid Ms 
CoaX is about five times higher, while the kcat-value is about a third than that of Pa PanK-III.   
The central problem encountered for Ms CoaX however is its instability.  Even without gel 
filtration or dialysis, the enzyme precipitated and rapidly lost activity after purification.  This 
raises the question of whether the determined parameters truly reflect the enzyme native 
activity or whether the slower observed rates are due to compromised enzyme quality.  The 
purification strategy would therefore need to be revisited to produce stable enzyme for 
future kinetic studies. 
Another possible reason for the decreased activity observed with Ms CoaX, and a possible 
explanation for the lack of activity with Mtb CoaX, is the two substitutions naturally 
occurring in the PHOSPHATE 1 and ADENOSINE motifs of the active site.  In both cases a 
small uncharged residue, Gly, is replaced by a larger charged amino acid, Asp and His 
respectively.  Referring back to the model of the Mtb active site in Figure 4.7(B2), it is clear 
that the two point mutations introduce H-bonding in the active site of the enzyme that 
partly obstructs the ATP binding site by clashing with the terminal phosphate-group of the 
bound ADP.  These interactions may prevent ATP from binding in the active site and hence 
prevent the phosphoryl transfer reaction.  
The inactivity of the Mtb CoaX H229G mutant suggests that the additional Arg may still block 
the binding of ATP.  It could be of interest to prepare the double mutant in which both the 
His and Asp are replaced by Gly as seen in other active enzymes. 
Finally the bacterial PanK-III candidate from B. anthracis, BA2901, previously reported as 
inactive, has been demonstrated to be a pantetheine kinase rather than a pantothenate 
kinase.  Compared to E. coli PanK-I utilizing the same substrate, the KM-value of BA2901 is 
four-fold lower and its catalytic efficiency ≈ 10-fold higher.  This enzyme appears to be more 
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effective than E. coli PanK-I in phosphorylating pantetheine and, subject to further 
characterization of the enzyme, may be a good candidate enzyme to use in biocatalytic 
studies. However, the enzyme is subject to substrate inhibition at high pantetheine 
concentration, for which a Ki-value ≈ 800 μM was measured. 
4.8  Conclusion  
Available information would appear to indicate that Mtb CoaX is a pantothenate kinase.  
This could however not be confirmed as the results obtained in the in vivo studies were 
ambiguous and the in vitro results are questionable due to purification and stability issues.  
Activity was confirmed for the homologous Ms CoaX, although this enzyme is less active 
than other characterized PanK-IIIs.   
Two major factors that may account for the loss or reduced enzyme activity include the 
overall instability of both Mtb and Ms CoaX and two substitutions in the PHOSPHATE 1 and 
ADENOSINE motifs.  These substitutions are not specific to our test strains, as multiple 
sequence alignment of various virulent Mtb strains and other Mycobacterial CoaXs showed 
these mutations to be common.  The same replacements across various species imply that 
this is not a random occurrence.  Rather, it is possible that the H-bond introduced by these 
mutations has a specific function, such as acting as gatekeeping residues that open under 
certain conditions.   
Lastly, the only other putative bacterial PanK reported as inactive, BA2901 from  
B. anthracis, was found to be active when tested with pantetheine as substrate, the 
precursor of the CoA salvage pathway.  Although this is an important breakthrough in our 
understanding of the B. anthracis PanK enzymes, Mtb CoaX is unlikely to behave in a similar 
manner due to the enclosed active site of the PanK-IIIs (section 2.7.3) and previous reports 
have indicated that both the Treponema pallidum21 and P. aeruginosa22 PanK-IIIs are unable 
to phosphorylate pantetheine.  However, this does support the hypothesis that this enzyme 
may have an alternative metabolic function and that inactivity should not be assumed 
prematurely. 
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4.9  Experimental 
M. tuberculosis H37Rv genomic DNA was a gift from Rob Warren from Medical Biochemistry 
at Tygerberg campus, University of Stellenbosch. 
M. smegmatis culture was a gift from Prof Daan Steenkamp from the Medical School, 
University of Cape Town.  
The B. anthracis BA2901 encoding plasmid construct was a gift from A.L. Claiborne from 
Wake Forest University School of Medicine, Winston-Salem, North Carolina. 
4.9.1  Genomic DNA isolation 
A culture of M. smegmatis was inoculated from freezer stocks into 7H9 media (0.52 g.l-1 
Middlebrook 7H9 broth base, 0.44% glycerol and 0.1% Tween 80 – mixed according to 
manufacturer’s instructions) and grown for 36 h at 37°C.  Genomic DNA was isolated from 
the culture using the the Gram-positive procedure purification of the Wizard™ Genomic 
DNA Purification kit from Promega (cat # A1120).  After the ethanol wash step, the DNA 
pellet was aspirated at 65°C overnight before rehydration with the rehydration solution. 
4.9.2  Amplification and cloning 
a)  General procedures 
All primers were synthesized by Inqaba Biotech.   Amplification was done using pfu enzyme 
(Fermentas) in the provided buffer with 0.4 mM dNTP mix, 1.0 mM forward primer, 1.0 mM 
reverse primer, 1.0 µl genomic DNA /plasmid template, varied MgCl2 concentrations  
(2.0 mM, 2.5 mM, 3.0 mM and 4.0 mM) and water to a final volume of 25 µl.  The PCR 
program started with an incubation step of 2 min at 94˚C before the cycle started with a 
denaturation step at 94˚C for 30 s, an annealing step at 60˚C for 30 s and a polymerization 
step at 68˚C for 1.5 min.  This cycle was repeated 30 times followed by an extended 
polymerization step of 6 min at 68˚C and the program ended with a hold step at 4.0˚C.  The 
reaction mixtures were analyzed by gel electrophoresis on 1.0% agarose gels and the bands 
visualized by staining with SYBR®gold on the Darkreader.  Product bands (in comparison to 
New England biolabs 2-log ladder marker) were purified from the gel with the GeneJET™ Gel 
Extraction kit (Fermentas). 
The PCR products and plasmids were digested with the relevant Fastdigest enzymes 
(Fermentas).  A double digestion mix typically consists of 2.0 µl Fastdigest buffer, 16 µl PCR 
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product/plasmid, 1.0 μl of each enzyme in a final volume of 20 µl.  The digestion mixures 
were incubated at 37˚C for 1 h before resolving the entire mixture on 1.0% agarose gels. The 
target DNA fragments were from the gels (as described above) and the concentration 
determined with Quant-iT™ dsDNA HS dye (Fermentas) with the Qubit™ fluorometer.   
Based on the concentration different ratios of insert: plasmids were combined in a volume 
of 5.0 μl with 5.0 µl Quick ligase buffer with 0.5 µl Quick ligase enzyme (New England 
Biolabs). The ligation mixtures were incubated at 37˚C for 1 h before the entire reaction 
mixture was transformed into E. coli Mach1 chemical competent cell, plated on Luria 
Bertani (LB) agar enriched with the relevant antibiotic and incubated overnight at 37˚C.   
Any colonies obtained the next day were screened by mixing a smear of each colony into  
25 µl Epilyse solution 1 (30 mM Tris-HCl, pH 8.0, 5.0 mM Na2EDTA, 50 mM NaCl, 20% 
sucrose, 0.047 µg.ml-1 lysozyme and 0.047 µg.ml-1 RNAse).  After 10 µl Epilyse solution 2  
(1 × TAE buffer, 2% SDS, 5% sucrose and 2 mg.ml-1 bromophenol blue) was added, the 
mixtures were analyzed on 1.0% agarose gels by comparing the samples to the undigested 
parent plasmid.  DNA-samples larger than the parent plasmid were subjected to further 
screening.  This involved a digest check of the purified target plasmids (purified from 
overnight cultures with the Zippy™ Plasmid Miniprep kit) with selected enzymes to screen 
base on the size patterns obtained.  If the band sizes were correct, the plasmids were sent 
to Inqaba Biotech for sequencing with T7 primers.  
b)  Mtb coaX 
pET28a(+)-coaX 
(Amplification and cloning of Mtb coaX was performed by Mrs LA Brand.) 
The coaX-gene was amplified from genomic DNA. The forward primers introduced an NdeI 
restriction sites and the reverse primers XhoI restriction sites (underlined) and was cloned 
into pET28a(+).   The following primer set was used: 
forward primer:  5’ – CGGTGTGGGATACATATG CTGCTGGCGATTGACGTCCGC– 3’  
reverse primer:  5’ –CGGCGCGCTGACGTCGATGCCGG CCTCGAGTCTGGG – 3’.   
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pPROEX-coaX 
The coaX-gene was subcloned from the pET28a(+)-coaX construct into pPROEX using the 
NdeI and XhoI RE sites.  
pENTR4N-coaX 
The coaX-gene was subcloned from the pET28a(+)-coaX construct into pENTR4N using the 
NdeI and XhoI RE sites. 
 pBAD EXP49-coaX 
(Cloning was performed by Ms Ndivhuwo Muneri.) 
This expression vector was constructed by making use of the Gateway™ LR reaction system.  
This system allows the formation of expression clones by adding together an entry plasmid 
(pENTR) containing the gene sequence and a destination plasmid (pDEST) together with LR 
clonase.  Both plasmids contain defined att-sites.  During the LR reaction the fragments of 
DNA between the att-sites get exchanged.  This allows the formation of an expression 
vector containing the target DNA sequence.   
For the LR reaction 1.0 μl pBAD DEST49, 0.5 μl pENTR4N-coaX, 0.5 µl LR clonase buffer and 
0.5 µl LR clonase was mixed together and incubated at 25˚C overnight.  The reactions were 
terminated by addition of 1.0 µl Proteinase K and incubation for 10 min at 37˚C.  The entire 
LR-mixture was transformed into E.coli Mach1 chemical competent cells and plated on LB 
plates enriched with 100 mg.l-1 ampicillin.  Starter cultures were made of the colonies 
obtained and after incubation at 37°C overnight the plasmid was extracted and digested 
with Fastdigest BsrGI (Fermentas).  BsrGI only digests within the att-sites of the expression 
clones if the LR exchange occurred correctly and thus a unique pattern is observed when the 
digestion mixture is resolved on a 1.0% agarose gel. 
c)  Ms coaX 
Ms coaX was amplified from genomic DNA by two rounds of amplification.  The first round 
amplified a region wider than the gene and the second round was targeted amplification of 
the target coaX-gene.  In the second set of primers the forward primer introduced an NdeI 
restriction site and the reverse primer a NotI site (underlined) for cloning into pET28a(+). 
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The following primer sets were used: 
First set:           forward primer:  5’ – AACGACCAGAACC CGAACTGCCCTGG – 3’ 
reverse primer:   5’ – CTCCCACCCGTGCACGACGTTCGACAAG – 3’ 
Second set:      forward primer:   5’ – CCGTGGCGC CGAGAATCCCATATGCTGCTCGCG - 3’ 
reverse primer:  5’ – CGTCGACCTGGTGCGGCCGC TCTTCTGATCAG – 3’ 
All amplification mixtures were supplemented with 5% DMSO.  The coaX-gene was cloned 
into pET28a(+).  
d)  Mutagenesis of Mtb coaX H229G 
(Amplification and cloning of Mtb coaX H229G was performed by Mr J. Albert Abrie.) 
The mutation was introduced with SOE PCR using pET28(a)-Mtb coaX plasmid as template.  
First set:           forward primer:  T7 forward primer 
reverse primer:   5’ – GGGCGCGGTA CCCCCGGTAGCCACG– 3’ 
Second set:      forward primer:   5’ – CGTGGCTACCGGGGGTACCGCGCCC– 3’ 
reverse primer:  T7 reverse primer 
Third set:           forward primer:  T7 forward primer 
 reverse primer:   T7 reverse primer 
The mutated gene was cloned into pET28a(+) and expressed as described above from 
pET28(a)-Mtb coaX. 
 
4.9.3  Protein expression and purification 
a)  Mtb CoaX 
Protein was produced in LB media (500 ml), supplemented with 30 mg/L kanamycin, and 
inoculated with plasmid containing E. coli BL21(DE3) starter culture.  The culture was grown 
until midlog phase was reached and induced with a final concentration of 1.0 mM isopropyl-
β-D-thiogalactoside (IPTG) and grown further at 37°C overnight.   
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The harvested pellet was resuspended in a volume of 10  the pellet weight of binding 
buffer (various buffers used) and cooled to < 10°C.  Cells were disrupted by sonication and 
the cell debris collected by centrifugation at 25 000 rpm for 20 min at 10°C.  To prepare the 
supernatant for purification it was filtered using CAMEO 25 AS acetate filters with a pore 
size of 0.45 micron before injection into the ÄKTAprime-system.  The His6-tagged protein 
was loaded to a 1.0 ml Amersham Biosciences HiTrap Chelating HP column preloaded with 
Ni2+.  After a wash step (15% elution buffer, 85% binding buffer) to remove any non-
specifically bound proteins from the column, the target protein was eluted by stepwise 
increasing the concentration of imidazole (the functional group of histidine) in the buffer.  
The elution was monitored by UV absorption at 280 nm.   
b)  Ms CoaX 
Expression was induced at midlog phase with a final concentration of 1.0 mM IPTG at 20°C 
overnight.  The protein was purified as above using Phosphate buffers (Table 4.2, entry 2). 
To stabilize the enzyme for freezing and thawing, glycerol was added to 10% of the final 
volume.  The enzyme was used “as is” in further applications without further purification by 
gel filtration due to instability problems.  
c)  Mtb CoaX H229G 
The protein was purified as above using Tris- based buffer at pH 8.0 supplemented with 10% 
glycerol (Table 4.2, entry 3).  Due to precipitation problems, the enzyme containing fractions 
were not desalted and used “as is” in further applications. 
4.9.4  Dialysis of Mtb CoaX 
All samples used for dialysis were purified using an ÄKTAprime liquid chromatography 
system with Tris-based elution buffer (Table 4.2, entry 1).  The dialysis set-up shown in 
Figure 4.9 consisted of the lid of an Eppendorf tube in which 100 μl of enzyme sample was 
pipetted before covering with SnakeSkin dialysis tubing (Thermo Scientific, Pierce).  The 
dialysis tubing was secured with parafilm and a dialysis clamp before suspending it in a 
beaker containing the relevant buffer (> 250× sample volume).  Dialysis was performed at 
4.0°C with continual stirring and the buffer changed every 2.0 h.  
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Figure 4.9:  Panel A – schematic representation of dialysis set-up.  Panel B – Photo of Eppi lid containing the 
sample, covered with SnakeSkin Dialysis tubing and secured with a dialysis clip.  Panel C – Photo of final set-up.   
 
4.9.5  Determination of protein purity and concentration 
The proteins were visualized by SDS PAGE.  All samples of the appropriate volume were 
mixed with an equal volume of 2  SDS PAGE loading buffer (0.125 M Tris-HCl, pH 6.8, 4.0% 
SDS, 30% glycerol, 1.5% β-mercaptoethanol and 0.02% bromophenol blue), boiled at 95°C 
for 5.0 min, loaded on the 12%  gel and ran in SDS PAGE running buffer (0.1% SDS, 0.025 M 
Tris-HCl and 0.192 M glycine).  After completion the gel was stained with Coomassie blue 
stain (45 ml methanol, 40 ml H2O, 10 ml CH3COOH and 250 mg Coomassie Brilliant Blue) and 
destained with Destaining solution (45% methanol, 45% H2O, 10% CH3COOH). 
The protein concentrations were determined using the Bradford method in comparison to 
bovine serum albumin (BSA) standards.   
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4.9.6  Functional complementation 
The relevant pBAD EXP49 constructs were transformed into chemical competent E. coli 
DV62 cells.  Starter cultures were made in the morning on the day of the experiment from a 
single colony in 5 ml LB media supplemented with 100 mg/L ampicillin.   
a)  Solid LB media 
The cultures were streaked unto either minimal media plates (2.0% E-salts, 0.2% glycerol, 
0.01% thiamine, 0.1% methionine, 0.2% arabinose, 10 mM β−alanine, 100 mg.ml-1 ampicillin 
and 1.5% agar) or rich LB plates (LB agar supplemented with 100 mg.ml-1 Ampicillin).  The 
plates were sealed with parafilm and incubated at the relevant temperatures (positive 
control:  30°C;  experiment:   42°C) for 24 h. 
b)  Liquid minimal media  
Complementation was done in Corning 24-well flat bottom cell culture plates using a 
Thermo Varioskan™ spectrophotometer.  To initiate the experiment, 10 ml minimal media 
(2.0% E-salts, 0.2% glycerol, 0.01% thiamine, 0.1% methionine, 0.2% arabinose, 10 mM 
β−alanine and 100 mg/L ampicillin) was inoculated with 10 μl starter culture.  The plate was 
incubated at 42°C with shaking and the increase in optical density followed at 600 nm by 
taking a reading every 30 min over a period of 30 h. 
4.9.7  Activity test 
PanK activity was measured by a continuous enzymatic coupled assay which links the 
formation of ADP to the consumption of NADH.14  All reactions were performed at 37°C in a 
Thermo Varioskan™ spectrophotometer.  Each 300 μl contained 100 mM HEPES, pH 7.5, 1.0 
mM MgCl2, 60 mM  NH4Cl2, 2.0 mM PEP, 0.5 mM NADH, 0.5 mM pantothenic acid,  
10.0 mM ATP, 2.75 U LDH, 2.0 U PK, and enzyme.  The reactions were initiated with the 
addition of the enzyme and the decrease of NADH measured at 340 nm over a period of 5 
min. 
4.9.8  Kinetic characterization 
The kinetic characterization of B. anthracis BA2901 was undertaken as described in Chapter 
3 for P. aeruginosa PanK-III with β-methylpantothenic acid. 
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Chapter 5: 
Expression and characterization of the putative 
Archaeal PanK-IV (COG1829) 
5.1  Background 
At the beginning of this study no PanK enzymes had been identified, isolated or otherwise 
characterized from any of the Archaea.  Homology searches of all available Archaeal 
genomes, using sequences of any one of the three known PanK types as search terms, failed 
to identify potential candidates of putative PanK-encoding genes.  By contrast candidates 
for the four remaining CoA biosynthetic enzymes could be identified.  The presence of these 
four enzymes indicates that the Archaea should be able to biosynthesize  
4’-phosphopantothenate, either through phosphorylation of pantothenic acid by an as yet 
uncharacterized type of PanK, or by a novel mechanism.  To identify the “missing” Archaeal 
CoA biosynthesis genes, Ulrich Genchel (from Technische Universitat, München) 
reconstructed the CoA biosynthesis pathway using of phylogenetic profiles and 
chromosomal proximity methods.1  This identified strong candidates for two of the “missing 
proteins” in the Archaeal pathway – COG1829 for the PanK and COG1701 for the 
pantothenate synthase (PS).  COG1829 was found to be unrelated to any of the three 
characterized PanK types.  The aim of this chapter was to isolate and characterize the first 
example of COG1829 as a putative Archaeal PanK-IV.   
5.2  Results – Identification, isolation and purification 
5.2.1  Functional complementation studies 
To determine whether the COG1829 candidates displayed pantothenate kinase activity as 
predicted by the Genchel study, functional complementation studies were done.  Candidate 
genes from Pyrococcus furiosus (Pf) and Pyrococcus horikoshii (Ph) were cloned into the 
pBAD-DEST49 vector, transformed into E. coli DV62 and the cultures grown in liquid minimal 
media at 42°C following the same procedure as outlined in section 4.4.1.  The gene products 
from both extremophile strains were able to rescue the E. coli mutant strain at 42°C (refer 
to Figure 5.1).  Based on the positive result obtained, we set out to isolate and characterize 
these enzymes in vitro. 
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Figure 5.1:  Functional complementation studies done in liquid minimal media clearly shows complementation 
of the temperature sensitive E. coli DV62 strain by Pf and Ph candidate COG1829s. 
 
5.2.2  Purification of the candidate COG1829 from Pyrococcus furiosus 
At the onset of this project the putative Pf PanK-encoding gene had already been cloned 
into pET28a(+), pDEST544 and pDEST566. Expression was obtained from the pET28a(+) 
construct, from which the target protein was expressed as an N-terminal His6-tag fusion, but 
the enzyme was found to aggregate in inclusion bodies.  Attempts to solubilize and purify 
the protein from the inclusion bodies failed to deliver active protein.   
The solubility of target proteins can often be increased by introduction of N-terminal fusions 
with highly soluble and relatively large protein partners.  Maltose binding protein (MBP) is a 
43 kDa fusion tag that is encoded by pDEST566, while nut utilization substance (Nus) protein 
is 54 kDa tag encoded by pDEST544.  The constructs in these destination vectors were 
designed in such a way that a His6-tag precedes the fusion partner, and a tobacco etch virus 
(TEV)-cleavage site is introduced between the tag and the target gene.  Soluble protein was 
only observed for the pEXP566-TEV-construct which produce the smaller His6-MBP-fusion 
(as appose to the larger His6-Nus-fusion).  However, purification of this protein by IMAC 
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failed because the Ni2+ appeared to be chelated and stripped from the column by the 
protein during the injection step.  Affinity purification with amylose resin of the His6-MBP-
fusion was also unsuccessful. 
In light of the problems experienced with IMAC purification, alternative purification 
methods were investigated for the MBP-tagged protein.  Ion exchange chromatography was 
attempted first, but the enzyme obtained in this manner was neither pure nor active.  Next, 
purification by heat denaturing of the contaminating E. coli proteins were investigated. 
Since the optimum temperatures of the organisms used in this study is ≈ 100°C, it was 
expected that the target extremophile kinase would remain soluble and in an active form, 
while the E. coli proteins would precipitate and be removed by centrifugation.  However, 
prior to heating, the MBP-tag would need to be cleaved from the target protein to prevent it 
from negatively affecting the heat stability of the latter.  
The pellet obtained from the expression of the MBP-tagged COG1829 candidate enzyme 
was lysed by sonication, and the lysate was subsequently treated with TEV protease in a 
ratio of 1:100 w/w of TEV protease: total protein in cell lysate.  The protein concentration in 
the cell lysate was determined by the Bradford method in comparison to BSA standards.  
After the digestion step, the fractions were heated to 90°C, the denatured E. coli proteins 
pelleted by centrifugation and the soluble fraction analyzed by SDS PAGE in comparison to a 
control experiment in which the lysate was not treated with TEV protease.  In Figure 5.2 a 
12% SDS-polyacrylamide gel is shown with the purified protein bands clearly visible.   
 
 
Figure 5.2:  Fractions obtained after heat purification of TEV digested (Exp) and undigested (Control) MBP-
tagged Pf COG1829;  M = PageRule™ unstained protein marker (Fermentas).   
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Although good purification was obtained with this method, there were three disconcerting 
factors:  (1) the protein purified in this manner was smaller than the expected 35 kDa of the 
target protein, (2) the purified protein displayed no noticeable activity in the LDH/PK 
coupled PanK assay (as described in section 3.5.4)2 and (3) the same bonds were observed 
with the negative control (boiled lysate undigested by TEV protease).  While the lack of 
activity could possibly be due to the LDH/PK assay conditions not being optimal for the 
determination of the activity of thermophilic enzymes (a shortcoming addressed in section 
5.3), the apparent decreased size of the target protein warranted further investigation. 
5.2.3  Characterization of the candidate COG1829 from Pyrococcus furiosus 
To determine whether the smaller size of the target protein obtained through the heat 
denaturing purification was due to degradation, the resulting protein band was analyzed by 
various mass spectrometry techniques.  However, neither ESI-MS, LC-MS, capillary MS nor 
MALDI-TOF were able to provide the size of the protein.  The 12% SDS-polyacrylamide gel 
from Figure 5.2 demonstrates that the purified samples contained other contaminating 
proteins.  To eliminate interference from these sample impurities with the MS analysis and 
to avoid extensive buffer exchange steps, the sample was purified by and extracted from 
the SDS-polyacrylamide gel.  The 12% gel was negatively stained with CuCl2
3 and the protein 
extracted by the gel extraction method A described by Cohen et al.4  The protein obtained 
by this method was analyzed by MS, but still the mass could not be determined. 
The problems in determining the size of the protein was interpreted to occur because the 
protein candidate was too large for the instrumentation.  To obtain smaller fragments 
peptide mass fingerprinting (PMF) was used.   This involves the digestion of the target 
enzyme to produce smaller fragments followed by the quantification of each band by MS.  
To do this analysis in house, COG1829 was extracted from the SDS-polyacrylamide gel and 
digested using clostripain as described by Shevchenko et al.5,6  Clostripain was chosen as it is 
predicted to cut COG1829 only 15 times compared to the 34 sites for trypsin.  The fewer and 
bigger bands are easier to visualize with SDS PAGE before analysis of the fragments by MS.  
After this in house analysis failed to produce usable results, the protein was sent to the 
Centre of Proteomic and Genomic Research, Faculty of Health Sciences, University of Cape 
Town for PMF analysis by digestion with trypsin followed by MS analysis.  This analysis 
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identified the protein as D‐ribose binding protein from E. coli (the top 5 hits all indicated this 
protein or mutants thereof) with 100% confidence in identity assignment. 
5.2.4  Further attempts to solubilize the candidate COG1829  
As heat precipitation could not be used for protein purification, extensive new expression 
trials were undertaken to produce native COG1829 protein or various fusion proteins 
thereof. The fusions tags tested included N- or C-terminal His6-, N-terminal His6-MBP-TEV 
and N-terminal thioredoxin. The proteins were produced using either E. coli BL21(DE3),  
E. coli C41 or C43 cell strains (for toxic protein expression) at various temperatures and cells 
were induced using increasing concentrations of IPTG. 
To further increase translation efficiency, co-expressions were performed with either the 
pRARE (Novagen) or pLysS (Lucigen) plasmids, which express the tRNAs of certain scarce 
codons (discussed in section 4.4.2).  None of these conditions yielded sufficient soluble, 
active protein for purification by IMAC.   
5.2.5  Methanocaldococcus jannaschii COG1829 candidate 
As all attempts to produce and purify the P. furiosus COG1829 protein failed, we set out to 
purify the same protein from a different Archaon. The gene encoding COG1829 from 
Methanocaldococcus jannaschii was subcloned into pET28a using NdeI and BamHI 
restriction sites.  Extensive expression trials in E. coli BL21(DE3) at various temperatures and 
induction with increasing IPTG concentration did not lead to clear bands of soluble protein 
being observed by SDS PAGE.  To identify whether any protein could be purified, batch 
expressions were done with the best results obtained from the expression trials and 
purification attempted by IMAC with Ni2+.  However no protein was purified in this manner, 
leading us to conclude that the soluble expression was unsuccessful. Based on an article 
published at this time (discussed in section 5.4.4), this study was abandoned. 
5.3  Results - Assay development 
5.3.1  Survey of available assay methods 
To determine the kinetic parameters of the extremophile PanKs an assay is required that 
can be performed at the predicted high optimal temperatures of these enzymes.  (Although 
it is presumed that the COG1829 candidate will function optimally at temperatures in excess 
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of 90°C, the optimal temperature will need to be determined first before full kinetic 
characterization is undertaken).  The continuous PanK assay that is most often used, the 
coupled LDH/PK assay described earlier,2,7 makes use of coupling enzymes which would 
denature at these high temperatures. We therefore investigated other, mainly 
discontinuous assays, which could be employed at elevated temperatures. 
Other established PanK assays include HPLC based and radioactivity assays.  However, 
currently it would be difficult to separate and detect pantothenate (the substrate) and  
4’-phosphopantohenate (the reaction product) by HPLC.  Assays with radioactive  
14C-pantothenic acid are widely used,8-12 as are methods that assay ATP consumption by 
following the time course with 31P NMR.13-15  These assays are known for their sensitivity 
and are preferable for accurate quantification.  However, for routine work we were 
interested in developing an assay that is easier to set up and cheaper to use.  Two other 
options were therefore investigated.  In the first assay, the concentration of ADP remaining 
after completion of the enzymatic reaction is quantified using the LDH/PK coupling enzymes 
normally used for the continuous assay.16  In the second method, Luciferase is used to 
quantify the concentration of the remaining ATP.17,18  We adapted the assay with the 
coupling enzymes to quantify the [ADP]. 
5.3.2  ADP quantification 
In the LDH/PK coupled assay (Figure 5.3) one molecule of pantothenic acid reacts with one 
molecule of ATP to form one molecule of ADP.  This ADP molecule is recycled by PK 
generating one molecule of pyruvate which in turn is consumed by LDH while one molecule 
of NADH and one molecule lactate are generated.  Thus for every molecule of ADP produced 
in the phosphorylation reaction, one molecule of NADH is consumed. 
 
Figure 5.3:  Coupled enzymatic assay used to quantify the [ADP] produced by the PanK reaction. 
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The assay was split into two parts.  First the enzymatic reactions are conducted at the 
required high temperature for a predetermined time.  After the enzymatic reaction is 
terminated, the assay mix, containing the coupling enzymes and reagents, are added to the 
reaction mixture and the absorbance of NADH measured at 340 nm.  Using a standard 
curve, the amount of remaining NADH can be determined and correlated to the amount of 
substrate consumed in the reaction.   
Our first course of action was to test the stability of our system at different incubation 
temperatures.  Solutions were made in Tris-buffer containing pantothenic acid and varying 
concentrations of ADP.  After incubation for 20 min at either 37°C or 90°C the assay mixture 
(PEP, PK, LDH and NADH) was added and the absorbance measured at 340 nm at 25°C.  The 
solutions were stable at the higher temperatures and excellent linear regressions were 
obtained as can be seen in Figure 5.4 for the ADP standard curve.  R2-values of 0.996 were 
obtained for linear regression fits on both data sets. 
Figure 5.4:  Standard curves for ADP and NADH 
For the NADH standard curve solutions of different concentrations were made in H2O and 
measured as is.  As shown in the graph in Figure 5.4, the NADH curve is only approximately 
linear to a concentration of 600 μM.  A final concentration of 500 μM NADH was used in all 
following assays as this value is within the linear range. 
Another aspect that had to be established was the degree of denaturation of PanK at the 
reactions at elevated temperatures.  Because the extremophile PanKs are believed to be 
heat-stable, the enzyme reaction cannot be terminated by heat denaturation, while 
stopping the enzyme reaction in any other way may influence the performance of the 
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coupling enzymes.  Various enzyme denaturing techniques were investigated, including 
additives (1 M NaOH (base), 1 M HCl (acid), detergents Tween and Triton, ethanol), flash 
cooling in ice water and removing the enzyme by syringe filter.  Addition of acid and base 
were found to be problematic as the pH had to be neutralized prior to the addition of the 
coupling enzymes.  Tween appear not to affect the enzyme.  Removing the protein by 
syringe filter, flash cooling in ice water, and the addition of Triton and ethanol all proved 
useful and resulted in comparable results.  For assays in Eppendorf tubes, flash cooling in ice 
water was used to stop the enzymatic reaction, while reactions in multiwell plates were 
stopped by the adding ≈ 5% ethanol.   
The LDH/PK coupled assay was successfully modified and used to quantify the concentration 
of ADP in the reaction mixtures and was used in all further screening work.  All assays were 
executed at 90°C since, E. coli PanK-I was observed to be marginally active at 60°C.   
5.4  Discussion  
5.4.1  COG1829 as a candidate PanK 
The candidate enzymes from Pyrococcus furiosus and Pyrococcus horikoshii were both able 
to rescue the E. coli mutant strain at 42°C, albeit at a slower rate than the E. coli PanK-I 
positive control. The slower growth rate was not a concern as the optimum growth 
temperatures of the extremophile, and subsequently the optimum activity temperature of 
the enzymes, are much higher than the assay temperature.  This result therefore supported 
the prediction of COG1829 being a PanK.  However, as we were unable to produce and 
purify a candidate COG1829 as described above, this interference could not be confirmed in 
vitro. 
New information published in 2009 (see below), indicated that COG1829 is not a PanK as 
originally postulated.  This study was therefore suspended. 
5.4.2  Assay development  
An initial screen indicated that the PK/LDH coupled enzymatic assay is not suitable to 
quantify Pf COG1829 activity as it is affected by the required high optimum temperatures.  
Variations of the techniques were investigated resulting in a discontinuous version of the 
above assay being employed in all further application. 
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5.4.3  Alternative pathway in Archaea 
A report from 2009 reported that PanK activity could not be detected in cell free extracts of 
the hyperthermophilic Thermococcus kodakaraenis.19 The study also aimed at characterizing 
the first example of an archaeal PanK.  The approach was, however, different in that an 
expression plasmid designed for extremophiles was constructed.  The candidate genes for 
both PS (COG1701, TK1686) and PanK (COG1829, TK2141) were cloned into the specialized 
plasmid and subsequently overexpressed and the enzymes purified to homogeneity.  
Enzyme activity tests indicated that T. kodakareanis displays very little PS and PanK activity.  
Instead these are two novel enzymes, pantoate kinase (PoK) and phosphopantoate 
synthetase (PPS).   
The kinetic parameters measured for the PanK alternative PoK, are listed in Table 5.1.  The 
enzyme has high KM-values for both pantoate and panthothenic acid, but its overall catalytic 
efficiency is higher with pantoate as substrate. 
Table 5.1:  Kinetic parameters for PoK 
 
In the classical CoA biosynthesis pathway (Figure 5.5), pantoate is condensed with  
β-alanine to form pantothenic acid by the enzyme PS, followed by phosphorylation to  
4’-phosphopantothenate by PanK.  In T. kodakareanis pantoate is first phosphorylated by 
PoK to 4’-phosphopantoate before the condensation reaction with β-alanine to yield the 
same end product. 
Homologs of the genes encoding the novel PoK and PPS are widely distributed among 
various Archaeal species suggesting that this is the route used in these organisms to 
produce 4’-phosphopantothenic acid.19  
However, this pathway is not universal or absolute in Archaea as a PoK gene was not 
identified in the Thermoplasmatales order.  A BLAST search on the complete genome 
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sequence of Picrophilus torridus identified the PTO0232 gene as a distant homolog of E. coli 
coaA.  This gene was therefore amplified, cloned, over-expressed from a pET28a(+) 
construct, purified with IMAC and kinetically characterized.  The Archaeal PanK-I has an 
extremely high KM-value for pantothenic acid (621 μM vs. 36 μM of E. coli PanK-I), while the 
KM-values’ for ATP is more or less the same as that of the E. coli enzyme.  The other major 
difference is that the P. torridus PanK-I, like S. aureus PanK-II, is refractory to feedback 
inhibition by CoA.  Based on these differences it was suggested that Archaeal PanK-I 
constitute a new subtype of type I PanKs.20 
 
 
Figure 5.5:  General pathway for the production of 4’-Phosphopantothenic acid in pro- and eukaryotes (right) 
and the alternative pathway in the Archaea (left).  
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5.5  Conclusion 
Research by ourselves and other groups indicate conclusively that Archaea do not harbor a 
Type IV PanK as had previously been though.  Instead Archaea have novel PoK and PPS 
enzymes that provide an alternative route for the biosynthesis of 4’-phosphopantothenate 
from β-alanine and pantoic acid.  The first of example of an archaeal Type I PanK has been 
characterized from P. torridus apart of this thesis.  The enzyme exhibits some unique 
characteristics and may constitute the first characterized example of a new subtype of the 
type I PanK enzymes. 
Our efforts to isolate and characterize an Archaeal PanK/PoK candidate enzyme proved 
unsuccessful. Background activity of E. coli PanK-I and co-purification of other  
E. coli proteins complicated purification strategies and activity determinations.  Nonetheless 
we were able to successfully develop a new discontinuous assay for thermophilic kinase 
enzymes.  This may prove useful in future studies.  
5.6  Experimental 
Three strains of Archaea were identified and used in this study - Pyrococcus furiosus, ATCC 
43587, Pyrococcus horikoshi, ATCC 700860, and Methanocaldococcus janaschii. 
Plasmid MJ0969, a pT7-7 construct containing the Methanocaldococcus janaschii candidate 
gene, was a gift from Robert White, Virginia Tech, US.   
5.6.1  Revival of extremophiles, DNA isolation and amplification 
a) Growing and stocking of organisms 
(Growing pure cultures was undertaken by Mrs Leisl Brand.)  
A 15 ml starter culture was prepared in pyrococcus medium enriched with 0.83 g/l Na2S 
(normally 0.5 g/l) and purged with 100% N2.  After incubation at 95°C for ± 24 h, the culture 
was used to inoculate 50 ml pyrococcus media, enriched with the same concentration Na2S, 
under inert atmosphere. This culture was grown overnight at 95°C, harvested by 
centrifugation, the supernatant decanted and the pellet resuspended in 3.0 ml TE buffer, 
divided into aliquots and stored at -80°C. 
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b)  Amplification for cloning into pET28a(+) 
(DNA was isolated and amplified by Mrs Leisl Brand.)  
Genomic DNA was extracted from cultures of the organisms and used as template for the 
amplification of candidate genes.  The forward and reverse primers introduced NdeI and 
XhoI restriction sites (underlined) respectively for the cloning into pET28a(+).  The following 
primer sets were used: 
Pyrococcus furiosus: forward primer:  5’ – GGAGGTGAGCATATGCTAATTAGAGC – 3’ 
reverse primer:   5’ – CTAG AAGTATAGTTCTCGAGAAAAGCAAATC – 3’  
Pyrococcus horikoshii: forward primer:   5’-GGTAAGGCATATGCTAATTCGAGCG -3’ 
 reverse  primer:  5’-TAT AGTTAATAACTCGAGGATATCTCTG-3’.  
c)  Amplification for cloning into pET22b(+) 
The COG1829 candidate gene was subcloned from the pET28a(+) construct.  The reverse 
primer introduced an XhoI-site (underlined) and removed the stop codon.  
Pyrococcus furiosus: T7 forward primer:  5'-TAATACGACTCACTATAGGG-3' 
reverse primer:   5’-GGGGGGGGCTCGAGCTCATTTGGTATCCACC-3’ 
The amplification utilized DreamTaq (Fermentas) polymerase and the PCR reaction mix 
contain of 1 ×  DreamTaq-buffer, 0.4 mM dNTP mix, 1.0 mM forward primer, 1.0 mM 
reverse primer, 1.0 µg genomic DNA, various MgCl2 concentrations (1.5 mM, 2.0 mM, 2.5 
mM, 3.0 mM and 3.5 mM), 2.5 U DreamTaq and H2O to a final volume of 25 µl.   
The PCR program started with an incubation step of 2 min at 94˚C before the cycle was 
initiated with a denaturation step at 94˚C for 15 s, an annealing step at 55˚C for 30 s and a 
polymerization step 72˚C for 1.5 min.  This cycle was repeated 30 times and the program 
ended with a hold step at 4.0˚C.  Reaction mixtures were analyzed by gel electrophoresis on 
a 1.0% agarose gel and the bands visualized by staining with SYBR®gold.  Product bands 
were obtained at 735 bp in all instances and the bands were purified from the gel with the 
Fermentas GeneJET™ Gel Extraction kit.   
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5.6.2  Cloning 
The same general procedures were used for cloning and expression trials as described in 
Section 4.9.2. 
a) Pyrococcus furiosus and Pyrococcus horikoshii 
(Cloning was performed by Mrs Leisl Brand.) 
The COG1829 candidate genes and plasmids, pET28a(+) and pENTR4N, were digested with 
NdeI and XhoI.  The genes were cloned into the respective plasmids using the Quick ligase 
method.  The only difference in the procedure involved the DNA being incubated at 60°C for 
5 min (to break any unproductive bonding in the DNA) before the Quick ligase buffer and 
ligase were added to the ligation mixture. 
Both genes were subcloned into pBAD DEST49, pBAD544 and pBAD566 using LR clonase and 
the relevant pENTR4N constructs. 
b) Pyrococcus furiosus:  Subcloning into pET22b(+) 
The PCR product (section 5.7.1c) was digested with NdeI and XhoI and cloned into digested 
pET22b(+) with Quick ligase to yield the construct without a stop codon before the C-
terminal His6-tag sequence. 
The COG1829 candidate gene was digested from the pET28a-construct with NdeI and XhoI 
and subcloned into digested pET22b(+) with Quick ligase to yield the construct for native 
expression. 
c)  Methanocalcococcus janaschii:  Subcloning into pET28a(+) 
The COG1829 candidate-gene was digested from the pT7-7 construct using 2 × Fermentas 
Tango buffer, 20 U NdeI (New England Biolabs), 20 U BamHI (Fermentas) in a final reaction 
volume of 20 μl.  After 2.5 h of incubation at 37 °C, the digestion mixture was resolved on 
1.0% agarose gel and purified from the gel with the Fermentas GeneJET™ Gel Extraction kit.  
The candidate gene was cloned into pET28a(+) using the Quick ligation method. 
5.6.3  Functional complementation studies 
The relevant pBAD EXP49 constructs were transformed into chemical competent E. coli 
DV62 cells.  Starter cultures were prepared in the morning on the day of the experiment 
from a single colony in 5.0 ml LB media supplemented with 100 mg/L ampicillin.  Comple-
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mentation was done in Corning 24-well flat bottom cell culture plates using the Thermo 
Varioskan™ spectrophotometer.  To initiate the experiment, 10 ml minimal media (2.0% E-
salts, 0.2% glycerol, 0.01% thiamine, 0.1% methionine, 0.2% arabinose, 10 mM β−alanine 
and 100 mg/L ampicillin) was inoculated with 10 μl starter culture.  The plate was incubated 
at 42°C with shaking and the increase in optical density was followed at 600 nm by taking a 
reading every 30 min over a period of 30 h. 
5.6.4  Expression of the putative COG1829 Pyrococcus furiosus candidate 
a)  MBP-tagged protein from pEXP566-TEV construct 
LB media (500 ml), supplemented with 100 mg/L ampicillin, was inoculated with plasmid 
containing E. coli BL21(DE3) starter culture.  The culture was grown to midlog phase and 
induced with a final concentration of 0.2 mM isopropyl-β-D-thiogalactoside (IPTG).  Growing 
continued at 37°C overnight.   
b)  Thioredoxin-tagged protein  from pBAD EXP49 construct 
LB media (500 ml), supplemented with 100 mg/L ampicillin, was inoculated with plasmid 
containing E. coli BL21(DE3) starter culture.  The culture was grown until midlog phase, 
induced with a final concentration = 0.2% L-arabinose and grown at 37°C overnight. 
5.6.5  Purification strategies   
a)  TEV cleavage of MBP-tagged protein 
The cell pellet, obtained from the pEXP566-TEV construct expression, was lysed using glass 
beads and vortexed for 10 min in TEV buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA).  
Novagen Bugbuster® protein extraction reagent was also used, but didn’t lyse the cells 
sufficiently.  TEV protease (24.8 μg) was added to the cell lysate containing 2.48 mg protein 
(quantified by Bradford) and the reaction incubated at 4.0°C overnight. 
b)  Purification by heat denaturation of E. coli proteins 
Aliquots (100 μl in 1.5 ml Eppendorf tubes) of the TEV cleaved reaction mixture were 
warmed in a heating block for a predetermined time at a predetermined temperature.  The 
denatured protein was pelleted by centrifugation at 13 000 rpm for 20 min at 4.0°C.  The 
supernatant was removed and used in further applications. 
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c)  Purification from 12% SDS-polyacrylamide gels 
The protein purification from a 12% SDS-polyacrylamide gel was based on the procedures 
described by Bricker et al.3 and Cohen et al.4 Protein samples were concentrated by 
centrifugation (Nanosep, centrifugal device, 10 K cut-off) and resolved on a 12% SDS-
polyacrylamide gel.  The gel was reversible stained with 0.3 M CuCl2 for 5 min before rinsing 
with distilled water to remove the excess CuCl2.   The protein band was excised from the gel, 
1 ml destaining solution (0.1 MTris-HCl, pH 9.0, 0.25 M EDTA) was added and followed by 
agitation for 10 min.  After removing solvent, the gel slice was rinsed with distilled H2O to 
remove traces of destaining solution and crushed.  Extraction buffer (40 μl, 1:3:2 (v/v/v) 
formic acid: H2O: isopropanol) was added to the crushed gel piece and incubated for 4 h at 
room temperature with continued agitation.  The gel debris were pelleted by centrifugation 
at 8 000 rpm for 20 min at room temperature, the supernatant removed and the gel debris 
washed with extraction buffer (40 μl).  The protein containing supernatants were combined 
and the buffer exchanged as described in the next section. 
d)  Buffer exchange strategies 
The buffer was exchanged using Bio-Gel P-6 DG (Bio-Rad) and micro Bio-Spin 
chromatography columns (Bio-Rad).  The gel was hydrated with either H2O or buffer (10 mM 
Tris-HCl, pH 7.2) for 4 h at room temperature.  Gel (800 μl) was added to each column.  
Excess liquid was allowed to drain by gravity and the columns were centrifuged at 6 000 rpm 
for 1.0 min.  Protein sample (75 μl) was added to each column and eluted by centrifugation 
at 2 000 rpm for 4.0 min.  Protein in the elution fraction was confirmed by 12% SDS PAGE 
analysis.   
5.6.6  In-gel clostripain digest 
The 12% SDS-polyacrylamide gel was reversibly stained and destained as described above.  
The protein containing bands were excised from the gel and cut into smaller pieces.  The gel 
pieces were covered with acetonitrile and incubated at room temperature for 10 min to 
dehydrate and shrink the pieces.  After removal of the acetonitrile, the pieces were 
rehydrated in 150 μl buffer 1 (100 mM NH4CO3, 10 mM DTT) for 1 h at 56 °C.  The samples 
were cooled, the buffer replaced by 150 μl buffer 2 (100 mM NH4CO3, 10 mM 
iodoacetamide buffer) and incubated for 45 min at room temperature in the dark with 
occasional vortexing.  After the solution was removed, the gel pieces were washed with 100 
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mM NH4CO3 (150 μl) and dehydrated again with acetonitrile (150 μl).  This step was 
repeated twice before removing the acetonitrile and air drying the pellet.  After the gel 
pieces were sufficiently dry, 100 μl digestion buffer (1% Trition X-100, 10% acetonitrile, 1 
mM DTT, 10 mM CaCl2, 100 mM Tris-HCl, pH 8.0) and clostripain (10 μl) was added.  The 
digestion mix was incubated for 45 min in ice water, the buffer replaced with 50 mM 
NH4CO3 (20 μl) and incubated overnight at 37°C.  The gel pieces were pellet by 
centrifugation at 13 000 rpm for 1 min and washed by incubating at room temperature for 
10 min with 20 mM NH4CO3 (100 μl).  The cleaved protein peptides were extracted from the 
gel by incubating the gel pieces in a 5% formic acid, 50% acetonitrile solution (100 μl) for 20 
min at room temperature before pelleting the debris by centrifugation at 13 000 rpm for 1 
min.  The extraction step was repeated twice.  All the supernatants were combined, dried 
and analyzed by 12% SDS PAGE.  
5.6.7  Expression trials 
Plasmids were transformed into E. coli strains:  BL21(DE3), C41 or C43 as required.  LB 
medium (1.425 ml), supplemented with 100 mg/L ampicillin, was inoculated with 30 μl 
starter culture.  The culture was grown at 37°C with vigorous shaking until midlog phase was 
reached and induced with 45 μl of a predetermined concentration of IPTG and incubated 
overnight. To increase the translation efficiency and solubility of the target protein, the 
following parameters were varied at which expression occurs after induction:   
1. IPTG concentration:  0.00 mM, 0.25 mM, 0.50 mM or 1.00 mM  
2. Expression temperature:  15˚C, 20˚C, 25˚C, 30˚C or 37˚C  
3. Co-expression with plasmids that encodes for the scarce codons - pRARE and pRARE2 
plasmids for expression from BL21(DE3) and pLysS for expression from C41 and C43.  
The cultures were harvested by centrifugation at 13 000 rpm for 20 min at 4.0°C and the 
pellet resuspended in 200 μl elution buffer (20 mM Tris-HCl, pH 8.0).  The suspended pellet 
was analyzed as is to determine the total protein content of the cell lysate.  To evaluate the 
amount of soluble expression, glass beads (equal to half the volume of the suspended 
pellet) was added to a 100 μl aliquot.  The pellet was manually lysed by vortexing for 10 min, 
the cell debris pelleted by centrifugation at 13 000 rpm for 2 min and the protein containing 
supernatant analyzed by 12% SDS PAGE.   
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5.6.8  Assay development 
a)  ADP and NADH standard curves 
For ADP standerd curves the reaction mixtures (5.0 mM Tris-HCl, pH 7.6, 2 mM KCl,  
1.0 mM MgCl2, 0.5 mM pantothenic acid, varying ADP concentrations and H2O instead of 
enzyme) were incubated at either 37°C or 90°C for 20 min.  After incubation the assay 
mixture (5 mM Tris-HCl, pH 7.6, 2.0 mM KCl, 1.0 mM MgCl2, 2.0 mM PEP, 0.3 mM NADH, 
2.75 U LDH and 2.0 U PK) were added to the reaction mixtures and incubated at 25°C for  
5 min before the absorbance was measured at 340 nm and 25°C in a Thermo Varioskan™ 
spectrophotometer. 
For the NADH standard curve solutions of different NADH concentrations were made in H2O 
and measured as is.  
b)  Terminating the enzymatic reaction 
Reaction mixtures (150 μl) were incubated 60 °C for 5 min before the reaction was 
terminated using one of the following methods.  The additives (10 μl) - 1.0 M NaOH, 1.0 M 
HCl, Tween, Triton or Tween (all neat) - were added directly to the reaction and the eppi 
was placed in ice water for flash cooling.  The flash cooling reaction was left in the ice water 
for an additional 5 min while the reactions containing additives were incubated for the 
additional 5 min at 60°C.  All reactions were quantified and compared to a positive control 
(incubate for 10 min at 60°C) and a negative control (no enzyme).  
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Chapter 6: 
Conclusion and Future work 
6.1  PanKs:  Remaining unanswered questions revisited 
PanK is the best studied enzyme of the CoA biosynthetic pathway.  Several gaps in our 
understanding of these kinases however still remain, especially in regards to the 
type III PanKs.  In Chapter 1 several lingering questions regarding the PanKs were listed.   
The studies described in this thesis were designed to answer some of these by: 
 Identifying alternative substrates and inhibitors of the type III PanKs from pathogenic 
bacteria.  
 Investigating the enzyme activity of two “inactive” PanKs:  the putative PanK-III from 
M. tuberculosis and PanK-II from B. anthracis.   
 Attempting to purify and characterize the first example of a type IV PanK from the 
Archaea.  
6.1.1  Identification of alternative substrates and inhibitors of PanK-IIIs 
At the beginning of the study the only known inhibitor for the PanK-IIIs was the ATP mimetic 
by Rowan et al.,1 a relatively poor competitive inhibitor of B. anthracis PanK-III.  In our study 
11 pantothenic acid analogs were designed, synthesized and tested as alternate substrates 
and/or inhibitors of P. aeruginosa PanK-III.   
Pa PanK-III showed a surprisingly selectivity for its substrate as only one of the 11 
pantothenate analogs tested, β-methylpantothenic acid, was characterized as an alternative 
substrate for the enzyme and only three, α- and β-methylpantothenic acid and  
β-trifluoromethylpantothenic acid,  were identified as PanK-III inhibitors (Figure 6.1). 
Inhibitor analysis showed that α-methylpantothenic acid and β-trifluoromethylpantothenic 
acid have very similar Ki-values, in the range of 80-90 μM, and that both are competitive 
inhibitors of pantothenate, the natural substrate.  β-Methylpantothenic acid displayed a 
mixed competitive profile with uncompetitive inhibition towards pantothenic acid at low 
concentrations and competitive inhibition at high concentrations.  The reason for this dual 
behaviour may be due to β-methylpantothenic acid also acting as a substrate of Pa PanK-III.  
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Figure 6.1:  Three compounds identified as inhibitors of P. aeruginosa PanK-III and their Ki-values. 
6.1.2  Investigating the activity of M. tuberculosis CoaX 
Even though all sequence and structural evidence concurs that Mtb CoaX could be a 
functional pantothenate kinase, we were unable to verify the activity in vitro.  This could be 
due to the instability of the purified protein in buffers with NaCl and imidazole 
concentrations below 250 μM.  Another possible explanation for the apparent lack of 
activity relates to the two point mutations observed in the PHOSPHATE 1 and ADENOSINE 
motifs of mycobacterial CoaX proteins, in which the small uncharged residue, Gly, was 
replaced by larger charged amino acids, namely Asp and His respectively.  These exchanges 
result in the introduction of a H-bonds in the active site of the enzyme that blocks the 
entrance of the active site, and therefore possibly ATP binding.  
Importantly, the homologous Ms CoaX was purified and shown to have PanK activity.  While 
the kinetic parameters of Ms CoaX show the enzyme to be catalytically less efficient than 
other known PanK-III enzymes, this finding strongly suggests that Mtb CoaX should also 
display pantothenate kinase activity under suitable physical conditions. 
6.1.3  B. anthracis BA2901 is a pantetheine kinase 
The putative B. anthracis PanK-II, BA2901, was the only other putative bacterial PanK that 
was reported to be inactive at the start of this study.  We demonstrated that although the 
enzyme is inactive towards pantothenic acid as substrate, it is active towards pantetheine, 
the substrate of the CoA salvage pathway.  While other PanK-I and PanK-II enzymes are 
known to have low substrate specificity and accept both pantothenate and pantetheine as 
substrates, BA2901 is the first known example of a kinase that exclusively accepts 
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pantetheine.  The specific reason for this specificity, and particular its molecular basis 
currently remains unclear.  Ideally the crystal structure of this enzyme would be able to 
address this.  However, since B. anthracis has a PanK-III enzyme that does not accept 
pantetheine as substrate, the specificity of BA2901 could allow for the operation of a 
functional CoA salvage pathway in this organism.  Both the fact that BA2901’s KM-value for 
pantetheine is a quarter of that of E. coli PanK-I,2 and that its catalytic efficiency is ≈ 10 
times higher, support this hypothesis. Importantly, B. anthracis is one of the few Gram-
positive bacteria (together with S. aureus) that relies on high levels of CoA to maintain its 
intracellular redox balance. 
6.1.4  Origin of 4’-phosphopantothenic acid in Archaea 
The Archaea do not harbor a type IV PanK as previously speculated.  Instead they have novel 
PoK and PPS enzymes which provide an alternative route for the biosynthesis of  
4’-phosphopantothenate from β-alanine and pantoic acid.  The first of example of an 
Archaeal type I PanK from P. torridus has also been characterized and suggested to 
represent a new subtype of the type I enzymes. 
6.2  Future work 
6.2.1  Further studies with the identified PanK-III inhibitors  
One possible explanation for the high Ki-values determined for the newly identified PanK-III 
inhibitors could be the methyl substituents in the β-alanine moiety of pantothenic acid gives 
rise to a new stereocenter.  In the inhibition activity tests, reaction mixtures contained both 
stereoisomers.  Both α-methylpantothenic acid and β,β-trifluoromethylpantothenic acid 
inhibit P. aeruginosa PanK-III with Ki-values in the range of 80-90 μM.  The true Ki-values 
may therefore be half or less of those determined in this study, depending on the 
stoichiometry of the stereoisomers.  Pure enantiomers may be investigated in future to 
determine the true Ki. 
Currently inhibition data of our inhibitors is limited to one enzyme, Pa PanK-III.  Future 
studies will expand the data to other PanK-IIIs, including the enzymes from Actinobacter 
baumannii, Bacillus anthracis, H. pylori and Treponema pallidum, as well as representative 
PanK-I and PanK-II enzymes. 
Stellenbosch University  http://scholar.sun.ac.za
 119 
 
Chapter 6:  Conclusion and Future work 
6.2.2  Synthesis of other analogs as potential inhibitors 
Our inhibitor characterization studies revealed that exchange of the methyl group of β-
methylpantothenic acid with the -CF3-group resulted in a three-fold decrease in the 
observed Ki-value.  Similar substitution of the methyl group of α-methylpantothenic acid 
may therefore possible result in a Ki of ≈ 30 μM, a third of the Ki for α-methylpantothenic 
acid.  Future work could therefore include the synthetic preparation and kinetic 
characterization of α-trifluoromethylpantothenic acid, shown in Figure 6.2, as inhibitor.   
 
Figure 6.2:  Structure of α-trifluoromethyl pantothenic acid and ω-methyl pantothenic acid 
 
Other areas of research may further include redesigning and executing the synthesis of  
ω-methylpantothenic acid, also shown in Figure 6.2.  
6.2.3  Utilizing synthesized scaffolds in pantothenamide synthesis 
Van Wyk et al. developed a method for the parallel synthesis of N-substituted 
panthothenamides from pantothenic acid as starting compound.3  The various pantothenic 
acid analogs synthesized in this study; including α- and β-substituted pantothenic acid 
analogs and 4’-deoxy- and 4’-methoxypantothenic acid could be used as starting materials 
to expand the current library of compounds in a similar manner.  A schematic 
representation of such a parallel synthesis is shown in Scheme 6.1.   
 
Scheme 6.1:  Synthetic scheme for the preparation of N-substituted pantothenamides from pantothenic acid 
analogs modified on the β-alanine moiety. 
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In the parallel synthesis the pantothenic acid analogs are converted to the corresponding 
thioester by thioesterification, followed by transformation into the final pantothenamide 
library through aminolysis.  The new library of compounds could be used in screening 
experiments to identify inhibitors for relevant PanK-I- and PanK-II-containing organism, such 
as E. coli, Plasmodium falciparum and Staphylococcus aureus. 
6.2.4  M. tuberculosis and M. smegmatis CoaX mutagenesis studies 
The Mtb CoaX H229G mutant was prepared to establish whether the disruption of the 
interaction of His and Arg (discussed in section 4.4.6) would restore activity to Mtb CoaX. 
This variant was, however, found to remain inactive.  The instability of the purified protein 
makes it unclear whether the inactivity is due to the protein preparation, or because 
exchange of the one residue is insufficient to unblock the active site.  Future work may 
include extensive mutagenesis studies to create and test the constructs containing single 
mutations – Mtb CoaX R8G, Ms CoaX R8G and Ms CoaX H228G - and the double mutants – 
Mtb CoaX R8G, H229G and Ms CoaX R8G, H228G.  The Ms CoaX homologs should be 
included because the activity of this protein has been confirmed, and the data obtained with 
this enzyme can be used to test the disruption of the salt bridge theory if the problems with 
Mtb CoaX persist. 
6.2.5  Addressing the other PanK related unanswered questions 
There are two remaining questions raised in Chapter 1 that have not been addressed in this 
study and which deserves further investigation: 
 Determination of the identity of the true phosphoryl donor of type III PanKs, or 
elucidation for the basis of the high KM for ATP that these proteins exhibit. 
 Investigation of the possible link between Baf (Bvg accessory factor) proteins and 
type III PanKs, or whether the activity observed for the B. pertussis coaX-encoded 
protein is unique to this organism. 
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